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1 
 
Abstract 
Children bear a considerable proportion of the impact of epidemics of influenza and measles and are 
a driving force in community-wide epidemics. This thesis considers this impact and the benefits of 
existing vaccination programmes.  
First, we estimated the impact of seasonal influenza outbreaks in primary schools. To estimate the 
health-related impact we started by conducting a review of the literature to determine the methods 
used to estimate health utilities in children and adolescents, establishing that a wide variety of 
systems have been used without clear guidance on an optimal method. Mean absence from school 
was 3.8 days (95% CI: 3.0-4.8) and 3.7 days (95% CI: 2.7-4.8) off work for caregivers. The mean loss in 
HRQoL was 2.1 QALDs (95% CI: 1.5-2.7).  
Next, we modelled the childhood influenza vaccination programme at a national- and community-
level, exploring the impact of heterogeneous coverage. Nationally, a vaccination programme that 
focuses on primary school vaccination supplemented with fewer vaccinations in secondary schools is 
optimal from the perspective of the healthcare provider, but heterogeneous uptake within targeted 
populations consistently resulted in a larger total burden of disease at the community level, 
emphasising the importance of adherence to school-based vaccination policies.  
Two studies of the measles outbreaks in England between 2012 and 2013 were conducted to further 
the understanding of the impact of measles infection. Significant work/school absence was reported 
by individuals with infection and their caregivers. Infection was associated with a mean loss of 6.9 
QALDs (95% CI: 5.8-8.0). The total economic cost of the outbreak was £4.4m in Merseyside alone, 
compared to a total cost of £182,909 over the previous five years to achieve herd immunity through 
the MMR vaccination programme. 
The findings demonstrate the importance of adherence to preventative vaccination programmes to 
reduce the potential for outbreaks of influenza and measles.  
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Chapter 1 - The structure of the thesis 
This thesis considers the social and economic impact of measles and influenza outbreaks, focusing on 
issues surrounding the measurement of impact metrics as well as public health preventative measures 
and control measures for outbreaks. After a general introduction to this broad field of epidemiology, 
we consider methods and instruments used to estimate health utilities in a paediatric population, 
before discussing wider investigations on the topics of influenza outbreaks in primary schools, 
modelling school-based influenza vaccination programmes and the impact of measles outbreaks in 
England. 
Chapter 2 introduces concepts and ideas central to this thesis, including a look at the application of 
both mathematical modelling of infectious diseases and health economics to reducing the burden of 
both seasonal influenza and measles in England. Techniques employed in mathematical modelling are 
discussed with reference to research that follows in subsequent chapters dedicated to modelling 
seasonal influenza vaccination coverage.  
Chapter 3 considers the methods used to facilitate the accurate estimation of health utilities from 
both children and adolescents, presenting a systematic review of the literature reporting on the 
progress made in developing methods to gather health utilities from this age group for the purpose 
of economic evaluations. Estimating health utilities for children and adolescents is a key part of several 
studies included in this thesis so an exploration of the current practice was valuable.  
An analysis of the impact of school-based influenza epidemics in England is presented in Chapter 4, 
including measuring health utilities for seasonal influenza in school children. We investigated the 
potential level of disruption at home for hypothetical school closures, in addition to both gauging 
acceptance for the childhood seasonal influenza vaccination programme and quantifying the impact 
of school-based influenza epidemics in the 2012-13 and 2013-14 influenza seasons in terms of QALYs 
and out-of-pocket expenses. 
Chapter 5 introduces mathematical modelling of seasonal influenza in England and aims to establish 
whether a policy of targeted vaccination in either primary or secondary schools would be more cost-
effective than a programme across the two age groups. The concept of heterogeneous vaccination 
coverage is further investigated in Chapter 6 with a modelling analysis of the impact of the burden of 
disease for school-based seasonal influenza vaccination programmes where school-level 
heterogeneity is simulated, this time using a stochastic SEIR-type model and a theoretical 
metapopulation framework. 
Chapter 7 describes an opportunistic undertaking to quantify the impact of measles infection in terms 
of QALYs during the 2012-13 nationwide measles epidemics. Questionnaires were distributed to 
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individuals with confirmed cases of measles in conjunction with Public Health England as part of their 
outbreak surveillance. 
The societal cost of the measles outbreak in Merseyside is discussed in Chapter 8. The regional Public 
Health England office commissioned the development of a costing model for the initial four months 
of the outbreak, then subsequently requested that we use their report to estimate the total cost of 
the outbreak from the societal perspective. 
Chapter 9 proposes areas for further research then considers both wider issues in outbreak mitigation 
for both diseases and related challenges for public health institutions. 
Chapter 10 is the appendix, containing questionnaires used to gather primary data as well as scripts 
used in the mathematical modelling exercises and supplementary figures. Chapter 11 contains print-
outs of the publications arising from this thesis. 
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Chapter 2 - Background to concepts covered in the thesis 
THE MOTIVATION FOR STUDYING BOTH INFLUENZA AND MEASLES 
This chapter will introduce the different concepts covered in this thesis. The work in subsequent 
chapters overlays different topics within the main goal of understanding the impact of both influenza 
and measles outbreaks. However, before commencing with the background to these topics it is 
important first to understand the motivation for studying both influenza and measles. 
VACCINE-PREVENTABLE DISEASES 
The United Kingdom has long-established publicly funded, free-at-the-point-of-delivery vaccination 
programmes that aim to reduce the burden of disease vaccine preventable diseases including both 
influenza and measles outbreaks. Influenza vaccinations have been available to those at high risk of 
serious morbidity and mortality since the late 1960s and the programmes have been extended several 
times to include more population groups: first to those aged 75 years and older in 1998 [1]; to those 
aged 65 years and older in 2000 [2]; and to pregnant women in their second and third trimester in 
2006 [3]. The measles vaccination programme commenced in 1968 with a single vaccination against 
infection until the introduction of the combined measles, mumps and rubella vaccination (MMR) in 
1988 [4], changing to a two-dose vaccination strategy in 1996 in line with World Health Organisation 
guidelines [5]. MMR is offered to all infants registered with a GP surgery as part of the NHS Childhood 
Vaccination Schedule [6].  
Vaccination coverage for seasonal influenza varies according to risk-group. Public Health England 
reported mixed coverage levels during the 2014-15 influenza season with 72.7% coverage in 
individuals aged 65 years and older; 50.3% coverage in those clinically at-risk and aged between 6 
months and 65 years; and 44.1% coverage in pregnant women. In addition, the vaccine was offered 
to children aged 2, 3 and 4 years with overall coverage of 38.5%, 41.3% and 32.9% respectively [7]. 
MMR vaccination coverage for individuals aged 5 years in England during the same period was 94.5% 
for the first dose and 88.6% for the second dose [8]. 
RECURRENCE OF NATIONWIDE OUTBREAKS 
Despite good vaccination coverage for both programmes, outbreaks can occur nationwide for both 
diseases as vaccine coverage for target groups falls below the targeted coverage levels for both the 
ECDC (75% seasonal influenza coverage for target groups [9] and 95% MMR coverage for target groups 
[10]). The 2012-13, 2013-14 and 2014-15 influenza seasons saw low-to-moderate activity with 
prolonged outbreaks across England and many community-level outbreaks occurring in settings such 
as schools and care homes [11-13]. During 2012 and 2013 a large nationwide outbreak of measles 
resulted in 3,873 laboratory-confirmed cases [14], with major outbreaks reported in Liverpool [15], 
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North-East England [16] and Manchester [17]. These outbreaks indicate that the achievements of both 
vaccination programmes have so far fallen short of eliminating sustained nationwide- and community-
level transmission.  
With both influenza and measles transmission still to be eliminated from the UK, this presents 
opportunities to study both the impact of outbreaks of these two diseases, as well as consider 
modifications to current vaccination programmes.  
MAIN TOPICS OF STUDY 
The thesis focuses on four main themes: 
1. Measuring health-related quality of life in children and adolescents 
Cost-utility analyses estimate the cost-effectiveness of health technologies based on their costs and 
benefits using quality-adjusted life years (QALYs) as a measure of benefit, and are used to support a 
recommendation to introduce new health technologies such as new vaccination programmes to 
prevent infectious disease outbreaks. The accurate measurement of QALYs is dependent on using 
appropriate methods to elicit health utilities and conducting such a task for children and adolescents 
is particularly challenging [18]. We address this topic in greater detail in the systematic literature 
review in Chapter 3. 
2. The social and economic impact of influenza outbreaks in schools in the community 
Children attending schools are a large driver of community-wide influenza outbreaks [19-21], due to 
a variety of factors including a high number of close contacts [22] [23], poor hygiene habits [24] and a 
lack of acquired immunity in children [22, 25]. Therefore controlling outbreaks of influenza in school 
not only benefits those children and the members of their household but also members of the wider 
community [26-31]. To inform parents and guardians of both the risks of influenza infection as well as 
the benefits of preventative vaccination, we conducted a study in English primary schools to assess 
the impact of those outbreaks (Chapter 4). 
3. The control of influenza outbreaks through preventative vaccination, both nationally and at 
a local level 
The seasonal influenza vaccination programme in England was recently extended to include all healthy 
children attending primary or secondary schools [32]. Mathematical modelling demonstrates that the 
new programme is highly cost-effective [33] but failed to consider heterogeneities in vaccination 
coverage between primary and secondary schools at a national level, as well as potential 
heterogeneities in the community at a local level. Heterogeneity in vaccination coverage has the 
potential to be damaging to the overall success of the programme if sufficient numbers of susceptible 
individuals cluster in the community [34, 35], but if the appropriate target population for the vaccine 
14 
 
is selected then heterogeneous coverage may also be advantageous to the healthcare provider [36]. 
We sought to establish the impact of heterogeneous vaccination coverage in Chapters 5 and 6. 
4. The social and economic impact of measles infection 
Measles is a highly contagious and potentially fatal disease, for which an effective vaccination 
programme exists that has already dramatically reduced the total burden of disease in England since 
its introduction [37]. However, measles outbreaks still occur within the community because 
vaccination coverage is not yet sufficient to provide herd immunity due to the clustering of susceptible 
individuals that have not been vaccinated [15]. To inform public health policy with the ultimate aim 
of increasing measles vaccination coverage through better educational materials on the risk of 
infection as well as the benefits of vaccination, we conducted two studies in Chapters 7 and 8 that 
sought to quantify the impact of measles infection on the individual, then separately on the 
community during an outbreak.  
This chapter will provide some background information to the following subjects: The Epidemiology 
of Influenza and Measles; Mathematical Modelling of Infectious Diseases; Infectious Disease 
Outbreaks in Schools; The UK Influenza Vaccination Programme Extension to Healthy Children; and 
Heterogeneous Vaccine Coverage. 
The subsequent chapter outlines the issues of measuring health-related quality of life in children and 
adolescents through a systematic literature review, before the findings of the review are then used to 
inform a wider research plan for the rest of the thesis. 
THE EPIDEMIOLOGY OF INFLUENZA AND MEASLES 
This section will outline the main challenges posed by the burden of disease of both influenza and 
measles, both in the United Kingdom and worldwide.  
THE EPIDEMIOLOGY OF INFLUENZA: WORLDWIDE AND IN THE UNITED KINGDOM 
ANNUAL BURDEN OF INFLUENZA 
Influenza is an infectious disease in both animals and humans that is transmitted through direct 
contact with nasal secretions, through contact with contaminated surfaces and through aerosols 
caused by coughing and sneezing containing the virus.  
Influenza-like-illness (ILI) is a diagnosis of possible influenza infection based on clinical symptoms. 
Diagnosis of ILI requires the following criteria for those clinical symptoms: 
 The sudden onset of symptoms 
 At least one of the following four systemic symptoms: 
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o Fever 
o Malaise (chills, feeling tired) 
o Headache 
o Myalgia (muscle or joint pain) 
 At least one of the following three respiratory symptoms: 
o Cough 
o Sore throat 
o Shortness of breath 
Case definitions for ILI vary worldwide and both the sensitivity and specificity of these case definitions 
are generally low, with low positive predictive values (23.3% to 59.7%) [38, 39]. Indeed, the case 
definition of ILI used by the ECDC (outlined above) is less sensitive than the definitions used by the 
WHO and CDC due to its reliance on self-reported fever rather than measured temperature [40].  
Diagnosis of influenza, meanwhile, requires that the criteria for clinical symptoms for ILI be met with 
at least one of the following four laboratory criteria [41]: 
 The isolation of influenza virus from a clinical specimen 
 The detection of influenza virus nucleic acid in a clinical specimen 
 Identification of influenza virus antigen by DFA test in a clinical specimen 
 Influenza specific antibody response 
Symptoms can start between 1 and 4 days after the influenza virus has entered an individual’s body. 
Infected individuals are infectious up to 1 day before the symptoms develop, with the infectious 
period lasting up to 7 days in adults and longer in children [42].  
Influenza belongs to the Orthomyxoviridae family of viruses which includes the A, B and C influenza 
virus types. In tropical regions, influenza epidemics can occur at any time of year but in more 
temperate climates influenza epidemics occur generally during the winter season and through 
circulation of influenza virus types A and B. Type A influenza is the main focus for public health officials 
because new and virulent strains of Type A tend to be both the cause of pandemics and the majority 
of the mortality burden for seasonal influenza [43]. In non-pandemic years influenza epidemics can 
cause 250,000 to 500,000 deaths [44], infecting 18% of unvaccinated individuals (95% CI: 16 – 22%) 
each influenza season [45]. Groups at risk of severe influenza infection include pregnant women, 
young children aged less than 5 years old, adults aged 65 years or older and those individuals with 
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underlying health conditions such as chronic disease to the heart, liver or kidneys as well as asthma 
and immunosuppression. 
In addition to the burden of disease, influenza is associated with costs related to the loss of 
productivity in addition to hospitalisation, primary care and treatment costs. In 2003 the total 
economic burden of influenza epidemics in the United States was US$87.1 billion [46].  
Influenza epidemics are driven by the high attack rates in children, with 20-30% of this population 
group affected over the course of a typical influenza season as they lack prior immunity. Infants and 
young children are likely to be hospitalised with influenza infection [47] although mortality from 
influenza is greatest in the elderly population [48]. Influenza infection in children causes a high societal 
impact in terms of absence from school or day care and a loss of productivity in the workplace when 
parents or guardians are required to be absent from work in order to care for their children at home. 
Influenza infection is associated with a mean absence from school or day care of 2.8 – 12.0 days for 
children infected and 1.3 – 6.0 days for their siblings in addition to an absence from work of 1.3 – 6.3 
days for their parents [49].   
112 acute outbreaks were reported in care homes (49%), hospitals (39%), schools (9%) and other 
settings (3%) during the mild influenza season of 2013-14 [11]  but virological testing shows that most 
outbreaks in care homes were caused by viral respiratory diseases other than influenza. Hospital 
outbreaks were caused by influenza A in the majority of cases. Very low levels of influenza B circulated 
(peak of 1.8% positive in week 18 of 2014), compared to 2012-13 (18.6% positive in week 52 of 2012). 
Influenza A (H1N1)pdm09 was the dominant circulating virus in 2013-14. Vaccine uptake reached 
52.3% in clinical at-risk groups and 73.2% in those aged 65 years and older. In addition, 42.6% of GP-
registered 2 year olds and 39.5% of GP-registered 3 year olds received the LAIV. A pilot programme in 
seven geographical areas saw 52.5% of primary school children receive the LAIV [50]. 
COMPLICATIONS FROM INFLUENZA INFECTION 
Cromer et al. (2014) highlighted the risks of complications from influenza infection in England using 
laboratory reports and the NHS Hospital Episode Statistics database [51]. They reported the annual 
burden of disease attributable to influenza using the hospital admission rate, estimated number of 
deaths and GP consultations.  
The highest influenza-attributable hospitalisation admission rate was for healthy children aged under 
5 years, split by 333 per 100,000 (95% CI: 321 – 345) for children aged under 6 months and 176 per 
100,000 (95% CI: 171 – 181) for children aged 6 months to 4 years. In comparison, healthy adults aged 
65 years and older had an influenza-attributable hospitalisation admission rate of 46 per 100,000 (95% 
CI: 45 – 47). 72% of influenza-attributable deaths occurred in adults aged 65 years and older with co-
morbidities. These figures show the uneven spread of the total burden of influenza infection within 
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an affected population. In addition, Rothberg and Haessler (2010) reported that patients with chronic 
medical conditions, such as heart disease, lung disease, diabetes, renal disease, rheumatologic 
disease, dementia, and stroke, are also at high risk for both seasonal and pandemic influenza 
complications, regardless of age [52]. These complications include primary viral pneumonia, 
secondary bacterial pneumonia as well as exacerbations of chronic underlying pulmonary diseases 
such as asthma and COPD. 
Accurate estimation of the total burden of influenza in terms of hospitalisations and deaths is difficult 
as many cases will not be virologically confirmed, nor indeed will data sources listing hospital 
admissions and death registrations specify the virologically-confirmed causative organism [53]. There 
is inherent uncertainty in the estimates of the total burden of seasonal influenza, which must be 
accounted for when seeking to establish methods for controlling influenza outbreaks. 
THE EPIDEMIOLOGY OF MEASLES: WORLDWIDE AND IN THE UNITED KINGDOM 
ANNUAL BURDEN OF MEASLES 
Measles is a highly infectious notifiable disease that can be severe in infants, pregnant women and 
immunocompromised individuals [37, 54]. It is caused by the measles virus, a member of the 
Paramyxoviridae family of viruses. It is highly contagious, spread by airborne droplets or direct contact 
with patient secretions. Measles is a leading cause of morbidity and mortality among young children, 
despite the availability of a safe and effective vaccine [55]. 
Measles infection is defined using the following criteria [56]: 
 Fever and maculopapular rash 
 At least one of the following: 
o Cough 
o Coryza (Rhinitis) 
o Conjunctivitis 
 At least one of the following laboratory criteria: 
o Isolation of measles virus from a clinical specimen 
o Detection of measles virus nucleic acid in a clinical specimen 
o Measles virus specific antibody response characteristic for acute infection in serum 
or saliva 
o Detection of measles virus antigen by DFA in a clinical specimen using measles 
specific monoclonal antibodies 
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Measles infection lasts between 7 – 10 days, with an incubation period of 10 – 12 days. Measles 
symptoms include: 
 Cold-like symptoms 
 Spot-like rash covering the body 
 Red eyes, sensitivity to light 
 A high temperature or fever 
 Koplick’s spots inside the mouth 
Measles is preventable through the measles-mumps-rubella vaccination programme (MMR), with 
measles vaccination introduced in the UK in 1968 [37]. In 1967, prior to the introduction of the vaccine, 
there was 460,407 notifications of measles infection and 99 deaths from the disease. By the mid-1990s 
the number of notifications had reduced to fewer than 20,000 with no deaths from measles recorded 
for the first time in 1994 [57].  
The World Health Organisation (WHO) estimated that 122,000 deaths occurred from 226,722 cases 
worldwide due to measles infection in 2012, down from 562,400 deaths and 853,480 cases in 2000 
[58]. The WHO aims to achieve elimination of measles infection in at least five WHO regions by the 
end of the year 2020 [59], though vaccination coverage is not yet reaching levels required to achieve 
this goal in any region [60]. 
 
Figure 2.1 - Annual measles notifications in England and Wales from 1989 to 2013 
Figure credit: [14].  
Public Health England reported 3,207 laboratory-confirmed cases of measles in England between 
January 2012 and June 2013, an increase over confirmed cases in previous years (Figure 2.1). Around 
230,000 children aged 10 – 16 years in England were unvaccinated against measles as of 31 March 
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2013 [61] as uptake of the national measles-mumps-rubella vaccination programme (MMR) fell in the 
late 1990s from 92% in 1996 to 80% in 2003 [62] after the suggestion of a potential link between the 
vaccine and autism [63] that subsequently proved to be unfounded [64-66]. MMR uptake has since 
recovered to its highest levels (92.8%) since its introduction [67]. 
COMPLICATIONS FROM MEASLES INFECTION 
Complication Number of complications from 
measles infections (n = 66,800) 
Any 19,443 (29.1%) 
Death 177 (0.3%) 
Diarrhoea 5,473 (8.2%) 
Encephalitis 96 (0.1%) 
Hospitalisation 12,854 (19.2%) 
Otitis media 4,875 (7.3%) 
Pneumonia 3,948 (5.9%) 
Table 2.1 - Rates of complications from measles infections in the United States between 1987 and 2000 
Table credit: [68].  
Measles infection can cause respiratory complications (otitis media, laryngotracheobronchitis and 
pneumonia), gastrointestinal complications (diarrhoea, mesenteric adenitis), neurological 
complications (febrile seizures, post-infectious encephalomyelitis and sub-acute sclerosing 
panencephalitis) and ocular complications (conjunctivitis and keratitis) (Table 2.1). Complications are 
more common in young children under the age of 5 years or in adults over the age of 20 years [68]. 
The rate of hospitalisation following measles infection can be high, with 42% of cases hospitalised in 
nine countries in the WHO European region in 2013, for those cases with a known hospitalisation 
status [69]. 
MATHEMATICAL MODELLING OF INFECTIOUS DISEASES 
This section will introduce the use of mathematical modelling in estimating the burden of disease and 
its use in economic evaluation. It will discuss both deterministic and stochastic modelling approaches 
and the use of social contact patterns to inform mathematical models of infectious disease 
transmission in populations. 
Mathematical modelling plays a large and important role in the planning of public health 
interventions. When a controlled trial is too difficult to implement because of logistical, financial or 
ethical considerations the simulation of possible outcomes can make assessments of both the burden 
of disease and potential interventions possible.  
When modelling the potential impact of new vaccination programmes, mathematical modelling 
provides the opportunity to study population-level outcomes (e.g. indirect protection offered to 
unvaccinated individuals and the overall impact on population-level burden of disease), the long-term 
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impact of the intervention and to assess several possible options for vaccination strategies. Estimating 
the impact of a population-wide vaccination programme would not be possible without the use of a 
mathematical model of disease transmission and the effect of vaccination. 
The following section lists different approaches to mathematical models used to evaluate vaccination 
programmes: Static and Dynamic models; Deterministic and Stochastic models; and Aggregate 
models. 
STATIC AND DYNAMIC MODELS 
Dynamic models include the indirect effects of interventions such as vaccination, by assuming that the 
force of infection is dependent of the number of infectious individuals in the population, in contrast 
to static models that assume that the force of infection (or the per-susceptible rate of infection) is 
constant during the duration of the outbreak(s) simulated. Disease incidence simulated in dynamic 
models does not decline in proportion to the increase in vaccination coverage achieved because 
individuals not reached by the vaccination programme still experience some benefit from its existence 
due to a lower risk of infection [70]. Chapters 5 and 6 detail the use of dynamic models to examine 
the impact of the childhood seasonal influenza vaccination programme in England, taking into account 
the potential indirect protection offered to the general population by vaccinating healthy children. 
DETERMINISTIC AND STOCHASTIC MODELS 
DETERMINISTIC MODELLING 
For a deterministic system, a model will continue to produce the same results if the initial conditions 
remain unchanged as the model does not use any degree of randomness or uncertainty in its 
computations. In the context of simulating infectious disease epidemics, the results of the model (e.g. 
final size, case fatality ratio, etc.) will be returned with each separate run of the model if the initial 
parameters (e.g. the proportion of susceptible individuals in the total population, the basic 
reproduction number, etc.) for each run remain the same. The behaviour of the system is limited by 
its history and the equations that govern the model.  
STOCHASTIC MODELLING 
A stochastic model will evolve over time using random variables. Even if the initial conditions remain 
the same for each simulation, the random variables that shape the progression of the system will 
ensure that the end results of each run will differ from the others. In infectious disease modelling a 
stochastic system will incorporate probability distributions in its parameters that permit important 
parameters to vary across the course of a simulation run, accounting for uncertainty in the estimation 
of this parameter. 
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An example of incorporating a random variable into a system describing the dynamics of an infectious 
disease outbreak is the Reed-Frost model [71]. The population is closed and time in the system is 
divided into discrete intervals. The probability that a susceptible individual becomes infectious at time 
i + 1 depends on the number of infectious individuals at time i.  
If we assume that the probability of escaping infection by an infectious individual is q, we can write 
the following: 
𝑃𝑟(𝐼(𝑗 + 1) = 𝑛|𝑆(𝑗) = 𝑘, 𝐼(𝑗) = 𝑙) = (
𝑘
𝑛
) (1 − 𝑞𝑙)𝑛(𝑞𝑙)𝑘−𝑛 
Equation 2.1 - The probability of n infectious individuals in a population at time j+1, as described by 
the Reed-Frost model 
The modelling exercise detailed in Chapter 6 used a stochastic model to simulate disease transmission 
dynamics between different schools in a small representative population. In contrast, the model used 
in Chapter 5 is a deterministic model that simulated influenza transmission in a much larger 
population, less dependent on stochastic processes. 
AGGREGATE MODELS 
When modelling an outbreak of an infectious disease in a large population a common approach to 
reduce computational resource use is to execute an aggregate model of the studied population [70]. 
That is the model calculates the proportion of susceptible individuals that become infectious per unit 
time; the proportion of infectious individuals that recover per unit time, etc. This type of model tracks 
groups of individuals, rather than the approach used in Individual-Based models that track each 
individual in the study population. 
INCLUDING SOCIAL CONTACT PATTERNS IN MODELS OF DISEASE TRANSMISSION 
The mixing patterns of the study population can be a critical determinant of the evolution of disease 
dynamics [72]. Therefore it is important that mathematical models of infectious disease outbreaks 
account for non-random mixing patterns by incorporating appropriate parameters into the system. It 
is also key that these parameters are informed by the accurate measurement of social mixing patterns.  
Edmunds et al. (2006) [73] plotted the age of both primary and secondary cases of measles and 
meningococcal disease in England and Wales between 1995-1998 (Figure 2.2), demonstrating the 
largely assortative nature of social mixing patterns and age-clustering of cases of the diseases. This 
information can be used to inform models of infectious disease outbreaks by introducing data on 
social mixing patterns into the β parameter that describes the rate of contacts within a population. 
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Figure 2.2 - The age of primary and secondary (based on date of onset) cases of measles (open squares) 
and meningococcal meningitis (filled diamonds) in clusters in England and Wales 1995-1998 
Figure credit: [73]. 
Data on social mixing patterns can be gathered from a population using prospective surveys that 
require participants to complete regular diary entries listing the number of people they have been in 
contact with along with their age and other demographic parameters. The results of these surveys 
then permit the introduction of mixing matrices into mathematical models.  
Mossong et al. (2008) [23] used contact diaries for one day in eight European countries, asking 7,290 
recruited participants of all ages to record their contacts along with the appropriate demographic 
factors. They found that contacts made by children and adolescents are highly assortative (Figure 2.3) 
and may help to explain why this subpopulation is so important in understanding the transmission 
dynamics of certain diseases. 
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Figure 2.3 - Smoothed contact matrices for eight European countries based on all reported contacts 
Figure credit: [23].  
INFECTIOUS DISEASE OUTBREAKS IN SCHOOLS 
This section introduces the topic of school-based outbreaks and school-based vaccination 
programmes as one of the main themes of the thesis. The unique social dynamics within schools and 
the population-wide impact of infectious disease outbreaks within schools makes this subpopulation 
so important in the context of infectious disease outbreaks in the community. 
SCHOOL SOCIAL DYNAMICS 
We’ve seen the use of social contact data in mathematical models of infectious disease dynamics to 
demonstrate how an infectious disease progresses through different age groups in a population based 
on the number of effective contacts between individuals of different age groups. Mossong et al. (2008) 
reported social contact data for age groups 0 to 4 years, 5 to 9, 10 to 14 and 15 to 19 with all age 
groups up to those individuals aged 70+ years. It was suggested that the high number of close contacts 
between school aged children can sustain the transmission of some infectious diseases within this 
subpopulation [23]. 
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Figure 2.4 - The number of contacts between individuals of classes A and B over two days of the study 
in French primary schools 
Figure credit: [74].  
Further studies have sought to add detail to the contact patterns of school children. High-resolution 
contact patterns were recorded using radio frequency identification devices in French primary and 
secondary schools by Stehlé et al. (2011) and Fournet et al. (2014) respectively [74, 75]. Figure 2.4 
shows the contact matrix obtained from the primary school study and how the observed contact 
patterns differ from previously hypothesised homogeneous contact patterns due to a high degree of 
age assortativity. 
School children, therefore, are an important subpopulation to consider when implementing a new 
preventative vaccination programme in the community [19-21]. Controlling outbreaks fuelled by 
children and adolescents attending schools can reduce the wider impact of outbreaks on the larger 
community. The next section will focus on exercises in the mathematical modelling of school-based 
outbreaks of disease and potential interventions (e.g. vaccination, or some social distancing policies) 
to reduce their impact. 
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PREVIOUS OBSERVATIONAL STUDIES ON THE IMPACT OF SCHOOL-BASED INFECTIOUS DISEASE OUTBREAKS 
Outbreak Impact Measured Reference 
North Carolina, 2006 - 24% workplace absenteeism for adults acting as 
caregivers for children affected by school closure 
 
- Childcare expenses for two families ($100 and $150 
respectively) 
[76] 
Seattle, 2000-01 - 28% attack rate in school 
 
- Influenza-attributable school absence rate of 62.9 
days per 100 children 
 
- 4.2 health care visits per 100 children 
 
- 19.8 days of work missed by parents per 100 
children 
[77] 
London, 2012-13 - Reported attack rates of 67.5%, 45.2% and 34.3% in 
schools 
[78] 
Odate City, 2012-13 - 70% of households experienced ILI transmission 
after a primary case in a school-attending child 
[79] 
Table 2.2 - Measured impact of school-based seasonal influenza outbreaks 
Table 2.2 shows the measured impact of school-based seasonal influenza outbreaks for four separate 
outbreaks. Johnson et al. (2008) [76] distributed questionnaires to 220 households after an outbreak 
of influenza B in 9 schools during October and November 2006 in North Carolina; Neuzil et al. (2002) 
[77] used surveys to gather impact data from families with children attending an elementary school 
in Seattle for the 2000-01 influenza season; McCann et al. (2014) [78] described the impact of 
outbreaks of influenza B in primary schools within the Thames Valley region of London during the 
2012-13 influenza season; and surveys were sent to households in Odate City, Japan during the 2012-
13 influenza season [79]. These studies together demonstrate the impact in the community of 
infectious disease outbreaks that occur in schools, and show the importance of successfully mitigating 
this impact through previously-modelling social distancing policies or the implementation of new 
vaccination strategies targeting this subpopulation. 
OUTLINE OF STUDIES MODELLING OUTBREAKS IN SCHOOLS 
SOCIAL DISTANCING – SCHOOL CLOSURES AND CLASSROOMS CLOSURES 
Social distancing policies in schools designed to mitigate infectious disease outbreaks have been 
studied using mathematical models, with varying predicted outcomes. In a recent review of 
mathematical modelling studies for school closures as a measure to mitigate seasonal and pandemic 
influenza outbreaks, the authors reported that peak incidence was typically predicted to fall by 20-
60%, though some studies predicted an increase in this metric, usually determined by the duration 
and timing of the school closure [80]. The value of R0 was a key determinant in the effectiveness of 
the school closure, with higher values reducing the overall benefit. 
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Other studies have considered social distancing policies such as targeted class closure, targeted grade 
closure and whole school closure [81, 82], finding that targeted class closures can be as effective as 
whole school closures, and long school closures are unlikely to be cost-effective.  
School children directly affected by a social distancing policy in their school would still have contacts 
within the wider community, and the unnecessary closure of classes or grades with no infectious 
individuals leads to the introduction of many susceptible individuals into the wider community. 
Therefore whole school closures can be less effective than a more targeted approach when the 
outbreak has spread to the wider community and is not just confined to the boundaries of the school. 
VACCINATION STRATEGIES 
Vaccinating school-age children against influenza greatly reduces the total burden of disease due to 
influenza infection by both direct and indirect effects of vaccination [36]. Seasonal influenza 
vaccination programmes in schools are likely to be very cost-effective [70], in part due to the 
substantial indirect protection offered to other individuals in the population not targeted by these 
programmes. A recent systematic review of mathematical modelling studies reported that the 
majority of these studies concluded that childhood influenza vaccination was cost-effective [83]. 
THE UK INFLUENZA VACCINATION PROGRAMME EXTENSION TO HEALTHY CHILDREN 
Following on from the discussion of school-based outbreaks and studies examining cost-effective 
interventions for such outbreaks, we now introduce the extension to the UK seasonal influenza 
vaccination programme to healthy children. 
RATIONALE FOR SCHOOL-BASED SEASONAL INFLUENZA VACCINATION PROGRAMMES 
Children and adolescents attending schools play a large role in the spread of influenza in the 
community [19-21]. Children have a large number of contacts outside their household [22] and indeed 
transmission within schools is maintained because of the high number of close contacts between 
school children [23] as well as less acquired immunity in children [22, 25], poor hygiene habits [24] 
and a longer period of increased virus-shedding once infected [84, 85]. The advantage of administering 
a free-of-charge vaccination programme in schools is that easy access to a preventative medical 
intervention is offered to the community and commonly-cited barriers to vaccination such as time 
demands, inconvenience and cost are eliminated [86, 87].  
OBSERVATIONAL STUDIES ESTABLISHING THE IMPACT OF SCHOOL-BASED PROGRAMMES 
School children are an appropriate target for seasonal influenza vaccination due to their role in 
infectious disease transmission and their accessibility for vaccine administration, first demonstrated 
by Monto et al. (1970) in Michigan [88] then subsequently in many other communities [26-31]. The 
study conducted in Tecumseh reported reductions in the weekly mean rates of respiratory illness for 
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all age groups during the period of the Hong Kong influenza outbreak in 1968-69 after a school-based 
seasonal influenza vaccination programme that achieved mean coverage of 85.8% for enrolled 
children. The vaccination programme was credited with interrupting the influenza transmission chain, 
providing indirect protection to unvaccinated individuals in the community. 
 School-based influenza vaccination reduces excess mortality and influenza complications in the wider 
population [27, 89]. The studies conducted in US Navy day care centres in California [26] and in 
communities in the US [27], Italy [28], Brazil [29] and Canada [30] have demonstrated that vaccinating 
children has the potential to reduce influenza episodes both in the vaccinated individuals, but also in 
individuals of all age groups who were not vaccinated, or who did not successfully seroconvert 
following vaccination. 
MATHEMATICAL MODELLING OF THE IMPACT OF SCHOOL-BASED PROGRAMMES 
Annual influenza vaccination for healthy children has been repeatedly shown to be a cost-effective 
extension of existing national influenza vaccination programmes [83]. Indeed, many studies using 
dynamic transmission modelling have shown economic benefits in vaccinating healthy children for 
seasonal influenza [36, 70, 90-97]. The interruption of community-wide transmission to reduce the 
burden of disease in school children, as well as in the unvaccinated communities, is estimated to result 
in large reductions in healthcare resource use, costs, influenza-attributable deaths and QALYs lost due 
to influenza [94]. 
A systematic review published in 2008 examined the economic evaluations of influenza vaccination 
for children that included direct individual benefits and indirect societal benefits [96]. Ten of the 15 
studies included in the review reported that such a vaccination strategy would be either cost-effective 
or cost-saving. 3 studies reported that vaccination was either cost-saving or cost-effective in certain 
conditions and 2 studies reported that vaccination provided no benefit regardless of the economic 
evaluation perspective considered. 
AN EXTENSION TO THE INFLUENZA VACCINATION PROGRAMME IN ENGLAND 
The Joint Committee on Vaccination and Immunisation (JCVI) in 2012 recommended extending the 
influenza vaccination programme to all children between the ages of 2-16 years [32]. This extension 
will be rolled out over several seasons and will see a live-attenuated influenza vaccination (LAIV) 
offered to children each year with the majority of vaccines administered in school settings.  
The LAIV is more effective than inactivated vaccines in children and adolescents and may also offer 
protection against drifted strains of influenza as well as herd immunity effects seen in the elderly 
population even at low LAIV coverage levels in children and greater cost-effectiveness than the TIV 
alternative [98-102]. A recent cluster randomised trial in Canada found that LAIV administration in 
school-based vaccination programmes was associated with increased vaccine uptake when compared 
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to intra-muscular injection vaccines [103], and a large comparative trial of TIV and LAIV in children 
aged 6-59 months showed a 55% high relative efficacy for LAIV [99].  
SUPPORTING THE JCVI RECOMMENDATION 
The JCVI recommendation was supported by three studies. The first used mathematical models to 
assess a series of alternative vaccination scenarios to reduce transmission of seasonal influenza using 
infection surveillance data from 1995 to 2009 [104] and recommended that targeting children in 
addition to older adults was the most efficient use of the seasonal influenza vaccine. The second study 
estimated the total burden of seasonal influenza in England and demonstrated the benefit of a 
childhood vaccination programme in addition to older adults to offer both direct protection to 
children as well as indirect protection to the wider population [51]. The final study used the same 
models mentioned above to assess the cost-effectiveness of alternative vaccination programmes and 
reported that the most efficient strategy was to extend the previous vaccination policy to school-age 
children whilst maintaining good coverage in those individuals in a clinical at-risk group [33]. The 
inclusion of school-age children was the most cost-effective extension to the existing vaccination 
programme in an incremental cost-effectiveness analysis. 
PILOTING THE EXTENSION TO THE INFLUENZA VACCINATION PROGRAMME IN ENGLAND, 2013-14 
A pilot of the extended vaccination policy was implemented for the 2013-14 influenza season. Seven 
geographically discrete areas of England were chosen to offer vaccination against seasonal influenza 
(A/California/7/2009 (H1N1)pdm09-like strain, A/Victoria/361/2011 (H3N2)-like strain and 
B/Massachusetts/2/2012-like strain) to primary school age children between September 2013 to April 
2014. Different models of delivery were included in the pilot, mainly focused on school-based and 
community-based administration. 
DEMOGRAPHICS 
The 7 geographically discrete areas chosen for the pilot programme were Cumbria, Gateshead, Bury, 
Leicester City and Rutland, Havering, Newham and South East Essex counties. Children aged from 4 – 
11 years were offered one dose of the live-attenuated influenza vaccination. 6 geographical areas 
implemented a school-based vaccination programme whilst 1 area delivered through pharmacies and 
primary care facilities. 
COVERAGE ACHIEVED  
Coverage in the seven areas varied from 35.8% (13,010/36,360) to 71.5% (17,687/24,723) with an 
average coverage level of 52.5% (104,792/199,475) for the pilot [50] (Figure 2.5). Six of the seven 
geographical areas used a school-based vaccination programme for which the overall average 
coverage level was 56.3% (91,782/163,115). In addition to the primary school cohort, children aged 
2-3 years were offered vaccination via primary care. During the 2013-14 influenza season, provisional 
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vaccination uptake for this cohort was 42.6% and 39.5% respectively [105].  Uptake varied according 
to deprivation, ethnicity and religious belief [106]. 
 
Figure 2.5 - Cumulative uptake of live attenuated influenza vaccine in primary school-age children in 
pilot areas, England, 2013-14 influenza season 
Figure credit: [50]. Contains Ordnance Survey data © Crown copyright and database right 2016. 
Contains National Statistics data © Crown copyright and database right 2016.  
PILOTING THE EXTENSION TO THE INFLUENZA VACCINATION PROGRAMME IN ENGLAND, 2014-15 
A further pilot of the extension to the influenza vaccination programme was conducted during the 
2014-15 influenza season. All children aged 2 – 4 years in addition to children in primary schools (aged 
4 – 11 years) and secondary schools (only 11 – 13 years) in pilot areas were offered a live-attenuated 
quadrivalent against seasonal influenza (A/California/7/2009 (H1N1)pdm09-like virus, 
A/Texas/50/2012 (H3N2)-like virus, B/Massachusetts/2/2012-like virus and B/Brisbane/60/2008-like 
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virus) between September 2014 and March 2015 [107]. Most pilot areas ran school-based 
administration, with two areas running a pharmacy-based model and one running a GP-based model. 
DEMOGRAPHICS 
Children attending primary schools in Cumbria, Greater Manchester, Leicestershire and Lincolnshire, 
London and Essex, Northumberland, Tyne and Wear formed part of the target population. The rest of 
the target population came from children of ages 11 – 13 years attending secondary schools in Arden, 
Birmingham and Black Country, Greater Manchester, East Anglia, Essex, Herefordshire and 
Worcestershire, Lancashire, London, North Yorkshire and Humber, Shropshire and Staffordshire, 
South Yorkshire and Bassetlaw and West Yorkshire (Figure 2.6). 
  
Figure 2.6 - Cumulative uptake of live attenuated influenza vaccine in primary school-age children in 
pilot areas, England, 2014-15 influenza season 
Figure credit: [107]. Contains Ordnance Survey data © Crown copyright and database right 2016. 
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COVERAGE ACHIEVED  
196,994 primary school children received one dose of the LAIV quadrivalent vaccine, giving an overall 
coverage level of 56.8%, though this varied from 32.3% to 63.1% across the pilot areas. 184,975 
secondary school children received one dose of the vaccine, an overall coverage level of 49.8% that 
varied from 21.2% to 62.0% across pilot areas. The authors reported that school-based programmes 
consistently achieved higher coverage than pharmacy-based programmes in both age groups. In 
addition, 44.1% of children aged 2 – 4 years received their seasonal influenza vaccine. 
HETEROGENEOUS VACCINE COVERAGE 
Previously we’ve discussed the uptake of the seasonal influenza vaccine in pilot areas during the 2013-
14 and 2014-15 influenza seasons. Although encouraging mean coverage was achieved across the pilot 
as a whole the coverage varied between pilot areas. For example, coverage in one pilot area in 2013-
14 reached 71.5% in primary schools whereas one pilot area in 2014-15 reported coverage of just 
21.2% in secondary schools [50, 107]. The mathematical modelling and cost-effectiveness analysis that 
justified the JCVI recommendation to extend the vaccination programme to health children assumed 
that coverage would be 50% in both primary and secondary school groups [33]. 
It is unclear if the potential heterogeneous coverage between different areas of the United Kingdom 
would affect the effectiveness of the new vaccination programme. Before examining that issue, first 
we discuss heterogeneity in vaccination coverage in more detail. 
DEFINITION OF AND REASONS FOR HETEROGENEOUS COVERAGE 
Damm et al. (2014) modelled the introduction of live-attenuated influenza vaccine for health children 
in Germany and when reporting their final estimate for the cost-effectiveness ratio they assumed 
uptake of 50% [90]. Baguelin et al. (2010) assumed that vaccination coverage against A/H1N1v would 
reach 70% in at-risk groups and 40% in all other groups targeted [108]. Both these modelling studies 
assumed a degree of homogeneity for the coverage of the new vaccination programme, but in 
vaccination coverage heterogeneity can occur for many different reasons. Lower vaccination uptake 
is associated with higher levels of deprivation in the community along with a higher proportion of non-
white residents [109-111]. For some groups, religious beliefs can influence the decision to vaccinate 
children [112-115], for example fears over the new LAIV seasonal influenza vaccination during 2013-
14 were raised within the Jewish and Muslim communities due to the porcine origin gelatin used in 
the manufacturing of the vaccine [116]. 
One major consequence of this heterogeneity is that some communities are more likely to experience 
infectious disease outbreaks than others if infection is introduced to an area of low coverage. Indeed, 
some studies confirm that areas with high rates of vaccine hesitancy have a greatly increased risk of 
outbreaks [34, 117]. Unvaccinated “pockets” or areas of low vaccination coverage have been 
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associated with outbreaks of vaccine-preventable diseases [34, 118]. Another consequence of vaccine 
refusal is that it negatively affects the health outcomes of those individuals who remain unvaccinated 
in the community and subsequently become infected in later life [119]. For infections like measles, 
varicella and rubella with health outcomes that increase in severity has age increases, vaccination 
programmes that target young children mean that the risk of being one of the last members of that 
community to be vaccinated directly increases the risk of complications from infection. Heterogeneity 
in vaccination coverage through vaccine refusal exposes unvaccinated individuals to an increased risk 
of hospitalisation and death. 
CONSEQUENCES OF HETEROGENEOUS COVERAGE 
Even when global vaccination coverage is high, local pockets of low vaccination coverage leave 
communities at risk of sustained infectious disease transmission. Omer et al. (2008) identified 23 
clusters of low vaccination for pertussis in Michigan and six clusters of pertussis cases occurred during 
the study period, with significant overlap between the two [34]. Overall vaccine exemption clusters 
were three times more likely to be in a pertussis cluster than non-vaccine exemption clusters (odds 
ratio 3.02, 95% CI: 2.52-3.61). The community-level risk of pertussis outbreaks increased when 
vaccine-exemption clusters existed.  
A similar situation was described in a study by van den Hof et al. (2001) when an outbreak of measles 
occurred in The Netherlands, a country with high measles vaccination coverage (96%) [35]. An 
orthodox reformed school of 412 pupils had a very low measles vaccination coverage of 7% and the 
introduction of the measles virus into the school caused an outbreak with an attack rate of 91% in the 
susceptible population. The authors concluded that clusters of unvaccinated individuals is a critical 
factor for measles elimination.  
The level of heterogeneity in measles vaccination coverage and its implication for localised outbreaks 
was further explored by Choi et al. (2008) by modelling the potential for measles transmission in 
England after studying the vaccination uptake in the country [62]. They found that 99 former district 
health authorities had an increased risk of sustained measles epidemics due to their low MMR 
coverage and the subsequent impact on the number of susceptible individuals within their borders.  
Low measles vaccination coverage was also responsible for an outbreak in Campania in Italy, where 
estimated coverage reached on 65% in 2002 [120]. Unvaccinated school-age children were most 
affected by the outbreak. Localised low vaccination coverage for measles infection was identified as a 
key factor for measles outbreaks in Germany by Herzog et al. (2010) [121]. 
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MODELLING HETEROGENEOUS COVERAGE 
Metapopulation frameworks (the division of a population into smaller subpopulations, separate from 
each other but with interactions between the subpopulations) have provided new perspectives for 
mathematical modelling exercises that are used to evaluate the potential effectiveness of 
preventative vaccination programmes. The new seasonal influenza vaccination programme in England 
was implemented after mathematical modelling demonstrated that it was both highly effective at 
reducing the total burden of seasonal influenza [104], and that it was also very cost-effective [33]. 
However, the mathematical model did not anticipate heterogeneity in vaccination coverage, 
something seen in recent studies that reported on regional pilots [50, 107]. Therefore, it may be useful 
to consider methods of incorporating heterogeneous coverage for the national influenza vaccination 
programme to test the robustness of the conclusion that the programme will be very cost-effective, 
or to identify potential weaknesses in the programme caused by potential heterogeneous coverage.  
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Chapter 3 - Measuring health utilities and health-related 
quality of life in children and adolescents: a systematic 
literature review 
Portions of this section were presented as a poster presentation at the London School of Hygiene and 
Tropical Medicine Research Degree Poster Day in January 2015 and published in PLoS ONE in August 
2015 [1]. 
ABSTRACT 
BACKGROUND 
The objective of this review was to evaluate the use of all direct and indirect methods used to estimate 
health utilities in both children and adolescents. Utilities measured pre- and post-intervention are 
combined with the time over which health states are experienced to calculate quality-adjusted life 
years (QALYs). Cost-utility analyses (CUAs) estimate the cost-effectiveness of health technologies 
based on their costs and benefits using QALYs as a measure of benefit. The accurate measurement of 
QALYs is dependent on using appropriate methods to elicit health utilities.  
OBJECTIVE 
We sought studies that measured health utilities directly from patients or their proxies. We did not 
exclude those studies that also included adults in the analysis, but excluded those studies focused only 
on adults.  
METHODS AND FINDINGS 
We evaluated 90 studies from a total of 1,780 selected from the databases. 47 (52%) studies were 
CUAs incorporated into randomised clinical trials; 23 (26%) were health-state utility assessments; 8 
(9%) validated methods and 12 (13%) compared existing or new methods. 22 unique direct or indirect 
calculation methods were used a total of 137 times. Direct calculation through standard gamble, time 
trade-off and visual analogue scale was used 32 times. The EuroQol EQ-5D was the most frequently-
used single method, selected for 41 studies. 15 of the methods used were generic methods and the 
remaining 7 were disease-specific. 48 of the 90 studies (53%) used some form of proxy, with 26 (29%) 
using proxies exclusively to estimate health utilities. 
CONCLUSION 
Several child- and adolescent-specific methods are still being developed and validated, leaving many 
studies using methods that have not been designed or validated for use in children or adolescents. 
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Several studies failed to justify using proxy respondents rather than administering the methods 
directly to the patients. Only two studies examined missing responses to the methods administered 
with respect to the patients’ ages. 
INTRODUCTION 
BACKGROUND 
Evaluation of healthcare interventions and technologies commonly assess both the cost and 
consequences of interventions, in addition to effectiveness and safety. Economic evaluations are 
increasingly being used by healthcare systems around the world before a decision is made on whether 
to recommend a new intervention. In the United Kingdom, for example, the National Institute for 
Health and Care Excellence (NICE) requires that the appraisal of new interventions and technologies 
includes a cost-effectiveness analysis containing an assessment of benefits and resource use [2]. A 
requirement in the evidence submitted is a cost-utility analysis (CUA) that compares costs with 
benefits using quality-adjusted life years (QALYs), a measure incorporating the length of life and 
quality of life.  
Quality of life is measured using health utilities that take values between 0 and 1, corresponding to 
utilities for dead and perfect health respectively. These utilities measured pre- and post-intervention 
are combined with the time over which the health states are experienced to calculate the QALYs that 
can be gained from new interventions. When evaluating several new health technologies the ratio of 
expected additional total costs to the expected additional QALYs gained incrementally is estimated 
for each technology, then cost-effectiveness is evaluated by comparing the incremental cost-per-QALY 
ratio against a pre-determined cost-effectiveness threshold, which in the UK is between £20,000 and 
£30,000 per QALY gained [2].  
A CUA is also the recommended economic evaluation for submissions to the Canadian Agency for 
Drugs and Technologies in Health (CADTH) [3]; in Australia with submissions to The Pharmaceutical 
Benefits Advisory Committee (PBAC) [4]; in Sweden with submission to The Swedish Council on Health 
Technology Assessment (SBU) [5]; in New Zealand with submissions to The Pharmaceutical 
Management Agency (PHARMAC) [6] and other countries [7]. 
Health state utility values are usually obtained from one of two sources. Either the relevant health 
states are directly valued, using techniques such as Time Trade Off (TTO) or Standard Gamble (SG), or 
an existing tariff is applied. This latter approach is generally used when valuing generic health states 
(such as the EuroQol EQ-5D [8]). The tariff to be applied is usually based on valuations of a general 
population sample again using techniques such as TTO and SG. The TTO is a choice-based method that 
establishes for an individual how much time in full health is equivalent to a specified period of time 
spent in a particular ill-health state.  The SG is another choice-based method that identifies the 
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probability of being in a better health state that makes an individual indifferent between the certainty 
of being in an intermediate health and a gamble between a worse health state and a better health 
state. 
Measuring utilities for health-related quality of life (HRQoL) for children and adolescents is a 
developing field of research. Methods used to obtain health utilities from adults are well established 
but many have not been validated for use in children and adolescents. NICE states that the EQ-5D is 
the preferred method for use in CUAs that focus on the adult population [2], but no specific guidance 
has been given to help health economists choose an instrument designed for children and 
adolescents. Indeed, NICE did not make a specific recommendation for a particular instrument in the 
publication of their most recent guidance on technology appraisal [2]. 
There is evidence that children and adolescents are able to report on the state of their own health [9]. 
Children aged 3 years can report on feelings of nausea and pain that are reliable and clinically 
meaningful [10-12]. If children can convey the state of their health using a standardised method such 
as EQ-5D or HUI-2 then accurate and meaningful health utilities may be obtained for a range of 
childhood illnesses and conditions, which would be highly desirable for conducting CUAs.  
It is important to recognise that methods suitable for young children may not be applicable to 
adolescents [13, 14], in the same way that adult-specific methods may not be appropriate for 
recording health utilities of adolescents [15]. Children may lack the cognitive ability to evaluate their 
health using abstract concepts in adult-specific indirect methods and direct methods such as TTO and 
SG. In addition, young children may lack the required linguistic skills to answer questions about their 
preferences for health using systems designed for self-completion by older children. The 
understanding of disease and its effect on HRQoL changes with the child’s age, consequently both the 
measurement and valuation of changes in health due to disease need to be facilitated using age-
specific instruments [13, 16]. 
Some methods have been developed for use exclusively in children and adolescents, and some 
existing adult-specific methods have been modified to make them child-friendly. The EQ-5D has been 
amended so that the questions for each dimension of health are easier to read and more accessible 
to children, resulting in a new child-friendly method called the EQ-5D-Y [17]. However, this uses the 
same utility weights in each dimension as the adult version, so does not yet incorporate child and 
adolescent preferences for health states. Adult preferences for health states may be different from 
the preferences of children and adolescents and the dimensions included may not cover all 
dimensions of health relevant to children and adolescents [18]. 
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GENERIC AND DISEASE-SPECIFIC CALCULATION METHODS 
Direct and indirect methods for the calculation of health utilities fall into two distinct domains – 
generic and disease-specific. Generic methods can be used to measure HRQoL in adults, children and 
adolescents (where appropriate) for a range of conditions, both chronic and acute. Commonly used 
generic methods include the EQ-5D and HUI-2. Disease-specific methods measure HRQoL with 
reference to a particular condition, such as the Asthma Control Questionnaire (ACQ) [19] and the 
Pediatric Asthma Health Outcome Measure (PAHOM) [20].  
The advantage of using generic calculation methods in CUAs is that results can be compared across 
populations, conditions, and for different treatments or interventions [21]. Disease-specific methods 
have the benefit of being more sensitive to small changes in the condition of the patient in question 
and may describe the functioning of a patient with the condition with greater clarity than a generic 
classification system that may overlook some aspects of HRQoL [22], but utilities calculated using 
these instruments lack comparability across different diseases.  
MEASUREMENT BY PROXY 
When measuring the HRQoL of young children some authors prefer to gather the health utilities via 
proxies as young children may not have the cognitive ability to evaluate their health and/or complete 
the required measurement tasks [18]. Proxy respondents include the child’s parents, clinicians and 
teachers. Parents are deemed to be the most useful proxies as they are the most familiar with their 
child’s health and life [23, 24], though it has been suggested that parents may misjudge the health of 
their child owing to their own anxiety during the illness [25, 26] and further studies have shown 
differences between parent and child ratings for the child’s health [27-29]. Clinicians’ knowledge of 
children’s conditions, symptoms, and functioning makes them useful proxies when evaluating HRQoL, 
though they will not have the same contact with children during their time away from clinics at home 
or in school [23, 30] so results are of questionable validity [31]. Teachers will not be able to provide 
HRQoL assessments for the child at home or in clinics [23] but will be able to evaluate a child’s 
emotional and physical functioning. 
In a systematic review published in 2005, Griebsch et al. [32] concluded that methods for measuring 
health utilities in children need further development. They noted the lack of methods that account 
for the development of the child, methods for children aged younger than 5 years, and a full 
understanding of the role of proxies in the evaluation of HRQoL in children and adolescents. Ravens-
Sieberer et al. (2006) concluded that HRQoL of children and adolescents can and therefore should be 
ascertained by self-rating [33].   
When performing a CUA in children and adolescents researchers must determine the best way to 
obtain utilities: expert opinion, measurement using patients or measurement using proxies. Each 
option will impose limitations on the study, and if the protocol calls for measurement then the 
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researchers need to choose the appropriate method. The method used in CUAs should be justified as 
each has limitations relevant to the estimation of health utilities and QALYs. 
RESEARCH QUESTIONS 
The objective of this review was to evaluate the application of direct and indirect methods used to 
measure health-related quality of life in children and adolescents in the context of cost-utility studies. 
In doing so, we aimed to answer the following questions: 
1. What direct and indirect methods have been used to obtain health utilities from children and 
adolescents in the context of cost-utility studies? How frequently have they been used? 
2. If the method has not been validated for use in the study population do the authors 
acknowledge the limits of the method and therefore the study? 
3. For study populations that include adults with children and adolescents, did the younger 
participants complete the calculation method to the same level as the adult participants? 
4. When proxies have been used to obtain health utilities have the authors acknowledged the 
problems related to obtaining such utilities from proxies rather than patients? 
5. How many studies have used HRQoL classification systems to obtain utilities for infectious 
diseases? 
PREVIOUS REVIEWS 
From whom were health utilities 
measured in the study? 
Direct measurement 
methods used 
Indirect measurement 
methods used 
Child (n = 5) Time trade-off EuroQol EQ-5D 
Parent as proxy (n = 10) 
Standard Gamble, 
Time trade-off, 
Visual Analogue Scale 
EuroQol EQ-5D, 
Health Utilities Index, 
Quality  of Well-Being Scale 
Health care provider as proxy (n = 3) None 
EuroQol EQ-5D, 
Health Utilities Index, 
16D-questionnaire 
Adults as proxy (n = 1) Time trade-off None 
Parent as unit of analysis (n = 1) Time trade-off None 
Table 3.1 - Results from Kromm et al. (2012) for studies that measured health utilities as part of a cost-
utility analysis 
Kromm et al. (2012) [15] used the Pediatric Economic Database Evaluation (PEDE) project’s online 
database to find a total of 213 CUAs for children and adolescents published in English between 1997 
and 2009 to use in a quality appraisal. Citing that CUAs were 8% of all published economic evaluations 
between 1976 and 2001 [34] and also that 10% of economic evaluations for children and adolescents 
published between 1980 and 1999 were CUAs [35], they assessed the quality of such CUAs using the 
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57-item Pediatric Quality Appraisal Questionnaire (PQAQ) [36]. Only 16 (8%) of the studies included 
in the review gathered health utilities as part of the analysis (Table 3.1). 
Other studies used health utilities from the researchers or literature (63%), health care provider 
opinion (6%), disability-adjusted life years (DALYs) (25%) and the remainder did not state the source 
of the utilities (1%). Kromm et al. (2012) argued that utilities gathered from the published literature 
might not be valid [37]. Study authors may assume that adult health utilities apply to children and 
adolescents and assume a uniform utility throughout childhood and adolescence, ignoring the child’s 
development [13, 14]. In conclusion, the authors stated that new instruments should be developed to 
obtain utilities from children, rather than relying on adult utilities from the literature and utilities 
gathered via proxy.  
Ladapo et al. (2007) [38] concentrated on CUAs in the United States, comparing analyses for adult, 
children and adolescent interventions. Using a database developed by the Tufts-New England Medical 
Center in Boston, they compared various aspects of 35 CUAs for children and adolescents with 491 
adult CUAs. They found that generic classification systems (EQ-5D, Quality of Well Being (QWB) and 
HUI only) were used in 29% of analyses for children and adolescents and such CUAs are 
methodologically similar to adult CUAs. The leading primary disease category for CUAs for children 
and adolescents was infectious, representing 31% of all such CUAs. Finally, the authors noted that 
published cost-utility ratios tend to be lower for children and adolescents than for adults. 
Griebsch et al. (2005) [32] considered all CUAs for patients aged younger than 17 years published until 
April 2004 in the Medline, Embase, Econlit, York Database of Abstracts of Reviews of Effectiveness, 
NHS Economic Evaluation Database , the Harvard Cost-Utility Analysis Database  and the Database of 
the PEDE project. 63 direct or indirect calculation methods were used to estimate health utilities, of 
which 22 (35%) used a generic method. The authors concluded that the variation in methods for 
estimating health utilities in children and adolescents meant that the process was not yet 
standardised. They called for the clear justification of the choice of methods for measurement. 
Recently, Adlard et al. (2014) [39] discussed how the practice of paediatric CUAs has evolved over 
time, with reference to methods described in the NICE reference case [2]. The review considered 43 
studies published between May 2004 and April 2012, of which only 11 obtained health utilities from 
children with the remaining 32 studies using utilities published in the literature. The authors noted 
that since NICE suggested investigators use the HUI-2 to obtain health utilities from children there has 
been no increase in use of this instrument, with many authors seeking to use the EuroQol EQ-5D or 
its derivatives. Adlard et al. recommended that research funding be targeted at those studies seeking 
to estimate health utilities directly from children, given a lack of published data specific to this age 
group and wide variation in the methods used to obtain these data in previous work. 
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In contrast to the reviews cited, this review examined the methods used by researchers and health 
economists to estimate health utilities for children and adolescents and the extent of the variation 
between them. Details of all methods administered in each study were collated to evaluate the 
suitability of each system given the age of study participants, mode of completion and the stated 
justification for use of each calculation method. 
METHODS 
CONDUCTING THE REVIEW 
ELIGIBILITY CRITERIA 
Studies eligible for inclusion in the final review needed to include primary data to measure health 
utilities from patients aged 17 years or under, through the administration of at least one direct or 
indirect method completed by either the patients or their proxies. Studies that included adult patients 
were not excluded, but studies that gathered HRQoL data exclusively from adults were excluded. We 
did not exclude studies based on language of publication, date of publication, journal or disease. 
Studies that used other methods to calculate HRQoL scores that are incapable of generating utilities 
without a further mapping process were excluded unless the study also used a method to calculate 
health utilities. 
Eligibility was not restricted to CUAs using primary data for HRQoL; studies detailing the validation of 
methods and studies that calculated health utilities for specified conditions but stopped short of 
collecting data related to healthcare resource use and patient-borne costs to calculate a cost-per-
QALY ratio were eligible for inclusion. 
Studies using health utilities gathered from previous studies were excluded, as were reviews, 
comment pieces and conference abstracts. All studies included in the full-text review had their 
references checked for additional studies to include in the review that did were not found through 
the online database search. 
INFORMATION SOURCES 
We searched for articles in the following databases: CAB Abstracts, Global Health, Ovid MEDLINE(R), 
Econlit and Embase Classic+Embase.  
SEARCH 
The search terms were taken from a systematic review published in 2005 by Griebsch et al. [32], 
appraising published CUAs in child and adolescent health care and looking at further issues still in 
doubt within the measurement of HRQoL in children and adolescents: 
1. Infant, newborn/ 
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2. Infant/ 
3. Child, preschool/ 
4. Child/ 
5. Adolescent/ 
6. 1 or 2 or 3 or 4 or 5 
7. expand quality-adjusted life years/ 
8. cost-utility or cost utility 
9. cost-effectiveness or cost effectiveness 
10. 7 and 9 
11. 8 or 10 
12. 11 and 6 
The search was performed on 30th September 2014. 
DATA ITEMS 
The following data were extracted from papers included in the full-text review: 
1. Reference  
2. Year of publication 
3. Country 
4. Direct or indirect calculation method(s) used 
5. Health condition (if applicable)  
6. Sample size 
7. Age range of participants 
8. Mode of assessment: 
9. Self-completion of questions 
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10. Completion of questions via proxy (parents, clinicians, primary caregivers, etc.) 
a. Patient interviews 
b. Interviews with proxies (parents, clinicians, primary caregivers, etc.) 
c. Other methods 
d. Methods not stated 
11. Study type: 
a. Validation of calculation method 
b. CUA 
c. Health utility assessment 
d. Comparison of calculation methods 
12. Investigation of infectious disease HRQoL impact 
We classified each study as one of four study types by the primary aim of each study: validations of 
calculation methods sought to validate or derive an instrument for estimating health utilities; CUAs 
first estimated health utilities then used these utilities in an economic evaluation; health utility 
assessments measured the burden of disease in individuals using health utilities; and comparisons of 
calculation methods used two or more instruments to measure health utilities then compared results. 
In addition, each paper was analysed to ascertain whether or not the method(s) used had been 
justified for use in the cohort, along with the acknowledgment of any data collection issues that were 
related to the participants’ understanding of the calculation method.  
RESULTS  
STUDY SELECTION 
INCLUSION AND EXCLUSION OF STUDIES 
Study selection: 1,780 studies were retrieved from an online database search and were imported into 
an EndNote X7 library. 433 studies were removed from the list as duplicates. The remaining 1,347 
studies underwent a title, abstract and type of publication review to exclude studies that did not meet 
the inclusion criteria. The remaining 227 studies were submitted for a full-text review. 150 studies 
were excluded from the full-text review as they did not use direct or indirect methods to gather 
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primary data for HRQoL in children and adolescents, whilst an additional 13 studies were found in the 
list of references. In total, 90 studies were included in the review (Figure 3.1). 
 
 
Figure 3.1 - Identification of studies of measuring HRQoL in children and adolescents 
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YEAR AND COUNTRY OF PUBLICATION 
 
Figure 3.2 - Year of publication for studies included in the review 
The earliest publication date for a study included in the review was 1994 (Figure 3.2). Since then the 
publication of measurements of health utilities in children and adolescents has steadily increased. The 
year with the most publications was 2010. 
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Figure 3.3 - Countries featured in studies using direct or indirect calculation methods for obtaining 
health utilities from paediatric patients 
25 different countries were featured in the studies included in the review (Figure 3.3). The UK was 
featured the most. Three studies included multiple countries [40-42]. 
STUDY CHARACTERISTICS 
TYPE OF STUDY 
47 studies (52.2% of 90) were CUAs of which 21 [43-63] (44.7% of 47) were incorporated into 
randomised controlled trials for interventions. 23 [40, 41, 64-84] studies (25.6% of 90) were health-
state utility assessments. Eight [20, 85-91] studies (8.9% of 90) were validations of calculation 
methods. The remaining 12 [63, 92-102] studies (13.3% of 90) were comparisons of calculation 
methods. 11 studies (12.2% of 90) had secondary aims of either comparing calculation methods (seven 
studies [63, 70, 72, 76, 78, 85, 89]) or providing health-state utility assessments (four studies [20, 42, 
94, 103]). 
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CALCULATION METHODS USED 
Family of calculation 
method 
Number of 
methods in family 
Frequency 
of use 
Direct Calculation 3 32 
EuroQol 3 52 
Health Utilities Index 2 26 
Short Form 3 8 
Other 11 19 
 22 137 
Table 3.2 - Frequency of use for calculation methods found during the review 
The 90 studies used 22 unique calculation methods to gather health utilities, with the total frequency 
of use in all studies being 137. 7 calculation methods were disease-specific and were used 11 times 
(8.0% of 137) in all. The 15 generic calculation methods were used 126 times (92.0% of 137).The 
EuroQol collection of indirect calculation methods was the most widely used, accounting for 38.0% of 
the total frequency of use (Table 3.2). The EQ-5D was used 41 times with its derivatives the EQ-5D-Y 
(used 10 times) and EQ-5D+ (a modification of the EQ-5D to include an additional dimension for 
cognitive functioning, used once) used separately. Direct calculation methods were also common, 
used 24.4% of the time. The stand-alone Visual Analogue Scale (VAS) was used 14 times, with the 
direct calculation methods of the SG and TTO each used nine times. The Health Utilities Index 
collection of indirect calculation methods was used 26 times (Table 3.3). 
11 studies did not specify the age range of all participants. Four of these studies stated the mean age 
of participants; one study used a hypothetical cohort of child and adolescent patients but did not 
specify any demographic details of this hypothetical cohort; three did not give any details of the ages 
at all but the title and/or study details refer to child and adolescent patients; the three remaining 
studies indicated in aggregated results tables that some children and adolescents participated without 
elaboration of demographic details. 
The number of participants varied from small studies of six children and adolescents [104] to studies 
sampling from large national databases of patients that included 84,443 patients of all ages [66] in 
their evaluation. 
35 studies gathered health utilities exclusively from child and adolescent patients. 48 studies 
administered the calculation methods to adults whilst the remaining seven studies did not specify the 
age range of patients or did not present enough detail about the age range to determine the overall 
age of the cohort. 10 studies did not specify how the calculation methods were completed. 
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Abbreviation Methods of obtaining utilities Generic or 
disease-specific 
Freq. 
of use 
15D 15D Instrument [105] Generic 1 
ACQ Asthma Control Questionnaire [106] Disease specific 3 
AQoL-6D Assessment of Quality of Life 6D [107] Generic 1 
CAVE Escala de calidad de vida del niño con epilepsia [108] Disease specific 1 
CHU-9D Child Health Utility 9D [109] Generic 3 
EQ-5D EuroQol 5D [110] Generic 41 
EQ-5D+ Expanded EuroQol 5D Disease specific 1 
EQ-5D-Y EuroQol 5D Youth Version [111] Generic 10 
HALex Health and Activities Limitation Index [112]  Generic 1 
HUI-2 Health Utilities Index 2 [113] Generic 10 
HUI-3 Health Utilities Index 3 [113] Generic 16 
Mini AQLQ Mini Asthma Quality of Life Questionnaire [114] Disease specific 2 
PAHOM Pediatric Asthma Health Outcome Measure [20] Disease specific 2 
PAQLQ Paediatric Asthma Quality of Life Questionnaire [115] Disease specific 1 
QLQ-C30 EORTC Quality of Life Questionnaire-Core 30 [116] Disease specific 1 
QWB Quality of Well Being [117] Generic 3 
SF-12 Short Form 12 [118] Generic 2 
SF-36 Short Form 36 [119] Generic 4 
SF-6D Short Form 6D [120] Generic 2 
SG Standard Gamble [121] Generic 9 
TTO Time Trade Off [122] Generic 9 
VAS Visual Analogue Scale [123] Generic 14 
Table 3.3 - Direct and indirect calculation methods to obtain health utilities from the paediatric 
population 
ANALYSIS OF THE USE OF DIFFERENT CALCULATION METHODS 
MEASUREMENT BY PROXY 
54 studies administered calculation methods directly to children and adolescents in line with previous 
recommendations that they are able to evaluate their own health states [9-12], although 22 of these 
also used at least one method of proxy completion for at least one of the calculation methods. Of 
these 22 studies, 16 used parental proxies; four used clinician proxies; and three used caregiver 
proxies. 
26 studies used proxies exclusively, with 17 using parental proxies, six using clinician proxies and five 
other proxies. One study used a combination of different proxies to obtain health utilities. 
Some studies commented on the use of proxies to obtain health utilities: Cheng et al. (2000) [124] 
acknowledged that proxy reporting may overestimate health utility gains for cochlear implants; Chiou 
et al. (2005) [20] discussed issues around the use of parental proxies in their study, stating that 
parental preference for health may be different from child preferences; Jelsma & Ramma (2010) [98] 
recommended the use of self-reporting rather than proxy-reporting, acknowledging the potential 
issues with proxy-reporting; Oostenbrink et al. (2002) [101] stated that health utilities for CUAs should 
be measured from patients rather than proxies, as proxies may have difficulty evaluating the impact 
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of conditions on dimensions of health such as pain and emotion; Tilford et al. (2005) [80] called for 
more research to be conducted on calculation methods for young child when discussing the issues 
surrounding the use of proxies; Tilford et al. (2012) [103] cite the use of proxies as a limitation in their 
study; Wasserman et al. (2005) [83] acknowledged a potential discrepancy between patient- and 
proxy-reported health utilities in their study. 
However, several other studies argued that proxy-reporting was appropriate: Bichey et al. (2002) [125] 
said that clinician-proxy was suitable due to the clinicians’ familiarity with each case; Bodden et al. 
(2008) [43] referred to previous studies that used EQ-5D through proxies; Chadha et al. (2010) [94] 
stated that their results showed no difference between self- and proxy-reported utilities; Friedman et 
al. (2004) [65] claimed that parental-proxy is consistent in evaluating HRQoL for children with atopic 
dermatitis; Gerald et al. (2012) [89] claimed that clinician-proxy reporting of health utilities is the gold 
standard; Hollman et al. (2013) [68] refered to previous studies to justify their use of proxy-reporting; 
Matza et al. (2005) [72] claimed that SG methods through parental-proxies are a suitable method for 
obtaining health utilities from children; Petrou & Kupek (2009) [74] claimed that there is no consistent 
evidence that parental- or caregiver-proxies either over-estimate or under-estimate health utilities for 
their children; Poley et al. (2001) [126] cite previous studies to support the use of proxies. van 
Litsenburg et al. (2013) stated that the HUI-3 calculation method is a parental-proxy method by design 
[82]. 
USE OF CHILD- OR ADOLESCENT-SPECIFIC CALCULATION METHODS 
Six calculation methods found in this review were designed specifically for use in the child and/or 
adolescent population (Table 3.4). The number of health dimensions included ranges from three to 
nine. Three methods are disease-specific with two focusing on asthma and one focusing on epilepsy. 
The remaining three methods are generic systems. 
Some studies discussed the short-comings of the calculation methods used. For example, Canaway et 
al. (2012), Oluboyede et al. (2011) and Wu et al. (2010) all discussed the lack of an appropriate tariff 
for the EQ-5D-Y [84, 93, 100], acknowledging that existing utilities have been taken from the adult-
specific EQ-5D, finally stating that the current EQ-5D-Y is not yet complete without the child-focused 
tariff. Thorrington et al. (2014) also commented on the lack of a child-specific tariff for the EQ-5D-Y 
[79]. It has previously been noted by Kromm et al. (2012) [15] that slow progress is being made in 
developing age-specific utility weights. 
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Abbreviation Name of calculation method Dimensions of health Studies found 
using this 
method 
AQoL-6D Assessment of quality of life 
(adolescent version) 
Independent living 
Relationship 
Mental health 
Coping 
Pain 
Senses 
[69] 
CAVE Escala de calidad de vida del niño con 
epilepsia 
Behaviour 
School compliance 
Learning 
Autonomy 
Social relations 
Frequency of seizures 
Intensity of seizures 
Parents opinions 
[127] 
CHU-9D Child health utility, 9 dimensions Worried 
Sad 
Pain 
Tired 
Annoyed 
School work 
Sleep 
Daily routine 
Joining with activities 
[90, 91, 93] 
EQ-5D-Y EuroQol 5 dimensions, youth version Mobility 
Self-care 
Usual activities 
Pain or discomfort 
Worried, sad or 
unhappy 
[64, 79, 81, 84, 
87, 93, 95, 97, 
98, 100] 
PAQLQ Paediatric asthma quality of life 
questionnaire 
Symptoms 
Activity limitations 
Emotional function 
[67] 
PAHOM Pediatric asthma health outcome 
measure 
Symptoms 
Emotion 
Activity 
[20, 89] 
Table 3.4 - List of child- and/or adolescent-specific calculation methods used 
Many other studies opted to administer calculation methods designed for a wide range of ages, such 
as the HUI-2 or the HUI-3. In addition, the EQ-5D system (originally designed for use in adults) was 
used 41 times, with the child-specific EQ-5D-Y version used only 10 times. Few studies adopting this 
approach discussed the suitability of their methods by evaluating the number of missing values for 
each returned calculation method. Hollmann et al. (2013) [68], Jelsma (2010) [97], Radford et al. 
(2013) [54], Thorrington et al. (2014) [79] Tilford et al. (2012) [103] and Wyatt et al. (2012) [63] all 
present data for missing or incomplete responses for their respective calculation methods, but only 
Jelsma (2010) [97] and Thorrington et al. (2014) [79] discuss these data with respect to the age of the 
respondents. 
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HRQOL AND INFECTIOUS DISEASES 
11 studies obtained HRQoL to assess the impact of infectious diseases or complications arising from 
infectious diseases [50, 60, 64, 68, 70, 79, 81, 94, 101, 128-130]. A list of these studies and their 
calculation methods is presented in Table 3.5. Methods for measuring the temporary deterioration in 
HRQoL were not consistent within the studies. For example, four studies focused on either H1N1 
influenza or measles but gathered their data using different methods: Baguelin et al. [64] and van 
Hoek et al. [81] and administered the EQ-5D (and derivatives) for the worst day of influenza infection 
then two weeks later for a baseline HRQoL reading. Thorrington et al. [79] used a similar methodology 
to estimate the impact of measles infection, but collected data points three weeks apart rather than 
two. Authors for all three studies assumed that HRQoL and duration are directly correlated both 
before and after the worst day of infection. In contrast, Hollman et al. [68] measured HRQoL during 
infection and assumed the drop from baseline was constant throughout infection.  
Reference Condition Calculation 
method(s) used 
Baguelin et al. (2010) H1N1 Influenza EQ-5D 
EQ-5D-Y 
Chadha et al. (2010) Juvenile-onset recurrent respiratory 
papillomatosis 
HUI-3 
VAS 
Hollman et al. (2013) H1N1 Influenza EQ-5D 
Lee et al. (2005) Pertussis TTO 
Oh et al. (1996) Acute otitis media VAS 
Oostenbrink et al. (2002) Permanent sequelae after bacterial 
meningitis 
EQ-5D 
HUI-2 
HUI-3 
Petrou et al. (2010) Otitis media with effusion HUI-2 
HUI-3 
EQ-5D 
Prosser et al. (2004) Pneumococcal infection TTO 
Thorrington et al. (2014) Measles EQ-5D 
EQ-5D-Y 
EQ-5D proxy 
van Hoek et al. (2011) H1N1 Influenza EQ-5D 
EQ-5D-Y 
Williamson et al. (2009) Persistent otitis media HUI-2 
HUI-3 
EQ-5D 
Table 3.5 - Health-state calculation methods used to gather HRQoL data for the impact of infectious 
diseases 
DISCUSSION 
SUMMARY OF EVIDENCE 
There is extensive variation in the methods used to estimate health utilities from children and 
adolescents. Issues that were raised by Kromm et al. (2012) and Griebsch et al. (2005) relating to the 
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need for a standardised method to collect health utilities from children and adolescents are yet to be 
fully resolved. Though this review found 22 different calculation methods that have been used 
between 1994 and 2013, many adult-specific methods have been used with children and adolescents 
without justification. Although several child- and adolescent-specific methods are currently in 
development, some existing adult-specific systems have been modified in order to fill the current gap.  
CURRENT CHILD- AND ADOLESCENT-SPECIFIC CALCULATION METHODS 
This review found six calculation methods designed for use in children and adolescents of which the 
most frequently used was the EQ-5D-Y, used 10 times. Another 16 methods either designed for a wide 
range of ages or designed specifically for use in adults but applied to younger patients. Development 
and use of child- and adolescent-specific methods is steadily increasing, though several issues of 
suitability still surround these methods. For example, this review found that the EQ-5D-Y has been 
used ten times even though the EQ-5D-Y does not differentiate between adult and child or adolescent 
preferences for health. Several authors acknowledge this discrepancy with some calling for further 
research and development of child- and adolescent-specific calculation methods. At the time of 
writing, EuroQol has not explored child-specific utility weights that use children’s preference for 
health states for use in the EQ-5D-Y [111]. 
USE OF PROXY RESPONDENTS 
Justification for the use of proxy respondents was mixed, and there is no consensus for the advisability 
of proxy-reporting in obtaining health utilities from children and adolescents. Several studies stated 
that proxy-reporting may differ from self-reporting in their studies, but others claimed that their use 
of proxy-reporting was justified by citing previous CUAs or health utility measurements. Some studies 
in this review did not discuss the use of proxy-reporting vs. self-reporting and how their results may 
have been influenced by proxy reporting from different sources. 
The use of proxies has been justified because of lack of verbal capacity of the children being evaluated 
[18]. Nevertheless responses should be elicited directly from those children being evaluated when 
verbal capacity is not a barrier [33]. 
USING MULTIPLE CALCULATION METHODS AND RESPONDENTS 
Only four studies compared self- and proxy- reported health utilities. Chadha et al. 2010 [94] found 
no difference between utilities. Gerald et al. (2012) [89] reported that PAHOM scores for parental 
proxies were significantly lower than self-reported scores from children. Jelsma & Ramma (2010) [98] 
found agreement with the EQ-5D-Y scores. Lock et al. (2010) [48] presented the mean and range of 
estimated utilities but did not perform a statistical test to verify that self-reported scores were 
different to proxy-reported scores. 
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MISSING DATA 
Discussions of missing data are essential in any study. In the case of the EQ-5D, a missing response to 
any of the five dimensions of health means that the response cannot be converted into a health utility. 
Analysis of missing responses would be helpful in deducing which aspects of measuring HRQoL in 
children and adolescents are particularly difficult and in developing new systems to minimise missing 
data in responses. 
RELIANCE ON ADULT-SPECIFIC CALCULATION METHODS 
Perhaps because the EQ-5D-Y still needs an appropriate tariff for children and adolescents, some 
authors continue to use an adult-specific method for children and adolescents in preference to a 
method under development for the appropriate age group. The first use of the EQ-5D-Y in this review 
was in 2009 [95], and since then 18 studies have used the standard EQ-5D system in children and 
adolescents or patients outside of the appropriate age range for the system [42, 46, 49, 52-57, 61, 62, 
68, 71, 74, 85, 92, 131, 132].  
INFECTIOUS DISEASES 
Few studies gathered HRQoL data to assess the impact of infectious disease. 11 studies administered 
a mixture of different generic calculation methods for only 8 conditions. HRQoL with respect to 
infectious disease is still a developing field of research, especially in the child and adolescent 
populations. Methods to measure deterioration in HRQoL due to infectious disease were inconsistent, 
even when different studies measured the impact of the same condition. 
LIMITATIONS OF THIS REVIEW 
This review only concerned published literature, which may be a source of bias as the gray literature 
was not considered. However, Griebsch et al. (2005) [32] argued that by not including unpublished 
works, they avoided reducing the overall quality of studies included in their review. 
It was the decision of the authors that focused the qualitative assessment on the use and justification 
of different calculation methods to measure HRQoL in children and adolescents. There are several 
other ways to assess the quality of a CUA, notably the PQAQ [36] and the checklist for economic 
analysis outlined by Drummond et al. (2005) [133]. However, we have not sought to assess the quality 
of each CUA in the review but instead to evaluate the use of each direct or indirect calculation method 
in addition to understanding the justification for different methods of eliciting health utilities from 
children and adolescents. 
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CONCLUSIONS 
Many authors examining child and adolescent HRQoL have relied on tools developed exclusively for 
adults. Further development of child- and adolescent-specific calculation methods is required to 
ensure that CUAs using health utilities of children and adolescents are valid, without relying on the 
assumption that adults, children and adolescents all have the same health preferences. 
Previous studies measuring HRQoL in children and adolescents have relied on proxy respondents 
without sufficient justification for their use. There is considerable debate in the literature about 
whether proxies can be used (and if so, which proxies). No clear consensus was found in the literature 
from this.  
Several calculation methods are in development that will facilitate the measurement of QALYs in 
children. These systems are needed by health economists as the application of adult-specific systems 
is of questionable validity. Adults, children and adolescents measure HRQoL, perceive and value health 
differently, so the assumption that adult-specific health utilities are valid in adolescents or young 
children is potentially misleading. 
Measuring children’s health states is extremely challenging and requires a suitable instrument for the 
estimation of paediatric health utilities that NICE can recommend for use to ensure the validity of 
future child- and adolescent-focused CUAs.  
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Chapter 4 - The social and economic impact of school 
influenza outbreaks in England 
Portions of this chapter were submitted to The Journal of School Health in October 2015 (accepted, 
in press). 
ABSTRACT 
BACKGROUND 
Seasonal influenza is a cause of considerable morbidity in England, particularly among young children. 
39% of all influenza-attributable GP consultations and 37% of all influenza-attributable hospital 
admissions occur in those aged under 15 years. The impact of influenza outbreaks has been studied 
at population level but fewer studies have quantified the impact on families whose children become 
infected with influenza. 
OBJECTIVE 
Here we sought to assess this impact in England during the 2012-13 and 2013-14 influenza seasons. 
METHODS AND FINDINGS 
We used paper-based and online questionnaires to obtain data from parents of children in three 
primary schools that reported an outbreak of an influenza-like-illness (ILI). We sought data on the 
impact of illness in terms of loss of productivity, costs borne by families and loss in health-related 
quality of life. Influenza-like-illnesses were identified using the reported symptoms and the symptoms 
criteria from both the European Centre for Disease Prevention and Control and the UK Flusurvey. 
For children with ILI, the mean absence from school was 3.8 days (95% CI: 3.0 – 4.8) with mean total 
time off work for all caregivers reported as 3.7 days (95% CI: 2.7 – 4.8). The mean loss in health-related 
quality of life was 2.1 quality-adjusted life days (95% CI: 1.5 – 2.7), compared to 2.92 QALDs for H1N1v 
influenza. The estimated total paediatric burden of disease for all reported school-based outbreaks 
during the two influenza seasons was 105.3 QALYs (95% CI: 77.7 – 139.0).  
CONCLUSION 
This study shows the potential social and economic benefit of vaccination of children during mild 
influenza seasons. 
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INTRODUCTION 
BACKGROUND 
Influenza epidemics are associated with a substantial socio-economic impact in terms of direct and 
indirect costs [1, 2], loss of productivity in the workplace, health-related quality of life and illness [3].  
Seasonal influenza can cause a significant health burden in the United Kingdom. It is estimated that 
approximately 10% of all respiratory admissions and deaths can be attributed to influenza. The highest 
admission rates for both influenza A and B strains are in children under five years of age and the 
highest influenza-attributed deaths rates occur in the group of elderly patients with co-morbidities 
[4].  
In England, seasonal influenza is estimated to account for over one million GP consultations per year 
and a large proportion of this burden comes from children aged under 15 years. 39% of all influenza-
attributable GP consultations and 37% of all influenza-attributable hospital admissions occur in this 
age group. Estimated annual hospital mortality from influenza in this age group is low at 1.3 per million 
but school-age children still account for a substantial proportion of the full burden of seasonal 
influenza [4].  
School children play an important role in the spread of influenza in the community [5-7]. The 2009 
H1N1 pandemic emphasised the importance of public health policies that tackle transmission within 
children and the school-age population [8] and the pandemic has since generated debate about the 
appropriate response to future outbreaks with respect to children and schools. Suggested 
interventions range from school-based initiatives that restrict contacts between children within 
schools [9] and school closures [10] to new vaccination strategies that target school-age children [11, 
12].  
Infectious disease outbreaks in schools will have both a health-related and an economic impact in the 
community. The health-related impact concerns the illness suffered by school children and any 
subsequent spreading of infection in the wider community [4]. The costs will include loss of earnings 
for those families where a parent or guardian must stay at home to supervise their children, along 
with the cost of medicines, etc. [1, 2]. Indirect costs may include the travel costs for friends and family 
members who help by supervising children who cannot attend school. 
This impact will be felt by families who must adjust their working and social schedules to stay at home 
with children either too ill to attend school or those sent home due to a reactive closure [13]. In order 
to assess the benefits of potential interventions for these outbreaks first the impact of such outbreaks 
must be quantified.  
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Including societal costs into an analysis to evaluate the cost-effectiveness of an intervention can be 
difficult as these costs can be difficult to obtain. Because of this, cost-effectiveness analyses may be 
restricted to including only direct costs (e.g. the cost of medical intervention to the healthcare 
provider) without considering the costs and impact on families, or the analyses may use estimates for 
childcare costs, loss of productivity, etc. from other data sources.  
QALY-loss assessment associated with infectious disease outbreaks can be examined by employing 
HRQoL measures aimed at patients infected [3]. The measure recommended by NICE is the EuroQol 
EQ-5D-3L [14]. This questionnaire has also been used in children to examine their health and inform 
cost-utility analyses for interventions [3, 15, 16] but QALYs and health utilities relating to infectious 
disease outbreaks in children barely feature in the published literature, as this is a developing field of 
research [17]. As a result from this, it is difficult to evaluate the cost-effectiveness of interventions for 
infectious disease outbreaks in children as the direct impact on the children’s quality of life is not 
understood. 
The previous chapter discussed the issues surrounding the accurate estimation of health utilities from 
children and adolescents – the extensive variation in methods and instruments available has led to 
authors and analysts using many different instruments, several of which may not be suitable or 
justified for use in the population at hand.  
PARENTAL ATTITUDES TO ANNUAL INFLUENZA VACCINATION 
The Joint Committee on Vaccination and Immunisation (JCVI) in 2012 recommended extending the 
influenza vaccination programme to all children between the ages of 2-16 years [12]. Parents’ or 
guardians’ knowledge of the recommendation from the JCVI for influenza are not understood. These 
attitudes may impact on the uptake of the offered vaccination programme, subsequently affecting 
regional preparedness for outbreaks in schools and communities.  
Surveys mailed to families with children attending elementary schools in 2001 were used by 
Nettleman et al. [18] to report that vaccine non-acceptance was low (13% of 954 responses) and a 
higher acceptance rate among parents or guardians of children whose child had been absent from 
school with a winter respiratory illness than those children not absent (33% vs. 24%, p < 0.01). In 
addition, parents or guardians required to miss work due to childcare responsibilities were more likely 
to accept a vaccine for a winter respiratory illness than those parents who were able to work during 
their child’s illness (35% vs. 25%, p < 0.01). 
Understanding the potential heterogeneity in the uptake of the offered vaccinations will help the 
healthcare authorities evaluate the cost-effectiveness of the proposed programme. Factors 
determining vaccine acceptance will help public health officials in designing programmes to improve 
vaccine uptake in low-coverage areas. 
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EPIDEMIOLOGY OF SEASONAL INFLUENZA IN 2012-13 AND 2013-14 
The influenza season of 2012-13 saw prolonged influenza activity in GP practices and hospitals [19]. 
460 acute outbreaks were reported in schools (36%), care homes (52%), hospitals (9%) and other 
settings (3%). Where data were available the majority of school outbreaks were attributable to 
influenza B. 112 acute outbreaks were reported in care homes (49%), hospitals (39%), schools (9%) 
and other settings (3%) during the influenza season of 2013-14 [20]. Influenza A (H1N1)pdm09 was 
the dominant circulating virus in 2013-14 [21]. 
RESEARCH QUESTIONS 
1. What was the impact of illness at home caused by an ILI outbreak in a child’s school in terms 
of disruption due to childcare, cost and HRQoL? 
2. How would parents and guardians arrange childcare in the event of a school closure for 
potential future outbreaks? 
3. What is the willingness-to-pay threshold for parents and guardians paying for childcare 
provided by a third party? 
4. What would be the likely uptake of an annual influenza vaccination offered to children? For 
what reasons might parents or guardians decline the offer of a vaccination offered to their 
children?  
METHODS 
The study was a population-based retrospective survey taking place in primary schools in three 
geographically distinct areas of England during the influenza seasons of 2012-13 and 2013-14: the 
South (excluding London), the Midlands and the North West.  
IDENTIFICATION AND RECRUITMENT OF SCHOOLS 
A local health protection team (HPT) in England received notification from a school of an outbreak. If 
the Head Teacher agreed their contact details were passed to the researchers at LSHTM so that a full 
discussion of the study could take place at a later time. The local HPT acted as facilitator by sending 
the contact details to LSHTM. These details were collected in a pro forma then sent to LSHTM via 
email. 
The LSHTM researchers contacted the Head Teacher to invite them to participate in the study. A 
sample questionnaire was sent to the Head Teacher and full details of the study aims, protocol and 
proposed outcomes, along with the plans for distribution of the online questionnaires were discussed. 
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If the school agreed to participate in the study then LSHTM sent the links to the online questionnaires 
to the school within one week of the notification or paper questionnaires in sealed blank envelopes 
along with stamped-addressed envelopes for return to LSHTM. The links consisted of a questionnaire 
for each child at the school in addition to a letter addressed to the parents or guardians of the children 
explaining the details of the study and what they needed to do if they wish to take part.  
HPT INVOLVEMENT AND RESPONSIBILITIES 
Existing working relationships between Public Health England, especially local HPTs and schools in 
England helped facilitate participation of schools in this study. Because QALYs should be gathered as 
quickly as possible during an outbreak it was essential that the study packs were sent to the school 
soon after the notification of an outbreak.  
FES and HPT involvement in this study was essential to recruit sufficient schools. Once a school notified 
the HPT of the outbreak and expressed an interest in participating then the management of the 
schools involvement was the responsibility of LSHTM who invited the school to participate before 
sending the links, collecting the responses and analysing the data. 
Further details of the responsibilities of the FES and local HPTs were agreed in discussions with PHEC 
Influenza Leads. 
INCLUSION CRITERIA 
Inclusion criteria analysis: 
 Notification from HPT of an influenza-like-illness (ILI) outbreak affecting a school 
EXCLUSION CRITERIA 
 Notification of an outbreak of ILI in a special needs education establishment 
 Patients identified as not suitable for recruitment; recent mortality in the family, inclusion in 
previous studies from PHE; other reasons identified by the HPT or school 
DISTRIBUTION AND COLLECTION OF QUESTIONNAIRES 
Head teachers were offered a choice of paper-based or online questionnaires. Paper-based 
questionnaires were posted in a batch to the school each with a letter explain more about the study; 
instructions for completing the questions; contact details of the lead investigators; and a self-
addressed envelope to return the questionnaire to the lead investigators. School staff distributed one 
questionnaire to each child at the school. 
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Online questionnaires took the form of a Google Form linked to a Google Docs spreadsheet. Schools 
that requested the use of online questionnaires emailed the link to all parents and guardians of 
children in the school. 
All responses to both forms of the questionnaire were anonymous.  
FINANCIAL INCENTIVES 
No financial incentives were given.  
LANGUAGES 
The questionnaires were written in English. 
DATA MANAGEMENT 
The final data files (as a csv file) were stored as a Google Sheet accessible only to Dominic Thorrington, 
the primary investigator based in LSHTM. The Google Doc spreadsheet was downloaded to a secure 
network drive for analysis once data collection has ceased. Only the investigators based in LSHTM had 
access to this file.   
Online questionnaires took the form of a Google Form linked to a Google Sheet. Schools that 
requested the use of online questionnaires emailed the link to all parents and guardians of children in 
the school. 
All responses to both forms of the questionnaire were anonymous.  
THE FORM OF THE QUESTIONNAIRES  
Paper-based and online questionnaires were used to gather data from parents and guardians of 
children attending schools that had reported an outbreak of suspected influenza to their local Health 
Protection Team during that influenza season. The paper-based and online questions were identical 
and are available from the authors on request. 
Questionnaires were offered to all parents and guardians, whether or not their children were ill during 
the outbreak. We sought information about parents’ attitudes towards childhood influenza 
vaccination; likely childcare arrangements in the case of a future school closure; and, for those parents 
whose children were ill during the outbreak, information about the children’s symptoms and the 
impact of the episode on the family. 
Copies of the questionnaires are available in the Appendix. 
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IMPACT OF ILLNESS 
We asked parents and guardians of children who were sick during the recent outbreak at their school 
to complete a section on their child’s illness. ILI was separated from other potential illness by asking 
parents or guardians to indicate the symptoms experienced during illness from a list provided from 
Flusurvey. ILI was identified according to the definition from the European Centre for Disease 
Prevention and Control [22], specifically: 
 The sudden onset of symptoms 
 And at least one of the following four systemic symptoms: 
o Fever 
o Malaise (chills, feeling tired) 
o Headache 
o Myalgia (muscle or joint pain) 
 And at least one of the following three respiratory symptoms: 
o Cough 
o Sore throat 
o Shortness of breath 
We asked about the duration of perceived symptoms; absence from school; and contacts with the 
health services during infection. Further data were requested on any childcare arrangements made 
during the child’s illness as well as an estimate of additional costs to the child’s primary caregivers and 
others who helped with childcare. 
We asked parents and guardians to complete a EuroQol EQ-5D assessment [23] on both the worst day 
of the child’s infection and then another on the date of completion of the questionnaire, to establish 
the loss of HRQoL. The version of the EQ-5D used for primary schools was the proxy version [24], to 
be completed on behalf of the child. The EQ-5D was chosen because it is the instrument of choice for 
Public Health England for use in outbreak investigations. Results from Chapter 3 indicate that is has 
been used extensively in the paediatric population and in particular in estimating the impact of 
pandemic influenza. To calculate the impact of infection in terms of QALYs we adopted the approach 
taken by van Hoek et al. (2011) [3] when estimating the impact of the 2009 H1N1 pandemic in England. 
95% confidence intervals of the mean loss of HRQoL were based on 1,000 bootstrap replications. 
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SECONDARY AIMS - CHILDCARE OPTIONS, VACCINATION UPTAKE AND ATTITUDES TO VACCINATION 
Parents and guardians were asked what childcare arrangements they would make if the school were 
closed for a future influenza outbreak for a period of one day, one week and one month and whether 
it would affect a normal working schedule to organise this childcare; a measure of potential disruption 
for each possible school closure through a 0-10 Likert scale [25, 26] (0 corresponding to “not 
disruptive” and 10 for “very disruptive”); whether the child was considered old enough to look after 
themselves at home; and how much parents and guardians would be willing to pay for childcare per 
day. 
Parents and guardians were asked if they would accept an annual influenza vaccination for their 
children. Those parents and guardians who indicated that they would accept the vaccination were 
asked where they would prefer the vaccination to be administered: the child’s school; the child’s GP 
practice; or no preference. Those parents that would refuse the vaccination were asked to indicate 
why they would choose to do so using a list of reasons for vaccine denial from the UK Flusurvey [27]. 
ETHICAL APPROVAL 
Ethical approval was obtained from the ethics committee at the London School of Hygiene & Tropical 
Medicine in addition to approval from the Public Health England Research and Development office. 
PHE has ethical approval to investigate the impact of an infectious disease outbreak in a community 
setting, including QALY data along with details of absence from school and work. However, PHE did 
not have such approval to collect data on the financial burden suffered by families affected by the 
outbreak. 
ANALYSIS OF DATA 
Data were analysed using R version 3.0.2 [28]. 
QUESTIONNAIRES USED IN THE STUDY 
1. For children 
i) HRQoL for those directly affected by the outbreak 
ii) Children attending secondary schools received the EQ-5D-Y. Children attending 
primary schools received the EQ-5D proxy version.  
2. For adults 
i) Response to a hypothetical school closure to all parents or guardians of children 
where an outbreak has occurred 
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ii) Knowledge and attitudes to the recommended changes to the annual influenza 
vaccination programme to offer the vaccine to children attending schools and 
preschools 
iii) Economic burden of the outbreak for those directly affected through their children’s 
illness 
DELIVERY METHOD AND FOLLOW-UP 
Online questionnaires were sent by LSHTM to the schools within a few days of the notification to the 
local HPT, with paper-based questionnaires sent to the school in bulk within one week from LSHTM. 
Head Teachers emailed the links to parents or guardians at their convenience and paper-based 
questionnaires were distributed to school children via their classroom teachers. Patient consent was 
implied through the return of a completed questionnaire. 
Parents or guardians who did not respond to the questionnaire were not followed-up. Schools that 
chose not to participate in the study were not followed-up. Schools that experienced a low rate of 
return for the questionnaires were not followed-up. 
COSTS 
Pre-paid postage envelopes were already available to the LSHTM researchers as existing stock from a 
previous study, therefore no costs were incurred in the administration of the study. 
RESULTS 
DEMOGRAPHICS AND EMPLOYMENT 
DEMOGRAPHICS 
Three schools participated in our study – one in south east England after a reported outbreak in 
February 2013 and two in North West England after reported outbreaks in January 2014. All three 
schools were state-run primary schools. 87 responses were received, of which 85 were paper-based 
questionnaires and 2 were questionnaires completed online. Table 4.1 displays the response rate for 
each school and the gender breakdown of the respondents. 85.1% of respondents belonged to a two-
parent family. 
 Response rate (total distributed) Male respondents 
School 1 26.3% (n=99) 46.2% 
School 2 12.8% (n=204) 46.2% 
School 3 14.6% (n=240) 62.9% 
Overall 16.0% (n=543) 52.9% 
Table 4.1 - Response rate and gender breakdown for participating schools 
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EMPLOYMENT 
74 questionnaires (85.1%) were completed by two-parent families and 13 (14.9%) by single parent 
families. Of the 160 adults identified as parents or guardians in the survey, 78 were in full-time 
employment (48.8%) (Table 4.2). Comparing our sample to the UK labour market statistics [29] we 
determined that those individuals unemployed or retired are overrepresented and students are 
underrepresented. 
Employment category Adults in 
the survey 
UK labour market 
statistics [29] 
 
Full-time employment 78 (48.8%) 52.5% p = 0.3472 
Part-time, shift or casual employment 33 (20.6%) 19.0% p = 0.6031 
Self-employed 25 (15.6%) 12.1% p = 0.1738 
Unemployed 18 (11.3%) 6.5% p = 0.0139 
Retired 11 (6.9%) 3.6% p = 0.0251 
Student 4 (2.5%) 6.3% p = 0.0477 
Table 4.2 - Employment breakdown of adults identified in the survey 
ILLNESS 
REPORTED ILLNESS AND SYMPTOMS 
43 (49.4%) parents or guardians reported that their child was absent from school with illness during 
the outbreak period at their child’s school. 34 of these children (79.1%) reported symptoms consistent 
with the ECDC case definition of ILI (Table 4.3).  
Reported symptoms for 
children reporting illness 
All children (n = 43) Children with symptoms 
consistent with ILI (n = 34) 
Fever 33 (76.7%) 28 (82.4%) 
Chills 20 (46.5%) 19 (55.9%) 
Feeling tired or exhausted 33 (76.7%) 29 (85.3%) 
Headache 24 (55.8%) 21 (61.8%) 
Myalgia 12 (27.9%) 11 (32.4%) 
Cough 29 (67.4%) 27 (79.4%) 
Sore throat 27 (62.8%) 25 (73.6%) 
Shortness of breath 5 (11.6%) 5 (14.7%) 
Table 4.3 - Reported symptoms for those children who reported illness during an outbreak of suspected 
ILI at their primary school  
Five individuals with symptoms not consistent with ILI met the ECDC case definition of acute 
respiratory infection (ARI) [22] (i.e. at least from the list of cough, sore throat, shortness of breath, 
and coryza). Three individuals with symptoms not consistent with ILI had fever but no additional ILI-
specific symptoms, and the remaining individual reported tiredness with vomiting. 
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COSTS 
 
Figure 4.1 - Costs attributable to ILI outbreak in schools for those families reporting their child had 
symptoms consistent with ILI 
For costs incurred by the parents or guardians of a child with symptoms consistent with ILI, 10 
respondents (35.7%) reported no additional costs due to their child’s illness; 14 (50.0%) reported 
spending up to £50 during their child’s period of illness; two respondents (7.1%) spent up to £100; 
one (3.6%) spent up to £150; and one (3.6%) spent over £250. For costs incurred by other family 
members 26 respondents (92.9%) reported no additional costs, one (3.6%) reported costs up to £100 
and one reported costs over £250 (Figure 4.1). 
HEALTH-RELATED QUALITY OF LIFE  
The overall health-related quality of life loss associated with infection consistent with ILI was 0.006 
QALYs per individual (95% CI: 0.004 – 0.008) or 2.1 QALDs per individual (95% CI: 1.5 – 2.7) (Table 4.4). 
The mean duration of perceived symptoms consistent with ILI was 5.3 days (95% CI: 4.4 – 6.3). The 
EQ-5D proxy questionnaires had no blank responses except for one individual who did not complete 
the VAS scores for both the worst day and background measurements. 
Children with symptoms consistent with ILI were absent from school for a mean duration of 3.8 days 
(95% CI: 3.0 – 4.8). During this time they were looked after by a mean of 1.7 caregivers (95% CI: 1.4 – 
2.0) who were absent from work for a total time of 3.7 days (95% CI: 2.7 – 4.8). Only one respondent 
sought professional childcare, employing two child minders. All other respondents organised childcare 
between parents and other family members 
Using the Wilcoxon test we found no evidence that the health-related quality of life loss metrics 
differed between those individuals with symptoms consistent with ILI and those individuals with 
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symptoms not consistent with ILI except for strong evidence for a difference between the background 
VAS scores (W = 71.5, p = 0.0181).  
 Symptoms 
consistent with ILI 
(n = 34) 
Symptoms not 
consistent with ILI 
(n = 9) 
Wilcoxon Test 
Statistics 
Mean duration of perceived 
symptoms (95% CI) 
5.3 days (4.4 – 6.3) 5.0 days (2.8 – 7.2) W = 174.5, p = 0.5283 
Mean duration of absence 
from school (95% CI) 
3.8 days (3.0 – 4.8) 3.8 days (3.0 – 4.8) W = 96.5, p = 0.6885 
Mean number of caregivers 
used during absence (95% CI) 
1.7 (1.4 – 2.0) 1.7 (1.3 – 2.1) W = 60.0, p = 0.1347 
Mean total time off work for 
all caregivers (95% CI) 
3.7 (2.7 – 4.8) 3.7 (2.8 – 4.8) W = 88.5, p = 0.9658 
Mean VAS score, worst day 
(95% CI) 
39 (31 – 45) 54 (33 – 74) W = 107.0, p = 0.2071 
Mean VAS score, background 
(95% CI) 
88 (81 – 94) 98 (97 – 100) W = 71.5, p = 0.0181 
Mean EQ-5D score, worst day 
(95% CI) 
0.2 (0.02 – 0.3) 0.3 (0.1 – 0.6) W = 111.5, p = 0.2205 
Mean EQ-5D score, 
background (95% CI) 
0.9 (0.8 – 1.0) 1.00 (1.00 – 1.00) W = 139.5, p = 0.3796 
Mean QALY loss (95% CI) 0.006 (0.004 – 0.008) 0.006 (0.002 – 0.009) W = 174.0, p = 0.5405 
Mean QALD loss (95% CI) 2.1 (1.5 – 2.7) 2.0 (0.8 – 3.5) W = 174.0, p = 0.5405 
Table 4.4 - Health-related quality of life scores reported for both individuals with symptoms consistent 
with ILI and those with other symptoms. 95% confidence intervals of the mean are based on 1,000 
bootstrap replications 
ESTIMATED TOTAL PAEDIATRIC BURDEN OF DISEASE IN QALYS 
Public Health England reported 165 acute influenza outbreaks occurring in schools during the 2012-
13 season and 10 in 2013-14 [19, 20]. Assuming that the estimated ILI attack rate from this sample 
(34/87 respondents, 39.1%) is representative of the attack rate from the reported 175 school-based 
outbreaks of the two influenza seasons and that the mean number of pupils in a state-funded primary 
school is 263 [30], the estimated total paediatric burden of disease for transmission in those primary 
schools reporting suspected ILI outbreaks during the two influenza seasons was 105.3 QALYs (95% CI: 
77.7 – 139.0) or 38,309 QALDs (95% CI: 28,165 – 49,844). 
SOCIAL IMPACT OF INFLUENZA OUTBREAKS 
HEALTHCARE SERVICE CONTACT 
13 (38.2%) parents or guardians of children reporting symptoms consistent with ILI visited their GP. 4 
(11.8%) spoke to a GP surgery receptionist over the telephone, 3 (8.8%) telephoned NHS Direct, 2 
(5.9%) spoke to a GP over the telephone and 1 (2.9%) used another unspecified NHS service. No 
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parents or guardians reported visiting Accident and Emergency departments with their child due to 
symptoms consistent with ILI.  
CHILDCARE OPTIONS AVAILABLE FOR HYPOTHETICAL SCHOOL CLOSURES 
The preferred option for childcare during hypothetical school closures was for a parent to stay at 
home. 82.1% of respondents preferred this option for a one day closure, decreasing to 60.5% in the 
event of a month long closure (Figure 4.2). The preferred alternative option for childcare for all three 
scenarios was another family member, selected 56.9%, 58.2% and 43.5% of the time for one day, one 
week and one month closures.  
 
Figure 4.2 - Preferred main and alternative options for childcare for three school closure scenarios 
49.3% of parents or guardians indicated that someone would have to take time off work for their main 
option for childcare for a one day school closure, with 47.8% for a one week closure and 46.4% for a 
one month closure. 96.4% of respondents thought that their child was not old enough to be alone at 
home; the remaining children able to be alone at home were all 11 years old. 
A potential future one day closure had a mean score of 3.4 (95% CI: 2.7 – 4.2) on the 10-point Likert 
scale for perceived disruption. Potential future week-long and month-long closures had mean scores 
of 6.1 (95% CI: 5.3 – 6.9) and 7.7 (95% CI: 6.8 – 8.3) respectively.  
WILLINGNESS-TO-PAY FOR CHILDCARE 
Families with one parent or guardian were prepared to pay a mean of £21.43 per day of childcare per 
child if their child’s school was closed at short notice. For families with two parents or guardians the 
mean was £36.92 per day of childcare per child (Figure 4.3). Using the Wilcoxon test there is good 
evidence of a difference in the willingness-to-pay for childcare based on the number of parents or 
guardians at home (W = 81, p = 0.01). 
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Figure 4.3 - Willingness-to-pay for one day of childcare for one child for single parents and two-parent 
families 
VACCINATIONS 
71 (81.6%) of parents or guardians stated that they would accept the offer of an annual influenza 
vaccine for their children. Of those answering the question about the location of vaccine 
administration, receiving the vaccine at their local GP surgery was the preferred option with 28 
(40.6%) responses. 14 (20.3%) preferred to have the vaccine administered at their child’s school and 
27 (39.1%) stated no preference between the two options.  
88.2% of parents or guardians whose child had symptoms consistent with ILI expressed a preference 
that their child received annual influenza vaccinations. The three most common reasons given by 
those expressing a preference for their children not to be given influenza vaccination for all parents 
or guardians were a preference for building natural immunity (78.6%), safety fears over the new 
vaccine (42.9%) and a belief that their child was unlikely to get influenza (28.6%). 
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DISCUSSION 
RESPONSE RATE 
We have used both paper-based and online questionnaires to examine the impact on families of ILI 
outbreaks in schools, with responses recorded during the 2012-13 and 2013-14 influenza seasons in 
England. Our response rate was typical of postal surveys [31].  
ILLNESS AND HEALTH-RELATED QUALITY OF LIFE 
For those children with symptoms consistent with ILI, their illness did not have a large financial impact 
on families. 35.7% of respondents reported no additional costs to themselves and 92.9% reporting no 
additional costs for others; mainly because parents and family were the preferred carers. The main 
socio-economic impact of influenza in schools is seen in the total loss of productivity due to illness: 
the mean absence from school was 3.8 days (95% CI: 3.0 – 4.8) with mean total time off work for all 
caregivers reported as 3.7 days (95% CI: 2.7 – 4.8). Therefore the total loss of productivity per child 
with symptoms consistent with ILI was approximately 7.5 days off both work and school. McCann et 
al. (2014) [32] investigated three outbreaks of laboratory-confirmed influenza B in schools in the 
Thames Valley during the 2012-13 influenza season and reported that the mean length of absence 
from each school was 3.5 days, 2.6 days and 2.8 days respectively, similar to our findings. 
The mean duration of perceived symptoms was 5.3 days (95% CI: 4.4 – 6.3) and mean loss of HRQoL 
was 2.1 QALDs per individual (95% CI: 1.5 – 2.7), both smaller than the estimates provided for H1N1v 
influenza (8.8 days duration and a loss of 2.92 QALDs [3]). For comparison with other diseases, the 
mean loss of HRQoL for measles was 6.90 QALDs [33] and 0.99 QALDs for natural varicella [34]. 
Seasonal influenza has a greater impact on HRQoL in children than varicella, though less than H1N1v 
pandemic influenza and measles. 
COSTS INCURRED BY FAMILIES 
35.7% of parents and guardians of children with symptoms consistent with ILI reported that their 
child’s illness did not result in additional financial costs on the family. 50% of parents and guardians 
of children with symptoms consistent with ILI reported spending up to £50 on out-of-pocket expenses 
with few parents or guardians reporting greater expense. 92.9% of other family members reported no 
additional costs due to the child’s illness. These figures suggest that two-thirds of families affected by 
seasonal childhood influenza in primary schools experience a small economic burden in terms of out-
of-pocket expenses, and that this burden usually does not extend to the wider family. 
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EQ-5D COMPLETION RATE 
The EQ-5D proxy questionnaires had no blank responses except for one individual who did not 
complete the visual analogue scale scores for both the worst day and background measurements. This 
is a very high completion rate for the EQ-5D health-state classification system as other studies have 
reported several respondents having difficulty in completing all aspects of the system [33], which in 
turn reduces the size of the cohort used to calculate the impact in HRQoL. 
ESTIMATE OF THE TOTAL PAEDIATRIC BURDEN OF DISEASE 
Our estimate of the total paediatric burden of disease in primary schools reporting suspected ILI 
outbreaks for the two influenza seasons of 105.3 QALYs (95% CI: 77.7 – 139.0) was much lower than 
the 22,267 discounted QALYs reported for total burden of disease during the H1N1v pandemic 
influenza in England [3]. We used the number of schools reporting a suspected acute influenza 
outbreak but the total number of such outbreaks in schools is unknown. We assumed a conservative 
overall attack rate of 39.1% from our sample in comparison to a mean attack rate of 53.0% from 
McCann et al. (2014) [32]. Also, we only considered the impact of infection associated with school 
transmission by excluding the potential secondary transmission of ILI to household members, which 
is likely to have occurred as previous studies have indicated [35, 36]. 
HEALTHCARE SERVICE CONTACT AND INTENTION TO VACCINATE 
The proportion of parents or guardians taking their child to their local GP (38.2%) was much higher 
than estimates provided by Flusurvey (10.0%) [27]. With a mean cost per GP appointment of £45 [37] 
this result would increase the cost of healthcare resource use in economic evaluations of strategies to 
manage both seasonal and pandemic influenza. 
Potential vaccination uptake for the annual influenza vaccination could be high in primary schools with 
81.6% of parents or guardians willing to consent to vaccination for their children. This figure is much 
higher than the mean uptake of 52.5% seen in the 2013-14 pilot programme [21], which may be 
indicative of response bias for this question – parents or guardians will be asked to consent to the 
annual influenza vaccination long before the majority of influenza transmission occurs. When 
compared to vaccination uptake for a long-running seasonal influenza vaccination programme in the 
United States, 39.4% of parents or guardians responding to a survey on attitudes to vaccination for 
seasonal influenza reported that they vaccinated their children each year, with another 28.2% said 
their children were vaccinated sometimes [38].  
Policy makers should note the reasons for vaccine refusal and address the attitudes of parents and 
guardians, particularly the commonly-held belief that acquiring immunity through influenza infection 
is a viable and positive alternative to vaccination (78.6%). Nearly half (42.9%) of vaccine refusers cited 
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vaccine safety fears as a reasons for potentially refusing an annual influenza vaccine for their child, in 
contrast to just 17.0% of non-NHS workers indicating in 2009 that they would refuse their own 
seasonal influenza vaccination [39]. Further work on communicating vaccine safety and efficacy to the 
parents and guardians of those children eligible for seasonal influenza vaccination is required, though 
correcting myths held by vaccine-hesitant individuals about the seasonal influenza vaccination is 
known to be difficult, as tackling such misconceptions about the vaccine can be counter-productive if 
the intention is to increase the intention to vaccinate [40]. 
LIMITATIONS 
SMALL SAMPLE SIZE 
This study was conducted over two influenza seasons of mild severity compared to many previous 
seasons. In conjunction with mainly paper-based questionnaires with no incentive for completion 
offered to the parents or guardians it means the sample size is smaller than other published analyses 
using surveys in schools with ILI outbreaks. Head teachers of schools were recruited via the health 
protection teams, so we do not know how many were offered participation or declined.  
It should also be noted that the study was conducted over a period of substantial managerial 
reorganisation in Public Health England, which may have impact on staff time to recruit schools to the 
study. However, even with a small number of schools participating in the study, we have conducted 
an important and novel study that describes the social and economic impact of influenza outbreaks in 
schools from the perspective of families affected. 
GENERALISING RESULTS TO WIDER COMMUNITY-BASED TRANSMISSION 
We sought to estimate the impact of influenza outbreaks in schools and to understand parental 
attitudes to seasonal influenza vaccination, but our study was conducted only within the context of a 
school-based outbreak rather than with wider community-based transmission occurring. The 
potential for sustained background transmission without large school-based outbreaks is not an 
unrealistic scenario, and in such a scenario it is possible that parents or guardians of children attending 
schools would not be as likely to obtain seasonal influenza for their children if they perceive the risk 
of infection to be low. Our results can therefore only be generalised to scenarios with community-
based transmission that also includes school-based outbreaks that would come to the attention of 
parents and guardians. 
SAMPLE REPRESENTATIVENESS AND SEVERITY BIAS 
In our sample the unemployed and retired individuals were overrepresented and students were 
underrepresented when compared to UK labour market statistics for the same period. This is likely to 
have biased our results for the willingness-to-pay for childcare and for the costs incurred during a 
child’s infection.  
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Nearly half of the responses to our questionnaires came from parents or guardians of children 
reporting illness during the outbreak period in their child’s school, but it is possible that the parents 
or guardians of the children with the most severe illness returned their questionnaires, introducing a 
potential severity bias to our study that we could not control for.  
NO LABORATORY TESTING OF SUSPECTED INFLUENZA CASES 
We did not confirm influenza infection using laboratory testing. The study would have been improved 
with the presence of this testing but in its absence we are confident that we have correctly identified 
ILI infection using the same list of symptoms as the UK Flusurvey and in turn from the ECDC. 
UNSUCCESSFUL IMPLEMENTATION ON ONLINE QUESTIONNAIRES 
Our study used data from 87 questionnaires of which only two were returned online. The process of 
printing, packaging and sending paper-based questionnaires was time consuming so we had hoped 
that more schools would request online questionnaire distribution only. In addition, the distribution 
of paper-based questionnaires along with the data entry process once paper-based questionnaires 
were returned to LSHTM meant that a study using online questionnaires exclusively would be a more 
attractive proposition for researchers, schools and research subjects alike. If the study were to be 
taken forward in future years with increased influenza activity then the protocol would be improved 
by moving all data collection to online survey tools. 
The poor online questionnaire response rate for our study may have been because of the combination 
of a hyperlink shortening service redirecting internet traffic across their server to our Google Forms 
survey tool. In order to allow head teachers to send a short hyperlink in an email to parents and 
guardians we used a service that shortens hyperlinks from the standard hyperlink provided by Google 
Forms (approximately 100 characters) to a shorter length of approximately 20 characters. The service 
may have triggered in-browser anti-virus software that prompted users to check whether they wanted 
to be redirected to a hyperlink with a very different address, which may have discouraged some users 
attempting to complete the questions online.  
After noticing a low response rate for online questionnaires we distributed the shortened hyperlink 
to colleagues at LSHTM who anecdotally reported the activation of their in-browser anti-virus 
software after clicking the hyperlink sent via email.  
MEASURING COSTS 
Costs incurred due to a child’s ILI infection were discretely grouped. Indicating costs using discrete 
groups was judged to be easier than requiring parents or guardians to list all individual costs incurred 
during ILI infection. Due to time delays in sending paper-based questionnaires to schools we thought 
that itemised costs would have been too difficult to report and therefore the exercise would be 
subject to substantial recall bias.  
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The grouped cost data obtained during the study showed that the majority of parents and guardians 
did not incur many out-of-pocket expenses due to their child’s ILI infection. This result is important as 
it can be used for economic analyses of different measures to mitigate seasonal influenza epidemics 
conducted from the societal perspective and may avoid overestimating the total costs incurred. 
However, for those parents and guardians that did incur such costs during infection, the lack of 
description about different potential costs meant it may have been difficult to estimate the total costs 
incurred. 
Rapid distribution of online questionnaires to the parents and guardians affected by a suspected ILI 
outbreak in their child’s school would reduce the potential for recall bias when reporting costs 
incurred. Additional information provided to parents and guardians to help them consider all potential 
costs would reduce the risk that they do not include all potential costs. 
INTENTION TO VACCINATE VS. SUCCESSFUL VACCINATION 
81.6% of parents and guardians expressed a preference for their child to receive an annual influenza 
vaccination in our study. However, uptake of the seasonal influenza vaccination was considerably 
lower than this, with Pebody et al. (2014) reporting 52.5% uptake in a pilot of seven discrete 
geographical areas in England during the 2013-14 influenza season [21].  
There is a distinction between those parents and guardians who would look favourably on an annual 
influenza vaccination for their child and those parents and guardians who consent to the 
administration of such a vaccine to their child. There may be many different reasons why those 
previously in favour of influenza vaccination do not subsequently consent to vaccine uptake, but the 
parents and guardians that do not vaccinate their child after previously expressing an interest to do 
so do not fall into the recognised category of “vaccine hesitant” caregivers.  
Understanding the reasons why parents or guardians have previously expressed their desire to 
vaccinate their child but ultimately failed to do so could be used to increase vaccination uptake in 
those parents and guardians not consenting to vaccination but who’re also not vaccine hesitant. If the 
difference between the 81.6% preference for vaccination reported in our study and the 52.5% uptake 
reported in the seasonal influenza vaccination pilots is due to more than just responder bias in our 
study then this would be a worthwhile study to pursue. 
INTERPRETATION FOR SCHOOLS 
The impact of ILI outbreaks in primary schools is mainly seen in the total loss of productivity due to 
illness. We did not find a large financial impact, but ILI infection contracted in school will have a socio-
economic impact at home. In the event of a suspected ILI outbreak occurring at a primary school, staff 
should contact their local Public Health England centre for advice on mitigating the outbreak to 
minimise this impact.  
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At the time of writing, a children’s influenza vaccine is available for primary school children in school 
years 1 and 2 which will offer direct protection to those children vaccinated as well as indirect 
protection for their family, carers and the wider population. Parents and guardians of children in these 
school years should be made aware of the benefits of annual influenza vaccination for their children. 
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Chapter 5 - Modelling seasonal influenza vaccination 
programmes, part I: targeted vaccination at a national level 
Portions of this section were published in Vaccine in August 2015 [1], tabled at the meeting of the 
Joint Committee on Vaccination and Immunisation on 3rd June 2015 [2] and presented at the 
Epidemics 5 conference in Tampa, FL USA in December 2015. © 2015 Elsevier Ltd. 
ABSTRACT 
BACKGROUND 
The UK commenced an extension to the seasonal influenza vaccination policy in autumn 2014 that 
will eventually see all healthy children between the ages of 2-16 years offered annual influenza 
vaccination. Models suggest that the new policy will be both highly effective at reducing the burden 
of influenza as well as cost-effective. 
OBJECTIVE 
We explore whether targeting vaccination at either primary or secondary schools would be more 
effective and/or cost-effective than the current strategy. 
METHODS AND FINDINGS 
An age-structured deterministic transmission dynamic SEIR-type mathematical model was used to 
simulate a national influenza outbreak in England. Costs including GP consultations, hospitalisations 
due to influenza and vaccinations were compared to potential gains in quality-adjusted life years 
achieved through vaccinating healthy children. Costs and benefits of the new JCVI vaccination policy 
were estimated over a single season, and compared to the hypothesised new policies of targeted and 
heterogeneous vaccination. All potential vaccination policies were highly cost-effective. Influenza 
transmission can be eliminated for a particular season by vaccinating both primary and secondary 
school children, but not by vaccinating only one group. The most cost-effective policy overall is 
heterogeneous vaccination coverage with 48% uptake in primary schools and 34% in secondary 
schools.  
CONCLUSION 
The Joint Committee on Vaccination and Immunisation can consider a modification to their policy of 
offering seasonal influenza vaccinations to all healthy children of ages 2 to 16 years. 
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INTRODUCTION 
The previous chapter details the investigation of the societal and economic impact of seasonal 
influenza infection as felt at home by those parents and guardians with children attending primary 
schools in England. The results from the investigation will be crucial to understanding the impact of 
influenza outbreaks on the community, providing an additional perspective on the far-reaching 
consequences of infectious disease outbreaks typically overlooked by cost-effectiveness analyses that 
use a more narrow perspective on overall benefits and costs. 
However, preventative measures for influenza outbreaks take the form of nationwide vaccination 
programmes. In England, cost-effectiveness analyses for new vaccination programmes are conducted 
from the healthcare provider perspective. The national influenza vaccination programme in England 
was introduced in Chapter 2 and is discussed further in the following section. Here, we investigate 
options to modify the planned roll-out of the school-based vaccination programme by considering the 
optimal vaccination coverage for both primary and secondary school populations, from the 
perspective of the healthcare provider. 
BACKGROUND 
THE UK SEASONAL INFLUENZA VACCINATION PROGRAMME 
The UK has had a long-standing seasonal influenza vaccination programme. Originally available to 
those in at-risk groups including those with underlying health conditions such as chronic heart disease, 
the programme was extended in 1998 to include people aged 75 years and over. Two years later it 
was extended again to include people aged 65 years and over. Pregnant women were included in 
2010. Any proposed alterations to a national vaccination programme should be accompanied by a 
cost-effectiveness analysis using quality-adjusted life years (QALYs) as the measured benefit, 
according to guidelines written by both The National Institute for Health and Clinical Excellence (NICE) 
and the JCVI [3, 4]. A cost-effective vaccination policy would have a cost per QALY ratio less than 
£20,000 per QALY, from the perspective of the healthcare provider [3]. In 2013 Baguelin et al. (2013) 
reported that it would be cost-effective to offer vaccination to children in addition to the other groups 
currently offered the vaccine [5]. 
EXTENSION TO THE SEASONAL INFLUENZA VACCINATION PROGRAMME 
Subsequently, the Joint Committee on Vaccination and Immunisation (JCVI) in 2012 recommended 
extending the influenza vaccination programme to all children between the ages of 2-16 years [6]. 
This extension would see a live-attenuated influenza vaccination (LAIV) offered to children each year 
with the majority of vaccines administered in school settings, and would become the largest 
vaccination programme in the UK measured in terms of number of doses administered. The LAIV is 
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more effective than inactivated vaccines in children and adolescents and may also offer protection 
against drifted strains of influenza [7, 8].  
Children and adolescents attending schools play a large role in the spread of influenza in the 
community [9-11]. Transmission within schools is maintained because of the high number of close 
contacts between school children [12], as well as less acquired immunity in children [13] and a longer 
period of virus-shedding once infected [14, 15]. Vaccinating children has the potential to reduce 
influenza episodes both in the vaccinated individuals, but also in individuals of all age groups who 
were not vaccinated, or who did not successfully seroconvert following vaccination. Several countries 
now offer annual influenza vaccination to healthy children as it has been repeatedly shown to be a 
cost-effective extension of existing national influenza vaccination programmes [16, 17]. 
Previous modelling analyses demonstrating the cost-effectiveness of vaccinating healthy children 
have consistently assumed that children in both primary schools (aged 4 – 11 years) and secondary 
schools (11 – 16 years) would be simultaneously vaccinated [18, 19]. For infectious diseases such as 
seasonal influenza, which has a low potential for transmission, it is possible to vaccinate a proportion 
of a population to eliminate the potential for sustained transmission (the threshold for “herd 
immunity” [20]). This threshold could be achieved with a successful vaccination policy implemented 
in only one of the two school groups. Indeed, the planned roll-out of the vaccination programme 
involves vaccinating the youngest children in primary schools (those aged 4-5 years) in autumn/winter 
2014-15, with each successive influenza season seeing vaccination offered to successive age groups. 
With this plan, autumn/winter 2020-21 will be the first year that all primary school children are 
vaccinated against seasonal influenza. Therefore, if successful vaccination in this cohort is capable of 
stopping large nationwide outbreaks of seasonal influenza the subsequent vaccination of children in 
secondary schools may not be required. 
This study aims to establish whether a programme of targeted vaccination in either primary or 
secondary schools would be more cost-effective than a programme stretching across both school 
groups, and whether it will be able to eliminate influenza transmission for that season. Given a range 
of coverage levels we also investigate how high coverage needs to be in order to maximise cost-
effectiveness. For comparability, we have used epidemiological and economic parameters from 
previous influenza vaccination analyses to inform national immunisation [5, 21], but adopted a simpler 
model to highlight key results related to optimally targeting age groups for paediatric vaccination.  
RESEARCH QUESTIONS 
1. Can the JCVI-recommended extension to the UK seasonal influenza vaccination programme 
be extended without homogenous vaccination between primary and secondary schools? 
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2. Would a targeted vaccination programme in either primary or secondary schools be cost-
effective? Would a heterogeneous vaccination policy be cost-effective? 
METHODS 
THE AGE-STRUCTURED MODEL 
This study uses a discrete time age-structured deterministic model with SEIR structure written in R 
version 3.0.2 using the tcltk2, mc2d, mgcv, MASS and lattice packages [22-27] to estimate the burden 
of disease. The model has age-structured compartments representing individuals susceptible to 
influenza infection (S), latently infected (E), infectious (I) and recovered (R).  The model is linked to a 
decision tree model also written in R to determine the cost-effectiveness of each proposed vaccination 
policy in comparison to the old UK policy. 
The SEIR framework has been modified to include classes of those vaccinated (V) as well as individuals 
assumed to have immunity from influenza due to exposure in previous seasons and therefore have 
associated antibodies in their immune systems (A). An individual in the model who has recovered from 
infection is assumed to have immunity from influenza for the remainder of the simulation (i.e. one 
influenza season). Persons successfully immunised also acquire immunity for the duration of the 
simulation but a fraction of those vaccinated were non-responders and remain susceptible [28]. All 
vaccination is assumed to take place at random within the targeted age groups before the annual 
influenza season commences when the first infection occurs. 
𝑑𝑆𝑖
𝑑𝑡
= −𝜆𝑖𝑆𝑖 
𝑑𝐸𝑖
𝑑𝑡
= 𝜆𝑖𝑆𝑖 − 𝛾𝐸𝑖   
𝑑𝐼𝑖
𝑑𝑡
= 𝛾𝐸𝑖 − 𝛿𝐼𝑖   
𝑑𝑅𝑖
𝑑𝑡
= 𝛿𝐼𝑖 
Equation 5.1 - The SEIR-type age-structured transmission model 
Si represents the number of susceptible individuals in age group i in the population N; Ei represents 
the number of exposed but not yet infectious individuals; Ii represents the number of infectious 
individuals and Ri represents the number of individuals whose period of infectiousness has ceased 
(either by recovery or death from infection). γ-1 is the time that an individual is exposed but not yet 
infectious and δ-1 is the time that an individual is infectious. λi is the force of infection for age group i. 
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𝜆𝑖 = ∑
𝛽𝑖𝑗𝐼𝑗
𝑁𝑗
𝑗
 
Equation 5.2 - The age-dependent force of infection 
βi,j is the matrix of the mean daily number of contacts between an individual of age group i with age 
group j. σi is the age-specific proportion of individuals in the S compartment who have not acquired 
immunity from clinical at-risk vaccination; from the new vaccination programme; or from previous 
influenza seasons.  
Contact rates between age groups in the population can be critical for determining model outcomes 
[29]. In our model the population of England is divided into 5 age groups (0 – 3, 4 – 10, 11 – 16, 17 – 
64 and 65+ years old) using 2011 mid-year estimates [30] (Table 5.1). Individuals have close contacts 
with others in the model according to the POLYMOD survey of contact frequency in Europe [12].  
Age group Total population [30] At-risk population [21] Vaccinated (baseline) [31]  
0 – 3 years 2,680,335 138,573 71,504 
4 – 10 4,221,738 218,264 112,624 
11 – 16 3,771,682 194,996 100,618 
17 – 64 33,703,747 1,742,484 899,122 
65+ 8,729,667 8,729,667 6,459,954 
Table 5.1 - Total population of England, at-risk population and the number of seasonal influenza 
vaccinations administered before new JCVI vaccination policy is implemented 
The mathematical model was informed with the age-dependent mixing patterns measured from the 
Great Britain arm of this eight-country survey in the form of a matrix of close contacts, βi,j (Figure 5.1). 
A significant proportion of influenza infections are subclinical. The definition of clinical influenza is 
fever with one other influenza-related symptom [32]. Clinical influenza incidence was estimated as a 
proportion of total infections generated by the model, derived from a review of volunteer challenge 
studies that found that 35% of individuals with influenza had fever, thereby providing an estimate of 
clinical influenza cases from suspected influenza infections [33]. 
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Figure 5.1 - Weighted social contact matrix from POLYMOD contact survey, showing the mean number 
of long-duration physical contacts per day for participants in Great Britain. The age group of 
participants and their contacts are shown on the axes. 
MODEL CALIBRATION 
The model was calibrated by fitting the incidence of clinical influenza to final size data of the 2006-07 
influenza season in England to ensure our model produced results comparable to the model of 
Baguelin et al. (2012) used to inform England’s original decision to vaccinate children [18]. Parameters 
for the proportion of each age group with prior immunity to influenza were estimated using Latin 
Hypercube sampling and binomial maximum likelihood estimation (Table 5.2). We drew 25,000 Latin 
Hypercube samples from uniform distributions over [0,1] for each of these parameters, and then 
selected those which minimised the binomial log-likelihood using the observed final size and the 
simulated final size for each age group. 
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Parameter Value Source 
R0, initial reproduction 
number † 
Triangular with min=1.30, 
max=1.59, mode=1.46 
[18] 
Vaccine efficacy † 70% (95% CI: 57 – 78) for 0 – 64 
46% (95% CI: -17 – 75) for 65+ 
years 
[28] 
Latent period 1.46 days [18] 
Infectious period 1.28 days [18] 
Susceptible proportion 
of 0-3 group † 
0.7837 Calibration exercise 
Susceptible proportion 
of 4-10 group † 
0.8943 Calibration exercise 
Susceptible proportion 
of 11-16 group † 
0.9819 Calibration exercise 
Susceptible proportion 
of 17-64 group † 
0.9496 Calibration exercise 
Susceptible proportion 
of 65+ group † 
0.9736 Calibration exercise 
Table 5.2 - Transmission model parameters 
In fitting the expected final size of ILI epidemics to the observed final size of the 2006-07 epidemics 
we sampled 25,000 sets of parameters for the age-specific proportion of susceptibles in the 
population using uniform Latin Hypercube sampling to cover the possible parameter space. Each of 
the 25,000 parameter sets was used in the model to estimate the expected final size in each age group. 
The parameter values used in the simulation of the model that minimised the binomial log-likelihood, 
defined below. 
ln ℒ = ∑ 𝑦𝑖 ln 𝑝𝑖 + (𝑛𝑖 − 𝑦𝑖)
5
𝑖=1
ln(1 − 𝑝𝑖) 
Equation 5.3 - The binomial log-likelihood minimised to estimate the age-specific proportion of 
individuals with previously acquired immunity 
ni represents the number of individuals in the population; yi represents the observed final size of the 
2006-07 epidemic; and pi represents the estimated final size from the model using the 5 parameters 
for age-specific prior immunity sampled using Latin Hypercube sampling. 
MODELLING VACCINATION 
We assumed that vaccination administered using LAIV requires one dose per individual. The baseline 
for all modelling scenarios was a continuation of the influenza vaccination policy in the UK prior to the 
introduction of paediatric vaccination (i.e. at-risk groups and adults ≥65 years only). The outputs from 
this scenario were then compared to modelling outputs from the following scenarios: 
1. Targeting primary schools only 
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2. Targeting secondary schools only 
3. Targeting both primary school and secondary school age groups, and achieving the same 
(homogeneous) level of coverage in both 
4. Targeting both primary school and secondary school age groups, and achieving different 
(heterogeneous) levels of coverage in either 
For each scenario the vaccination coverage achieved prior to the start of each influenza season was 
varied from 0-100%. The economic impact of such coverage was analysed in the economic evaluation. 
Individuals in at-risk clinical and age groups were vaccinated according to the previous influenza 
vaccination programme, with uptake data taken from Public Health England [31]. At-risk individuals 
were assumed to have the same pre-vaccination susceptibility and mixing patterns as not-at-risk 
individuals of the same age. We assumed that those school-age individuals vaccinated due to their at-
risk status were not vaccinated again at school because their parents or guardians would be aware of 
their vaccination status and would not need to consent to a second vaccination. 
For homogenous coverage vaccination occurred in both age groups at the same level. For targeted 
vaccination only one age group was vaccinated. For the heterogeneous policy we allowed coverage in 
primary schools to vary from 0-100% then at each level examined the effect of supplementary 
vaccination in secondary schools from 0-100%, including the homogenous case.   
ECONOMIC EVALUATION 
From the estimates of the burden of disease from the epidemiological model a proportion of 
infections were assumed to result in clinical infections. Individuals with clinical influenza then use 
health services during their period of infection with each health service having an associated cost to 
the health care provider. Clinical influenza was associated with a risk of consultation with their GP, 
hospitalisation, intensive care admission and death. 
We compared the total costs and number of QALYs saved for each possible vaccination coverage level 
for each of the four scenarios, arranging each coverage level by total cost in ascending order. The 
incremental cost-effectiveness ratio was calculated by comparing the ratio of an increase in the cost 
of a different coverage level achieved with the difference in QALYs saved. Those coverage levels that 
saved fewer QALYs than a less costly coverage level were dominated and therefore eliminated from 
the analysis.  
Parameters used in the economic evaluation were first used by Baguelin et al. (2010) [21] with sources 
updated where possible (Table 5.3). Estimates of the use of GP services and the risk of hospitalisation 
due to influenza infection were taken from the published literature. We used the ratio of consultations 
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and hospitalisations from Cromer et al. (2014) [34]. We also assumed at all deaths due to influenza 
infection occur after a hospital admission and that all intensive care admissions also require first an 
admission to hospital.  
Parameter Value Source 
Proportion of infected cases with clinical ‘flu 0.35 [33] 
Hospitalised case fatality ratio 0.0009 for 0 – 3 years 
0.0012 for 4 – 16 
0.0258 for 17 - 64 
0.1486 for 65+ 
[34] 
Quality-adjusted life expectancy 67.34 quality-adjusted life years at birth 2009 data 
Proportion of ILI cases visiting their GP 0.1 [36] 
Proportion of GP visits subsequently requiring 
hospitalisation † 
0.0375 for 0 – 3 years 
0.0036 for 4 – 16 
0.0105 for 17 – 64  
0.1087 for 65+ 
[34] 
Proportion of hospitalised cases requiring 
intensive care 
0.0557 RMN, FluZone 
Cost of GP consultation † Log normal from N(µ=£45, σ=£8.4) [37] 
Cost of hospital admission (non-elective) † Log normal from N(µ=£1,489, σ=£192.1) [38] 
Cost of admission to intensive care † Triangular with min=£1,449, max=£2,300, 
mode=£2,034 
[38] 
Cost of vaccine per dose † £14 [39] 
Cost of vaccine delivery and administration per 
dose † 
£3.03 [40] 
QALY loss (not hospitalised) † N(µ=0.0074, σ=0.00085) for 0 – 16 
N(µ=0.0082, σ=0.00180) for 17+ years 
[18, 35] 
QALY loss (hospitalised) † N(µ=0.0160, σ=0.00180) for 0 – 16 
N(µ=0.0180, σ=0.00180) for 17+ years 
[18, 41] 
Discount rate 3.5% per annum [3] 
Table 5.3 - Economic evaluation model parameters 
QALY loss due to clinical influenza were taken from EuroQol EQ-5D-3L surveys conducted in the United 
Kingdom during the 2009 H1N1v pandemic [18, 35]. Life expectancy data were taken from quality-
adjusted life expectancy tables. 
We used the same cost items as Baguelin et al. (2010) [21], but updated sources to reflect 2013 costs 
where possible. Costs for GP surgery consultations, hospitalisations and intensive care stays were 
taken from published sources. Costs relating to vaccinations were taken as the unit cost of the Fluenz 
vaccination [39] plus 10 minutes of a Band 7 nurse’s time [40]. 
The cost-effectiveness of each vaccination scenario was estimated using the net incremental cost per 
quality-adjusted life year saved (ICER), comparing each modelled vaccination uptake level to the next 
best non-dominated uptake level. We calculated an ICER for each vaccination policy by adjusting the 
vaccination coverage level by increments of 1%. The optimally cost-effective level of uptake was 
deemed to be the highest uptake possible with an ICER of less than £20,000 per QALY gained, the 
threshold at which an intervention is considered cost-effective according to NICE [3]. 
98 
 
SENSITIVITY ANALYSIS 
A multivariate parametric sensitivity analysis was performed to assess the sensitivity of the model to 
different parameters: R0, the proportion of each age group susceptible, vaccine efficacy in school 
children, risk of hospitalisation in school children, QALY loss for hospitalised and non-hospitalised 
school children, the cost of a GP consultation, the cost of a non-elective hospital admission, the cost 
of admission to intensive care and the total cost of the vaccine per dose. Ranges for parameters were 
defined as a uniformly distributed ±5% of the parameter value used in the model, or according to the 
distributions from previous studies as shown in  Table 5.2 and Table 5.3 (marked with †). We ran 5,000 
simulations of the most cost-effective coverage levels for each vaccination policy to plot cost-
effectiveness estimates compared to no JCVI programme extension. 
In addition to the multivariate parametric sensitivity analysis we used the best-fitting 1% and 5% of 
realisations from the calibration exercise to check how sensitive the model results are to the 
proportion of each age group with prior immunity to influenza by reporting the proportion of the best-
fitting parameters that confirmed the dominance of the most cost-effective vaccination policy. 
RESULTS 
MODEL CALIBRATION 
Figure 5.2 shows the epidemic curves from the best-fitting realisations of the model. We used the set 
of parameters that minimised the binomial log-likelihood but we kept the best-fitting 5% of 
realisations for sensitivity analyses.  
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Figure 5.2 - The epidemic curves of the best fitting models from 25,000 parameter sets sampled using 
uniform Latin Hypercube sampling 
NO EXTENSION TO THE SEASONAL INFLUENZA VACCINATION PROGRAMME 
BURDEN OF DISEASE 
The proportion of the total population infected over a season prior to the extension of vaccination to 
low-risk children is 25.0% (13.3m), of which 4.7m are clinical influenza cases (Figure 5.3). 4,309 deaths 
occur due to influenza and 35.8% of those are deaths in the 65+ years age group. Baguelin et al. (2012) 
estimated 370-4,700 seasonal influenza-attributable deaths per year in a low-severity scenario, a 
range that includes the estimates from our model [18].  
COST-EFFECTIVENESS 
The outbreak costs £188m from the perspective of the health care provider with 38,600 QALYs lost 
due to infection. 
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Figure 5.3 - Epidemic curve plotting the fraction of each age group infected for the baseline scenario, 
in which there are no vaccination programme extensions beyond those in at-risk groups and adults of 
age 65+ years 
HOMOGENEOUS VACCINATION PROGRAMME EXTENSION 
BURDEN OF DISEASE 
Vaccination of school children, in addition to the current regime of vaccination, can eliminate 
influenza transmission. The model predicts fewer than 10 cases of clinical influenza at 66% vaccine 
coverage.  
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COST-EFFECTIVENESS 
 
Figure 5.4 - QALYs gained per vaccination administered for each vaccination policy. Homogeneous 
vaccination efficiency across both primary and secondary schools (black) peaks when coverage reaches 
32%. QALYs gained per vaccination in primary schools (green) peaks  
The most cost-effective level of vaccine coverage is 42% (ICER of £14,394 per QALY saved). At this level 
the policy costs £210.7m and saves 38,505 QALYs over baseline. The number of QALYs gained per 
vaccination administered is maximised when vaccination coverage reaches 38%, where each 
vaccination dose administered saves 0.0126 QALYs, equivalent to 4.62 QALDs (Figure 5.4). Between 
30% and 38% coverage the number of QALYs gained per vaccination administered increases faster 
than for lower vaccination coverage levels, highlighting the indirect benefit to the whole population 
of vaccinating school-age children for seasonal influenza. 
TARGETED VACCINATION IN PRIMARY SCHOOLS 
BURDEN OF DISEASE 
Primary school vaccination alone cannot eliminate influenza transmission. Even at 100% coverage the 
model predicts a total of 149 influenza-attributable deaths. 
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COST-EFFECTIVENESS 
The optimal cost-effectiveness occurs when coverage reaches 100% (ICER of £3,117 per QALY, Figure 
5.5). At this level of coverage the targeted policy costs £226.1m and saves 37,244 QALYs over baseline 
(Table 5.4). 
The number of QALYs gained per vaccination administered is maximised when coverage reaches 92% 
and each vaccination administered saves 0.0093 QALYs, equivalent to 3.39 QALDs (Figure 5.4). The 
mean number of pupils in a state-funded primary school in England is 263 [42] so achieving 92% 
coverage in each primary school saves 2.25 QALYs or 820 QALDs per school over the course of an 
influenza season. 
The number of QALYs gained per vaccination administered increases to the maximum value from 60%. 
This sharp increase in programme effectiveness is due to herd immunity and the indirect impact on 
the wider population of vaccinating a large percentage of the primary school children. 
 
Figure 5.5 - (1) The total costs of the vaccination policies plus healthcare and treatment costs, (2) the 
QALYs lost due to influenza, (3) the incremental cost-effectiveness ratio and (4) the number of deaths 
averted over baseline. Homogenous vaccination (black), targeted vaccination in primary schools 
(green) and targeted vaccination in secondary schools (blue) 
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TARGETED VACCINATION IN SECONDARY SCHOOLS 
BURDEN OF DISEASE 
Secondary school vaccination alone cannot eliminate influenza transmission and reduces transmission 
to a lesser degree than at the same level of coverage for primary school vaccination - at vaccination 
coverage of 100% in secondary schools the overall final size of an outbreak is 11.89% (6.31m total 
infections of which 2.21m would be clinical influenza).   
COST-EFFECTIVENESS 
The optimal cost-effectiveness occurs threshold when coverage reaches 100% (£4,280 per QALY 
saved, Figure 5.5). The number of QALYs saved per vaccination administered in secondary schools 
peaks at 0.0063 QALYs or 2.30 QALDs at 12% coverage. 
HETEROGENEOUS COVERAGE ACROSS PRIMARY AND SECONDARY SCHOOLS 
BURDEN OF DISEASE 
The minimum coverage required to eliminate influenza transmission is 79% in primary schools and 
48% in secondary schools. The model predicts fewer than 10 cases of clinical influenza with this 
vaccine coverage. 
COST-EFFECTIVENESS 
The optimal cost-effectiveness occurs at a coverage level of 48% in primary schools and 34% in 
secondary schools (£16,152 per QALY saved, Figure 5.6). At this level of coverage the total cost of the 
policy is £210.0m and saves 38,496 QALYs over baseline. The next most costly vaccination coverage 
was to achieve 48% in primary schools and 35% in secondary schools, with incremental costs of 
£603,108 and 26.8 additional QALYs saved (ICER of £22,526/QALY, above the cost-effectiveness 
threshold of £20,000). 
The number of QALYs gained per vaccination administered is maximised when coverage reaches 45% 
in primary schools and 28% in secondary schools. Each vaccination saves 0.0128 QALYs, equivalent to 
4.67 QALDs. Using the mean number of pupils in a primary school and a secondary school (263 and 
956 respectively [42]), implementing a policy of heterogeneous coverage to these coverage levels for 
one primary school and one secondary school saves 4.94 QALYs or 1,804 QALDs. 
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Figure 5.6 - Examining the impact of heterogeneous vaccination coverage. (1) final size of outbreak, 
(2) the QALYs gained per vaccination administered (3) the total cost of the vaccination policy (£ 
millions) and (4) the costs per vaccination administered (£).Horizontal axis shows the proportion of 
vaccination coverage in primary schools and the vertical axis shows the vaccination coverage in 
secondary schools 
 Most cost-effective 
scenario 
Maximum QALYs 
gained per 
vaccination 
Minimum total costs 
per vaccination 
Targeted policy in 
primary schools 
100% (ICER = £3,117) 0.0093 (92% 
coverage) 
£9.13 (92% coverage) 
Targeted policy in 
secondary schools 
100% (ICER = £4,280) 0.0063 (12% 
coverage) 
£11.26 (1% coverage) 
Heterogeneous policy 48% and 34% 
(ICER = £16,152) 
0.0128 (45% and 28%) £6.14 (44% and 29%) 
Table 5.4 - Comparing three new vaccination policies 
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Sensitivity analysis 
PROBABILISTIC SENSITIVITY ANALYSIS 
Figure 5.7 shows that the uncertainty in the parameters used to calculate the cost-effectiveness ratios 
does not impact on probability that each vaccination strategy could be cost-effective at the 
willingness-to-pay threshold of £20,000 per QALY, when compared to no extension of the seasonal 
vaccination policy. There is more uncertainty in the total number of QALYs saved than in the total cost 
of the new vaccination policies. 
 
Figure 5.7 - Sensitivity analysis of the most cost-effective strategies of each of the four different 
vaccination policies when compared with no implementation of the new JCVI-recommended 
programme. Grey and black lines denote the £30,000 per QALY and £20,000 per QALY ratios 
respectively  
In addition, in 208 (83.2%) of the best-fitting 1% of model realisations, the heterogeneous vaccination 
policy was the dominant option, with a targeted vaccination policy in primary schools dominant just 
42 (16.8%) times. When extending to the best-fitting 5% of model realisations, the heterogeneous 
vaccination policy dominated other options 793 (63.4%) times. 
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DISCUSSION 
We investigated the optimal influenza LAIV coverage levels in primary schools and secondary schools 
to examine potential modifications to the JCVI influenza vaccination programme. We varied coverage 
levels in both primary and secondary schools between 0 – 100% and calculated the ICERs for each 
coverage level for four different vaccination strategies.  
Overall, the optimum coverage level is 48% in primary schools and 34% in secondary schools in a 
heterogeneous vaccination strategy with an ICER of £16,152 per QALY saved. As the two targeted 
strategies and one homogenous coverage strategy are subgroups of the heterogeneous strategy we 
conclude that a policy of heterogeneous coverage should be pursued by the UK. 
We examined the impact of the uncertainty of all parameters in the model and concluded that the 
cost-effectiveness estimates are not affected by these uncertainties. The heterogeneous vaccination 
policy was the dominant policy for the majority of model realisations. 
STUDY LIMITATIONS 
UNCERTAINTY IN PARAMETER ESTIMATES 
Our sensitivity analysis explored the uncertainty in the model results using a range of values ±5% of 
the parameter value used in the model. This range may not have captured the full uncertainty of some 
parameters in the model and therefore our sensitivity analysis may not have fully assessed the 
robustness of our estimates. 
The accurate estimation of the duration of both the latent and infectious periods for influenza is 
difficult, therefore it is likely that the fixed values for both parameters used in our model do not 
capture the uncertainty for these parameters. Similarly, the value used for the proportion of cases 
with clinical influenza as well as rates of hospitalisation and mortality do not capture uncertainty in 
these parameters. All of these values are very difficult to measure so not incorporating the 
appropriate parameter distributions limited our ability to properly evaluate the uncertainty in our 
results. 
MODELLING A SINGLE INFLUENZA SEASON 
For simplicity, we have only modelled a single influenza season and did not model immunity between 
seasons (other than to assume that an age-dependent proportion of individuals are immune at the 
start of the season). Immunity from influenza will wane, whether acquired through influenza infection 
or through vaccination. This may impact the cost-effectiveness estimates in our model but is likely to 
improve cost-effectiveness if acquired immunity lasts longer than one influenza season. Modelling 
influenza outbreaks over a longer time horizon is more complex as many other ideas such as cross-
immunity, antigenic drift and competing strains could be incorporated into the model. It is possible 
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that primary school children have less time than secondary school children to acquire immunity for 
different influenza viruses from past infection and this can impact on the number of susceptible 
individuals in the model. Indeed, our model already sees that more primary school children are 
susceptible to the single pathogen assumed to cause this single outbreak, but additional circulating 
strains could change our results.  
CONTACT PATTERNS ON TERM-TIME CONTACTS ONLY 
We used data on contact patterns only during term-time at school and did not include changes in 
these contact patterns during school holidays or weekends for simplicity. Studies have shown that the 
daily number of age-dependent contacts for children can vary between term-time and holidays or 
weekends [43-45]. The inclusion of additional contact matrices in the model would improve the 
accuracy of the mathematical model in estimating the daily number of contacts sufficient for influenza 
transmission between children and their contacts. The simplest adaption of the model to include 
dynamic contact patterns is to reduce the daily number of contacts that school children have with 
other school children whilst increasing the daily number of contacts that school children have with 
adults during school holiday periods, as reported by Eames et al. (2011) [43]. Further adjustments 
could be made to include typical weekend contact patterns by assuming that school holiday contact 
patterns and weekend contact patterns are similar in nature. 
In addition, we divided the school population into two age groups that saw children aged 4-10 years 
in primary school with those aged 11-16 years in secondary school. This broad distinction isn’t 
reflective of school age distributions and a more detailed age-structured model could account for a 
proportion of those children aged 11 years attending primary school with the complement attending 
secondary school. 
CONTACT PATTERNS FOR INDIVIDUALS WITH INFECTIOUS DISEASES 
Including contact patterns from the European contact surveys conducted by Mossong et al. (2008) 
[12] makes an assumption that individuals with infectious diseases maintain daily contact patterns 
throughout their period of infection, consistent with their regular contact patterns when healthy. This 
assumption can be challenged using data from our studies on the impact of influenza and measles, as 
large proportions of those infected with each disease reported several days at home from school or 
work. Their typical contact patterns during periods of good health - assumed to approximate to the 
POLYMOD contact matrices – would be the daily contact patterns experienced whilst at school or 
work, therefore their infection and subsequent change in their daily routine would dramatically 
change their daily contact patterns. This is not reflected in our mathematical modelling and such a 
change in daily contact patterns is likely to change an individual’s potential for transmission in the 
community. 
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Recording contact patterns for individuals with infectious disease would require further contact 
studies utilising diaries for reporting contacts before, during and after infection. Recruiting a sufficient 
sample size to be comparable to Mossong et al. (2008) would involve challenges in identifying enough 
individuals in a large population that would subsequently acquire influenza during the influenza 
season. Self-selecting online surveys such as the UK Flusurvey [46] record contact patterns for those 
reporting symptoms consistent with ILI, which would assist in adapting mathematical models of 
influenza and ILI transmission. 
HOMOGENOUS AGE-SPECIFIC VACCINATION UPTAKE 
We assumed that age-specific vaccination uptake would be homogenous in England. The recent pilot 
of seven models for vaccine delivery for children attending primary schools showed variation in the 
coverage levels, even in those six geographical areas using school-based vaccine delivery [47]. In 
reality, community-level vaccination coverage is likely to be patchy, so an improved mathematical 
model would account for this community-level heterogeneity even if a policy aims for homogeneous 
age-specific uptake as we recommended. 
MODELLING VACCINATION UPTAKE IN 2-3 YEAR OLDS 
The new seasonal influenza vaccination policy includes the vaccination of 2-3 year olds in addition to 
children attending primary and secondary schools [6]. Uptake in these age groups was 42.6% and 
39.6% respectively [48]. Our model includes vaccination in these age groups but only for those 
individuals in a clinically at-risk group, where we assumed 2.67% uptake in all individuals aged 0-3 
years.  
Vaccinating healthy children in the 2-3 years age group in addition to vaccinating those children in a 
clinical at-risk group is likely to provide some indirect protection to members of households with 
young children. The impact of this indirect protection on any vaccination policy in health school-age 
children should not therefore be considered negligible. 
ESTIMATION OF PREVIOUS-ACQUIRED IMMUNITY THROUGH MODEL CALIBRATION 
Data for previous-acquired immunity from influenza were not available, so we estimated this in the 
model calibration process. The sensitivity analysis demonstrated that the cost-effectiveness estimates 
for each scenario are robust when compared to no policy extension, though there was more 
uncertainty in the total QALYs saved than in the total cost of the modelled programmes. There are 
some years where acquired immunity is less protective against the seasonal strain, which leads to 
larger outbreaks of influenza and hence less proportional effect from the same level of vaccine 
coverage. 
Our parameter calibration process used binomial maximum likelihood to fit the expected final size 
from the model to the observed final size of a single epidemic period. The model may be further 
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improved by using different values for parameters in the economic evaluation (e.g. proportion of GP 
visits subsequently requiring hospitalisation) for those individuals in clinical at-risk groups. 
CALIBRATED TO THE FINAL SIZE OF A MILD INFLUENZA SEASON 
Finally, the model was calibrated to 2006-07 data which was a year of low incidence (as have been 
recent years [49, 50]) , so we may have underestimated the cost-effectiveness of vaccination (but also 
the potential of vaccination to eliminate influenza for that year). We used recently-published data on 
health care resource use that have been used in scenarios of high severity influenza. We examined 
the possibility of high incidence years by varying R0 in the multivariate parametric sensitivity analysis 
and concluded that our cost-effectiveness estimates were not affected by uncertainty in the incidence 
of future influenza seasons. 
Despite these limitations, our conclusion that primary school vaccination alone is not able to eliminate 
influenza in the UK appears to be robust, even in a season of low influenza activity. Further work using 
a model calibrated to data from multiple influenza seasons and taking into account long-term natural 
and acquired immunity may allow a more precise estimate of the level of coverage to aim to achieve 
in order to optimise cost-effectiveness. 
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Chapter 6 - Modelling seasonal influenza vaccination 
programmes, part II: heterogeneous vaccination coverage 
between schools in a theoretical representative 
metapopulation framework 
Portions of this section were presented at the Epidemics 5 conference in Tampa, FL USA in December 
2015. 
ABSTRACT 
BACKGROUND 
Mathematical models show the new seasonal influenza vaccination programme in healthy children 
will be both highly effective at reducing the burden of disease as well as cost-effective, but such 
models do not explore the potential for heterogeneous uptake between schools where the 
vaccination programme is implemented.  
OBJECTIVE 
We investigated the potential impact of heterogeneities in vaccination uptake on a theoretical 
population, representative of a small administrative district in England. We investigated the problem 
of unintended heterogeneity in coverage (i.e. one or more schools reporting lower vaccination uptake 
than other schools in the area), then we considered the possible impact of intended heterogeneity in 
vaccination coverage (i.e. concentrating vaccination delivery in specific schools, maintaining a mean 
target coverage level across the area). 
METHODS AND FINDINGS 
An age-structured stochastic transmission dynamic SEIR-type mathematical model with a patch-
structured metapopulation of ≈78,000 individuals were used to simulate influenza epidemics. 
Vaccination programmes targeting different age groups were simulated in order to assess their impact 
on the total burden of disease for the community. Heterogeneity in vaccination coverage was 
managed by assigning each school with its own level of coverage. Targeted vaccination in only primary 
or secondary schools is insufficient to stop sustained transmission, even at very high coverage. 44.5% 
homogeneous coverage stopped the outbreak from spreading across all metapopulation patches 
whilst 47.8% coverage stopped influenza epidemics from occurring at all. 
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CONCLUSION 
Unintended heterogeneity through schools failing to achieve the target level of coverage in either 
primary or secondary schools increases the expected mean final size of epidemics. For low levels of 
coverage, one under-achieving secondary school increased the final size of epidemics but one under-
achieving primary cannot. Intended heterogeneity in vaccination programmes that target either one 
or both school groups through the concentration of coverage in selected schools consistently 
increases the mean final size of epidemics. Heterogeneity in vaccination coverage between schools is 
unlikely to be beneficial to public health officials designing vaccination programmes. 
INTRODUCTION 
The previous chapter considered the impact of modifications to the new national influenza vaccination 
programme. The investigation proposed the division of the sub-population group of school children 
into two groups: primary school children and secondary school children and heterogeneity in the 
uptake of the vaccine is considered between these two groups. This plan, however, treats each age 
group as a homogenous group with homogenous vaccination uptake in all schools. Whilst this is a 
sensible assumption for modelling and economic analyses for national vaccination programmes, it is 
unlikely to reflect reality at a smaller level as schools in each district of the country may report 
different coverage levels for many reasons. 
In this section we discuss a mathematical modelling analysis to determine the impact of 
heterogeneous vaccine coverage between schools, in a theoretical district of England using a 
representative study population.  
BACKGROUND 
INTRODUCING HETEROGENEOUS VACCINATION COVERAGE 
Vaccination programmes aim for high levels of coverage to minimise the possibility of sustained 
community-wide infectious disease transmission caused by the introduction of a pathogen. However, 
reporting high levels of coverage over a large population and geographic area can hide low levels of 
coverage in small communities in that area [1]. The existence of these pockets of low vaccination 
coverage expose those communities to an increased risk of disease transmission, triggering minor 
outbreaks in the larger population [2]. This type of heterogeneity in vaccination coverage is a result of 
the vaccination programme not reaching as many individuals as it was designed to do, and can 
therefore be described as Unintended Heterogeneity. Increasing the vaccination coverage in the small 
pockets of lower levels of vaccination coverage to decrease this type of heterogeneity has associated 
costs but may reduce the likelihood of further minor outbreaks in the population [3].  
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Another source of heterogeneity in vaccination coverage is how a mean coverage level is spread over 
all patches of a metapopulation. Achieving a mean vaccination coverage level of v across the 
metapopulation can be achieved by: 
1. Vaccinating a proportion v inhabitants of each metapopulation patch, or 
2. Vaccination of all inhabitants of a proportion v of the number of equally-sized 
metapopulation patches, or 
3. Vaccination a proportion v1 of inhabitants of one group of equally-sized metapopulation 
patches, and a proportion v2 of inhabitants of inhabitants of another group of equally-sized 
metapopulation patches, with an overall vaccination coverage of v 
This form of heterogeneity in vaccination coverage is a result of the design of a targeted vaccination 
programme, and can therefore be labelled Intended Heterogeneity. 
SUSCEPTIBILITY CLUSTERING AND CONSEQUENCES 
An outbreak of measles ensued in San Diego, California, in January 2008 after an intentionally 
unvaccinated boy returned home from Switzerland with measles [4]. The boy exposed 839 persons to 
measles infection and infected 11 more unvaccinated persons. Nine of the 12 unvaccinated individuals 
with measles had parents who had deliberately rejected vaccination, with the remaining three too 
young to receive their vaccinations. The authors of the indicated that the outbreak was fuelled by 
intentionally unvaccinated individuals [4]. 
Choi et al. (2008) reported on the potential for measles transmission in England, even though at the 
time measles had been eliminated from both England and Wales for more than 10 years [5]. The 
increased risk of community-wide transmission was due to several district health authorities reporting 
declining MMR coverage [1]. 14 of the 99 district health authorities contained enough susceptible 
individuals to have an effective reproduction number greater than one, facilitating the 
reestablishment of measles within the community should the pathogen be introduced. Indeed, in 
2009 the Health Protection Agency reported 876 laboratory-confirmed cases of measles in England 
and Wales with a significant number of additional confirmed cases in all subsequent years [6]. 
An example of an under-vaccinated community fuelling an outbreak of a vaccine-preventable disease 
when the general population had very high vaccination coverage is the 1999-00 measles outbreaks in 
the Netherlands [7]. In 1999 national MMR coverage was 96% but 34 of the 539 municipalities of the 
country reported coverage below 90%. The outbreak started in an orthodox reform elementary school 
with MMR coverage of just 7%. By May 2000 3,292 confirmed cases of measles had been reported 
with 72 hospitalisations and three measles-related deaths in the Netherlands.  
116 
 
PREVIOUS MODELS CONSIDERING UNINTENDED HETEROGENEOUS VACCINATION COVERAGE 
A metapopulation framework divides the study population into distinct spatial domains, allowing 
individuals from different domains to interact whilst maintaining their grouping based on 
demographic factors. Given a suitably large population, one can divide the large geographical area it 
inhabits into smaller regions along lines of population density (e.g. cities, counties), recognised 
boundaries (e.g. countries, continents), or population centres (e.g. schools, workplaces). 
Glass et al. (2004) considered heterogeneous vaccination coverage for measles in the Netherlands by 
dividing a population of 1 million persons into 1,000 patches, each of 1,000 people [8]. Population-
mixing was determined by three parameters that summed to one and are defined in Table 6.1. 
ɛ1 Coefficient of mixing between metapopulation and the external population  
ɛ2 Coefficient of between-patch mixing 
ɛ3 Coefficient of within-patch mixing 
Table 6.1 - Population-mixing parameters as defined by Glass et al. (2004) 
This metapopulation framework facilitated the study of the effect of metapopulation dynamics on 
infectious disease transmission by using and SIR-type transmission model. The overall vaccination 
coverage level was split between 350 high-coverage patches and 650 low-coverage patches. Increased 
heterogeneity in the vaccination coverage lead to an overall increased risk of infection, but particularly 
in the patches of low-coverage. An increase in the overall risk of infection also lead to a decrease in 
the mean age of infection during simulated outbreaks. 
THE CHILDHOOD SEASONAL INFLUENZA VACCINATION PROGRAMME AND THE ROLE OF UNINTENDED VACCINE COVERAGE 
HETEROGENEITY 
As discussed in previous sections, in 2012 the Joint Committee on Vaccination and Immunisation (JCVI) 
recommended extending the seasonal influenza vaccination programme of England and Wales to 
include all school children [9]. Modelling analyses demonstrating the cost-effectiveness of vaccinating 
healthy children have consistently assumed that children in both primary schools (aged 4 – 11 years) 
and secondary schools (11 – 16 years) must be simultaneously vaccinated [10, 11], achieving 
homogenous coverage across the study population. However, other studies [1, 4, 7, 12] have 
highlighted the potential problems caused by vaccine coverage heterogeneity. Indeed, the pilot study 
to test different administration methods for the new programme extension displays some 
heterogeneity in coverage, with uptake varying from 35.8% in Cumbria to 71.5% in South East Essex 
[13]. This pattern may be repeated at the local level, with individual schools within a district reporting 
differing vaccination coverage levels as per Omer et al. (2008) [12], affecting the possible disease 
transmission dynamics. 
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RESEARCH QUESTIONS 
1. Within a theoretical metapopulation framework, what impact would a targeted vaccination 
policy focused on either primary schools or secondary schools have on the potential for 
community-wide seasonal influenza epidemics? How does a targeted vaccination policy in 
one school group compare to homogeneous vaccination across both groups? 
2. What is the impact on the potential burden of disease of one low-coverage school in the 
metapopulation within different vaccination strategies? How does increasing this unintended 
heterogeneity in uptake affect the potential for influenza epidemics? 
3. Can intended heterogeneity in a vaccination programme be advantageous in reducing the 
potential burden of disease over the same number of vaccinations administered 
homogeneously in the metapopulation? 
METHODS 
MODELLING BOTH UNINTENDED AND INTENDED HETEROGENEOUS VACCINATION COVERAGE 
To describe the effect of heterogeneous vaccination coverage we used a mathematical model of 
infectious disease coupled with a metapopulation framework that divides the study population into n 
patches, with each patch assigned a level of vaccination coverage. The level of coverage was defined 
as high- or low-coverage, with the difference between the two a measure of heterogeneity in the 
study population. 
Using methods similar to Glass et al. (2004) [8], the metapopulation was not spatially explicit and 
assumed that mixing patterns in the framework occurred on three levels: 
i. Within-patch mixing 
ii. Between-patch mixing 
iii. Mixing with the external population 
SOCIAL CONTACT PATTERNS 
Mixing patterns at all levels described above were governed by a seven age group POLYMOD social 
contacts matrix for Great Britain (Figure 6.1)  [14].  
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Figure 6.1 - Social contact matrix for Great Britain based on close contacts weighted by sampling 
weights 
Age groups in the model were chosen to be able to model infectious disease dynamics by paying close 
attention to those individuals directly affected by the new seasonal influenza vaccination programme 
[9]. The metapopulation framework facilitated the modelling of the impact of an influenza outbreak 
in a community - we chose to model a community rather than utilise a metapopulation framework for 
a larger population both for computational reasons and to use a spatially explicit metapopulation 
model with a representative study population [15]. This framework provided a sufficiently large 
experimental space in which to test different vaccination strategies and the impact of heterogeneous 
vaccination coverage in English schools.  
METAPOPULATION FRAMEWORK 
Each patch within the metapopulation represented a small community unit with the collected patch 
framework representing a wider community. Modelling potential interventions for infectious disease 
epidemics using a small representative population has been successful in the past, notably with 
modelling childhood vaccination in the US [16] and social distancing measures in Australia [15]. In both 
cases the age distribution of the study populations approximate that of the wider populations for each 
respective country. 
THE NUMBER OF SCHOOLS 
We chose a metapopulation of 25 primary schools and 5 secondary schools to match the ratio of state-
funded primary schools to secondary schools in England in 2014 [17]. Using a larger total number of 
schools would be computationally difficult. Each patch in the metapopulation represented one school. 
In the same year 4.4m children attended state-funded primary schools and 3.2m children attended 
state-funded secondary schools [17]. For ease of computation in the infectious disease transmission 
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model this was rounded to an average of 250 children per state-funded primary school and 1,000 
children per state-funded secondary school.  
THE TOTAL NUMBER OF PATCHES 
 
Figure 6.2 - The metapopulation framework used to model heterogeneous influenza vaccination 
coverage in English schools  
In addition to modelling infectious disease transmission within schools we included an external 
population of those either too young or too old to attend primary or secondary schools. These 
individuals were assigned to a single patch and are subsequently referred to as the external 
population. Our metapopulation therefore consisted of 31 patches in total. Mid-year population 
estimates were used to complete the study population [18]. Figure 6.2 shows the metapopulation 
framework with large squares representing secondary schools, small squares representing primary 
schools and the large surrounding square representing the external population. 
SOCIAL MIXING PATTERNS BETWEEN METAPOPULATION PATCHES 
Social mixing was determined by a seven age group POLYMOD social contact matrix for close contacts, 
M with elements mij. Social contacts occurred on three levels so the POLYMOD social contact matrix 
was adjusted to facilitate this mixing in the metapopulation: 
Case 1: Individuals mixing with other individuals in their own metapopulation patch  
Patches 1 to 25 contain individuals belonging to age group 3 only and patches 26 to 30 contain 
individuals belonging to age group 4 only, whilst patch 31 contains all other individuals. Applying the 
POLYMOD social contact matrix to an individual’s social contacts within their own patch requires the 
introduction of a parameter ε1 on the interval [0,1] to define the proportion of that individual’s social 
contacts within that age group within that patch. 
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m1,1 m1,2 0 0 m1,5 m1,6 m1,7 
m2,1 m2,2 0 0 m2,5 m2,6 m2,7 
0 0 ε1m3,3 0 0 0 0 
0 0 0 ε1m4,4 0 0 0 
m5,1 m5,2 0 0 m5,5 m5,6 m5,7 
m6,1 m6,2 0 0 m6,5 m6,6 m6,7 
m7,1 m7,2 0 0 m7,5 m7,6 m7,7 
Equation 6.1 - The POLYMOD social contact matrix for contacts made within an individual's own patch 
An individual in age group 3 has m3,3 social contacts within that age group per day. As individuals in 
that age group are split across 25 primary schools a proportion ε1 of those contacts will be in the same 
patch with the remaining proportion 1-ε1 split across all remaining patches. The same is true for 
individuals of age group 4 who have m4,4 social contacts with individuals in secondary schools. 
Individuals in the external population (i.e. those individuals in age groups 1, 2, 5, 6 and 7) contact 
other individuals in these age groups according to the POLYMOD social contact matrix without the 
need for scaling parameters. Equation 6.1 shows the matrix used in the model. 
Case 2: Individuals mixing with other individuals in a different metapopulation patch 
0 0 0 0 0 0 0 
0 0 0 0 0 0 0 
0 0 (1-ε1)m3,3 0 0 0 0 
0 0 0 (1-ε1)m4,4 0 0 0 
0 0 0 0 0 0 0 
0 0 0 0 0 0 0 
0 0 0 0 0 0 0 
Equation 6.2 - The POLYMOD social contact matrix for contacts made by an individual and another 
from a different metapopulation patch 
To complement the social contact matrix for contacts within an individual’s patch, the proportion of 
contacts within their age group but not in the same patch is 1-ε1. These contacts are divided over the 
number of patches remaining that contain individuals of that age group. Equation 6.2 shows the matrix 
used in the model. 
Case 3: Individuals mixing between the school patches and the external population  
For those individuals in age groups 3 and 4, their contacts with the external population are described 
by the elements of the original POLYMOD social contact matrix. Equation 6.3 shows the matrix used 
in the model. 
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0 0 m1,3 m1,4 0 0 0 
0 0 m2,3 m2,4 0 0 0 
m3,1 m3,2 0 0 m3,5 m3,6 m3,7 
m4,1 m4,2 0 0 m4,5 m4,6 m4,7 
0 0 m5,3 m5,4 0 0 0 
0 0 m6,3 m6,4 0 0 0 
0 0 m7,3 m7,4 0 0 0 
Equation 6.3 - The POLYMOD social contact matrix for contacts made by an individual and individuals 
in the external population 
The sum of all three contact matrices is the original POLYMOD social contact matrix for seven age 
groups in Great Britain. This meant that individuals in the metapopulation framework would have as 
many age-specific daily contacts as if we used a modelling framework without the metapopulation. 
For those individuals of school-attending age, their daily contacts with other individuals of the same 
age group were split using the ε1 factor. 
MATHEMATICAL MODEL OF THE BURDEN OF DISEASE 
STOCHASTIC COMPARTMENTAL SEIR MODEL 
Compartment Meaning 
S Susceptible individuals 
E Exposed individuals 
I Infectious individuals 
R Removed individuals 
W Total vaccinated individuals 
V Successfully vaccinated individuals 
A Individuals with prior immunity 
Table 6.2 - Compartments of the mathematical model 
The infectious disease transmission model used was an age-structured stochastic SEIR-type model. 
The total population N was divided into seven age groups. The compartments for the model are listed 
in Table 6.2. An SEIR-type framework was chosen to follow the natural progression of influenza 
infection. 
Susceptible individuals (S) move to the compartment for exposed individuals (E) after contact with an 
infectious individual sufficient for disease transmission. Once infectious the individuals transfer to the 
infectious compartment (I) before removal and finishing in the last compartment (R). Some individuals 
are vaccinated before the outbreak (W) but not all acquire immunity; those that do remain immune 
(V) for the duration of the epidemic. Some individuals have are already immune from infection remain 
in their own compartment (A) for the duration of the epidemic 
Movement from the susceptible compartment to the exposed compartment was governed by a 
probabilistic process based on a binomial distribution with parameters B(Spa,ŧλpa), where λpa is the 
patch- and age-specific force of infection and ŧ is the time step set to 1 day, ensuring high precision in 
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calculation without reducing feasibility in computational requirements. The force of infection is 
defined in Equation 6.4: 
𝜆𝑝𝑎 = ∑ ∑ 𝛽𝑚𝑎?̂?
𝐼?̂??̂?
𝑁?̂??̂?
7
?̂?=1𝑝=𝑝∈[1,31] + ∑ ∑ 𝛽𝑚𝑎?̂?
𝐼?̂??̂?
𝑁?̂??̂?
7
?̂?=1𝑝≠𝑝∈[1,30] + ∑ ∑ 𝛽𝑚𝑎?̂?
𝐼?̂??̂?
𝑁?̂??̂?
7
?̂?=1𝑝∈[1,30]⇒𝑝=31
𝑝=31⇒𝑝∈[1,30]
 
Equation 6.4 - The force of infection for the stochastic compartmental SEIR model 
Equation 6.4 consists of three expressions; the force of infection for within-patch transmission, the 
force of infection for between-patch transmission and the force of infection for two-way transmission 
between schools and the external population. The parameter mij is the social contact matrix as 
previously described.  
β is reverse-engineered from Equation 6.5, dividing the product of the basic reproduction number R0 
and the reciprocal of the infectious period γ by the maximum eigenvalue of the social contact matrix. 
𝛽 =
𝑅0𝛾
𝐸𝑖𝑔𝑚𝑎𝑥(𝑀)
 
Equation 6.5 - Calculating β 
Individuals in the exposed compartment (E) become infectious at a rate δ-1, recovering at a rate γ-1. 
For consistency, we used parameters from the model described in Chapter 6. All model parameters 
are shown in Table 6.3.  
The model was seeded with one infectious individual in a randomly chosen primary school. The model 
was executed in R version 3.0.2 [19]. 
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Parameter Explanation Value 
R0 Basic reproduction number 1.46 
ɛ1 Proportion of contacts within patch 0 to 1 
γ Infectious period (days)-1 0.7813 
δ Latent period (days)-1 0.6849 
vp High-vaccination coverage in primary schools 0 to 1 
vs High-vaccination coverage in secondary schools 0 to 1 
τ Proportional reduction in vaccination coverage 
between high- and low-vaccination schools 
0.5 vp/s 
initial_susi Proportion of age group initially susceptible 0.7837 (0-1 years) 
0.7837 (2-3) 
0.8943 (4-10) 
0.9819 (11-16) 
0.9496 (17-24) 
0.9496 (25-64) 
0.9736 (65+) 
risk_groupsi Proportion of age group in at-risk group 0.0517 (0-1 years) 
0.0517 (2-3) 
0.0517 (4-10) 
0.0517 (11-16) 
0.1356 (17-24) 
0.1356 (25-64) 
1.0000 (65+) 
uptake_riski Vaccination uptake for at-risk groups 0.516 (0-1 years) 
0.516 (2-3) 
0.516 (4-10) 
0.516 (11-16) 
0.516 (17-24) 
0.516 (25-64) 
0.740 (65+) 
vac_efficacyi Vaccine efficacy 0.70 (0-1 years) 
0.70 (2-3) 
0.70 (4-10) 
0.70 (11-16) 
0.70 (17-24) 
0.70 (25-64) 
0.46 (65+) 
ageSizei Population 2,000 (0-1 years) 
2,000 (2-3) 
6,250 (4-10) 
5,000 (11-16) 
8,300 (17-24) 
41,500 (25-64) 
13,000 (65+) 
Table 6.3 - Parameters used in the mathematical model of infectious disease transmission 
MODELLING INFLUENZA VACCINATION: UNINTENDED HETEROGENEITY THROUGH LOW-COVERAGE METAPOPULATION 
PATCHES 
vp and vs are the parameters that represent high-vaccination coverage levels in primary and secondary 
schools respectively. Vaccination coverage levels of 0%, 20%, 40%, 60%, 80% and 100% were chosen 
for each vaccination policy for ease of implementation due to the metapopulation configuration. In 
addition to this, the parameter τ represents the reduction in vaccination coverage for low-vaccination 
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patches. τ is defined as 0.5 times the value of vp or vs, meaning that low-coverage patches in the 
metapopulation have half the vaccination coverage of high-coverage patches. 
Before the recommendation for a school-based influenza vaccination programme many individuals in 
at-risk groups received the trivalent seasonal influenza vaccination from their GP or another local 
health care provider. Coverage figures and the number of at-risk individuals were obtained from Public 
Health England [20] and Baguelin et al. (2010) [21]. We assumed an age-specific proportion of the 
population belonged to an at-risk group and an age-specific proportion of those individuals accepted 
the offer of seasonal influenza vaccination. We used age-specific vaccine efficacy data from Flemming 
et al. (2010) [22].  
To model unintended heterogeneity in the vaccination uptake we sequentially assigned different 
schools to be low-vaccination coverage, with all other schools assigned to be high-vaccination 
coverage. The vaccination of those individuals outside of the school system was not changed. 
MODELLING INFLUENZA VACCINATION: INTENDED HETEROGENEITY THROUGH FIXED COVERAGE SPREAD UNEVENLY 
Rather than vaccinating metapopulation patches to vp and vs coverage levels, we modelled a mean 
coverage level of v across the target population using different metapopulation configurations to 
achieve this coverage level. 
Vaccination coverage levels of 20%, 40%, 60% and 80% were chosen for each vaccination policy for 
ease of implementation due to the metapopulation configuration. For example, vaccinating 20% of 
primary school children can be achieved by administering vaccination to 20% of all children attending 
the 25 primary schools, or by achieving 100% coverage in 5 of the 25 primary schools. It can also be 
achieved by vaccinating 4% of all primary school children and 40% of all secondary school children, as 
well as many other combinations of coverage levels. 
For targeted vaccination policies in primary and secondary schools we varied vaccination coverage v 
by: 
1. Vaccinating a proportion v children of each school in the targeted population, and 
2. Vaccination of all children of a proportion v of the number of school in the targeted 
population, and 
3. Vaccination in all schools in a targeted population to two different coverage levels, with mean 
overall vaccination coverage v 
For homogenous vaccination coverage ν є (20%, 40%, 60%, 80%), an equivalent overall vaccination 
coverage can be achieved by vaccinating to different levels in the primary schools and secondary 
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schools. The coverage levels in each age group for concentrated coverage are listed below in Table 
6.4. 
Homogeneous 
vaccination coverage, ν 
Number of primary schools 
with 100% coverage, p 
Number of secondary schools 
with 100% coverage, s 
20% 9 
5 
1 
0 
1 
2 
40% 18 
14 
10 
6 
2 
0 
1 
2 
3 
4 
60% 19 
15 
11 
7 
2 
3 
4 
5 
80% 24 
20 
16 
3 
4 
5 
Table 6.4 - The number of primary and secondary schools required to achieve the same level of 
vaccination coverage as a homogeneous vaccination policy in all schools 
The concentration of vaccination coverage in both primary and secondary schools could be used by 
Public Health officials in the design of vaccination programmes. For example, to achieve the same 
number of vaccinations administered for 20% coverage in the metapopulation, Public Health officials 
could concentrate this coverage in primary schools by vaccinating 100% of the children in 9 primary 
schools. Alternatively, by vaccinating 100% of the children in 2 secondary schools and supplementing 
this with 100% coverage in a primary school, the vaccination programme is concentrated in secondary 
schools. 
However, these scenarios require several metapopulation patches to be completely unvaccinated. 
Another option to achieve homogeneous coverage ν є (20%, 40%, 60%, 80%) is to vaccinate in all 
metapopulation patches of the target population, with some patches reporting lower coverage than 
others. Details of these coverage levels are listed in Table 6.5. 
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Targeting primary schools 
Coverage 
in target 
group 1 
Number of 
patches in 
group 1 
Coverage 
in target 
group 2 
Number of 
patches in 
group 2 
Overall coverage 
for targeted 
population 
80% 5 5% 20 20% 
60% 5 10% 20 20% 
40% 5 15% 20 20% 
80% 5 30% 20 40% 
60% 5 35% 20 40% 
20% 5 45% 20 40% 
80% 5 55% 20 60% 
40% 5 65% 20 60% 
20% 5 70% 20 60% 
60% 5 85% 20 80% 
40% 5 90% 20 80% 
20% 5 95% 20 80% 
 
Targeting secondary schools 
Coverage 
in target 
group 1 
Number of 
patches in 
group 1 
Coverage 
in target 
group 2 
Number of 
patches in 
group 2 
Overall coverage 
for targeted 
population 
80% 1 5% 4 20% 
60% 1 10% 4 20% 
40% 1 15% 4 20% 
80% 1 30% 4 40% 
60% 1 35% 4 40% 
20% 1 45% 4 40% 
80% 1 55% 4 60% 
40% 1 65% 4 60% 
20% 1 70% 4 60% 
60% 1 85% 4 80% 
40% 1 90% 4 80% 
20% 1 95% 4 80% 
Table 6.5 - Targeted vaccination strategies in primary schools and secondary schools with 
heterogeneous uptake, ensuring all patches in the targeted population receive some coverage 
Finally, vaccinating in both age groups to achieve a mean overall vaccination coverage ν є (20%, 40%, 
60%, 80%) can be achieved by vaccinating all primary schools with coverage level νp and all secondary 
schools with coverage level νs, ensuring that no school patch goes unvaccinated. Details of each 
vaccination strategy to achieve coverage level ν are listed in Table 6.6. 
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Primary school 
coverage, νp 
Secondary school 
coverage, νs 
Mean overall 
coverage, ν 
4% 40% 20% 
60% 15% 40% 
20% 65% 40% 
8% 80% 40% 
24% 60% 40% 
56% 20% 40% 
80% 35% 60% 
40% 85% 60% 
100% 10% 60% 
92% 20% 60% 
76% 40% 60% 
44% 80% 60% 
28% 100% 60% 
100% 55% 80% 
96% 60% 80% 
64% 100% 80% 
Table 6.6 - Heterogeneous vaccination strategies in the metapopulation to achieve an overall 
vaccination coverage ν 
Methods to calculate the epidemic duration, final size and other metrics are displayed in the appendix.  
MODELLING THEORETICAL SEASONAL INFLUENZA VACCINATION STRATEGIES 
In implementing a new vaccination programme in the theoretical metapopulation, Public Health 
officials would have a choice from four different programmes: 
I. No extended vaccination policy 
Included as an option in this study for the purpose of providing a baseline measurement of 
effectiveness, this option sees the continuation of the previous seasonal influenza vaccination 
programme without offering additional seasonal vaccinations to healthy school children. 
II. Targeted vaccination in primary schools only 
Seasonal vaccination is offered only to those children attending primary schools in the 
metapopulation. 
III. Targeted vaccination in secondary schools only 
Seasonal vaccination is offered only to those children attending secondary schools in the 
metapopulation. 
IV. Vaccination across both primary schools and secondary schools 
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Seasonal vaccination is offered to all children attending primary schools or secondary schools in the 
metapopulation. The programme is implemented with a target of either homogeneous coverage 
across the two school groups or heterogeneous coverage between them. 
Four possible heterogeneities in vaccination coverage were explored in theoretical vaccination 
programmes II-IV: 
1. Variation in the vaccination coverage. 
vp and/or vs were varied to examine the impact of increasing vaccination coverage in the 
metapopulation. 
2. Variation in the number of high-coverage primary schools, from 1-25. 
By default, the model simulates epidemics with 25 high-coverage primary schools. This can be reduced 
incrementally to one high-coverage primary school. 
3. Variation in the number of high-coverage secondary schools, from 1-5. 
By default, the model simulates epidemics with 5 high-coverage secondary schools. This can be 
reduced incrementally to one high-coverage secondary school. 
4. Fixed number of vaccinations with variation within the schools included in the target 
population 
Vaccination is heterogeneous within the specified target population, through the concentration of 
vaccination in some schools at the expense of others. 
The different theoretical vaccination programmes and scenarios are described below. 
NO EXTENDED VACCINATION POLICY (BASELINE) 
vp and vs were set to zero and the continuation of the previous seasonal influenza vaccination policy 
was executed, to act as a baseline against all subsequent vaccination strategies. 
TARGETED VACCINATION IN PRIMARY SCHOOLS 
vp varied, vs = 0. Vaccination in secondary schools is ignored and the vaccination policy targets only 
primary schools in the metapopulation. Three heterogeneities are explored with this vaccination 
programme: 
1. The vaccination coverage of high-coverage primary schools. 
2. The number of low-coverage primary schools. 
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3. The difference between fixed vaccination coverage spread evenly across the population 
against the same coverage concentrated in a small number of primary schools. 
TARGETED VACCINATION IN SECONDARY SCHOOLS 
vs varied, vp = 0. Vaccination in primary schools is ignored and the vaccination policy targets only 
secondary schools in the metapopulation. Three heterogeneities are explored with this vaccination 
programme: 
1. The vaccination coverage of high-coverage secondary schools. 
2. The number of low-coverage secondary schools. 
3. The difference between fixed vaccination coverage spread evenly across the population 
against the same coverage concentrated in a small number of secondary schools. 
VACCINATION IN BOTH PRIMARY AND SECONDARY SCHOOLS 
As with (i), with vp = vs and varied. This strategy represents successfully achieving high homogeneous 
coverage in every primary school and secondary school in the metapopulation. Four heterogeneities 
are explored with this vaccination programme: 
1. The homogeneous vaccination coverage of both high-coverage primary and secondary 
schools. 
2. The number of low-coverage primary schools. 
3. The number of low-coverage secondary schools. 
4. The difference between fixed vaccination coverage spread evenly across the population 
against the same coverage concentrated in a small number of primary and secondary schools. 
For each vaccination strategy the model was executed 5,000 times. Data were output to a .csv file and 
analysed with R version 3.0.2 [19]. To remove those simulations with rapid stochastic fadeout we 
present the results from simulations with a final size of ILI epidemics above 0.5% of the population, 
assuming these simulations were the results of quick stochastic fadeouts.  
All 95% confidence intervals of the mean for each presented metric were calculated using 1,000 
bootstrap replications and the strength of evidence for a difference between two metrics was 
examined using the Wilcoxon rank sum test statistic.  
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RESULTS 
NO EXTENSION TO THE SEASONAL INFLUENZA VACCINATION PROGRAMME 
To provide a baseline against which other results would be compared, the model was executed with 
the assumption that healthy school children would not be offered to participate in the seasonal 
influenza vaccination programme. 
BASELINE RESULTS 
62.9% of simulated epidemics resulted in an overall ILI final size less than 0.5% of the total population. 
From the remaining simulated epidemics the mean overall ILI final size was 16.40% (95% CI: 16.36 – 
16.44%) (Figure 6.3). Further results are reported in Table 6.7. 
 
Figure 6.3 - Results from 5,000 simulations of the metapopulation model with stochastic fadeouts 
excluded 
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 Mean 95% CI of the mean 
ILI Final Size 16.40% 16.36 – 16.44% 
ILI Duration 169.90 days 168.81 – 171.04 days 
ILI Peak 0.468% 0.466 – 0.471% 
ILI time for all patches to be infected 52.74 days 52.06 – 53.43 days 
ILI Peak Time 85.32 days 84.59 – 86.16 days 
Table 6.7 - Results from 5,000 simulations of the metapopulation model with stochastic fadeouts 
excluded 
Table 6.8 shows the age-specific results from the 5,000 simulations for each age group with the 
stochastic fadeouts excluded. The mean greatest burden of disease was in the primary school and 
secondary school age groups with final sizes of 37.99% (95% CI: 37.90-38.87%) and 39.99% (95% CI: 
39.88-40.10%) respectively. Mean duration of the ILI epidemics ranged from 134.70 days (95% CI: 
133.61-135.87 days) in the 2 – 3 year age group to 165.42 days (95% CI: 164.38-166.50 days) in the 25 
– 64 years age group.  
 Age ILI Final Size ILI Duration (days) ILI Peak 
0-1 12.55% (12.50-12.60%) 138.04 (136.90-139.17) 0.584% (0.580-0.589%) 
2-3 10.30% (10.25-10.34%) 134.70 (133.61-135.87) 0.504% (0.500-0.508%) 
4-10 37.99% (37.90-38.87%) 160.35 (159.32-161.45) 1.21% (1.20-1.21%) 
11-16 39.99% (39.88-40.10%) 154.69 (153.63-155.70) 1.30% (1.29-1.31%) 
17-24 19.32% (19.26-19.38%) 154.85 (153.78-155.86) 0.645% (0.641-0.649%) 
25-64 14.22% (14.18-14.25%) 165.42 (164.38-166.50) 0.424% (0.422-0.427%) 
65+ 3.58% (3.57-3.59%) 146.14 (145.11-147.13) 0.145% (0.144-0.146%) 
Table 6.8 - Mean and 95% CIs of ILI Final Size, ILI Duration and ILI Peak for each age group in the model 
with stochastic fadeouts excluded 
Patch-specific results are shown in Table 6.9. The comparatively high vaccination coverage of the 
external population, due to coverage in the oldest age group of 65+ years, is a likely contributor to the 
lower mean final size of epidemics in the external population is much smaller than in the school 
patches. The mean durations of ILI epidemics in the primary and secondary school patches were 
shorter than in the external population; 108.84 days (95% CI: 108.61-109.07 days) for primary schools 
and 134.12 days (95% CI: 133.66-134.758 days) for secondary schools, with a mean duration in the 
external population of 165.85 days (95% CI: 164.81-167.01 days). 
The mean duration in the school patches differs from the mean duration in their respective age groups 
(160.35 days (95% CI: 159.32-161.45 days) for all those attending primary schools compared to 108.84 
days (95% CI: 108.61-109.07 days) for the mean duration of epidemics in primary schools, for example) 
because the latter result is the mean duration for each school. The mean duration of epidemics in a 
primary school according to this model was 108.84 days, but at the community level the infection 
existed in that age group for a mean time of 160.35 days. 
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 Median (min – max) Mean (95% CI) 
ILI Final Size (all primary schools) 38.00% (0.00-57.20%) 37.99% (37.90-38.87%) 
ILI Final Size (all secondary schools) 40.10% (0.80-50.20%) 39.99% (39.88-40.10%) 
ILI Final Size (external population) 12.63% (0.55-14.42%) 12.61% (12.58-12.65%) 
ILI Duration in days (all primary schools) 106.00 (0.00-257.00) 108.84 (108.61-109.07) 
ILI Duration in days (all secondary schools) 131.00 (44.00-269.00) 134.12 (133.66-134.58) 
ILI Duration in days (external population) 163.00 (91.00-289.00) 165.85 (164.81-167.01) 
Table 6.9 - Results from 5,000 simulations of the metapopulation model with stochastic fadeouts 
excluded 
Figure 6.4 shows the epidemic curve for each age group during a typical simulated epidemic with no 
vaccination other than in the clinical at-risk groups. The stochastic model results agree with the 
deterministic model results from Chapter 6 that show the greatest burden of disease is seen in the 
primary and secondary school age groups.  
Figure 6.5 shows patch-specific epidemic curves for the same epidemic. Dark blue curves represent 
the epidemics in each of the primary school patches; light blue curves for the secondary school 
epidemics and the single black curve for the external population. The single orange curve marks the 
primary school patch randomly chosen by the model to be seeded. The mean epidemic peak across 
primary schools varies from approximately 1.5% in one patch to 3% in another. 
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Figure 6.4 - Age-specific epidemic curves for a typical epidemic simulated using the model 
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Figure 6.5 - Patch-specific epidemic curves for a typical epidemic simulated using the model. The final 
size of the epidemic is plotted on the vertical axis and the epidemic duration (in days) on the horizontal 
axis 
VARYING THE Ε1 PARAMETER 
The mean final size of ILI epidemics in the metapopulation declines as ε1 is increased from 0 to 1 (Table 
6.10). That is, in a metapopulation where individuals of school-attending age have no contacts with 
those individuals in both the same age group and metapopulation patch the mean final size of ILI 
epidemics is at its maximum of 16.50% (95% CI: 16.47-16.54%) and a minimum of 16.28% (95% CI: 
16.23-16.32%) when all contacts between school children occur in their own school with no mixing 
with other individuals in their age group from other schools.  
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 ε1 = 0.00 ε1 = 0.25 ε1 = 0.50 ε1 = 0.75 ε1 = 1.00 
 Mean  
(95% CI) 
Mean  
(95% CI) 
Mean  
(95% CI) 
Mean  
(95% CI) 
Mean  
(95% CI) 
ILI Final Size 16.50% 
(16.47-
16.54%) 
16.49% 
(16.46-
16.53%) 
16.46% 
(16.42-
16.50%) 
16.40% 
(16.36-
16.44%) 
16.28% 
(16.23-
16.32%) 
ILI Duration (days) 168.03 
(167.01-
169.07) 
169.21 
(168.09-
170.43) 
169.32 
(168.26-
170.42) 
169.90 
(168.81-
171.04) 
173.95 
(172.81-
175.10) 
ILI Peak 0.479% 
(0.477-
0.483%) 
0.476% 
(0.472-
0.479%) 
0.475% 
(0.472-
0.478%) 
0.468% 
(0.466-
0.471%) 
0.454% 
(0.452-
0.457%) 
ILI time for all 
patches to be 
infected (days) 
43.04 
(42.43-
43.67) 
45.88 
(45.19-
46.60) 
48.75 
(48.10-
49.47) 
52.74 
(52.06-
53.43) 
60.09 
(59.36-
60.85) 
ILI Peak Time (days) 84.10 
(83.32-
84.89) 
84.60 
(83.80-
85.48) 
84.55 
(83.72-
85.33) 
85.32 
(84.59-
86.16) 
87.42 
(86..63-
88.18) 
Table 6.10 - Model results after varying the ε1 parameter 
The scenario with ε1 = 0 is unlikely to occur as this would require all school-age children attending 
their respective schools to avoid contact with all other children attending their school. If ε1 = 1 then 
all mixing in a school child’s age group takes place in their own school, which is also an unrealistic 
assumption. In the context of this metapopulation, the variation in ε1 results in an absolute difference 
in the mean final size of epidemics of 172 infections for the community. 
There was strong evidence for a difference in the mean final size when ε1 = 0.25 and ε1 = 0.75 
(W=1,751,612, p=0.00076), and when ε1 = 0.50 and ε1 = 0.75 (W=1,645,503, p=0.03284), but not 
between ε1 = 0.25 and ε1 = 0.50 (W=1,678,938, p=0.2168). However, in absolute terms the difference 
between the mean final size of epidemics when ε1 = 0.25 and ε1 = 0.75 is just 70 infections for the 
community. Both the mean duration of ILI epidemics and the mean epidemic peak time of ILI 
epidemics show minor variation with ε1 between 0 and 0.75, but ε1 = 1 increases both metrics.  
As ε1 increases from 0 to 1 the mean time for infection to reach all 31 metapopulation patches 
increases exponentially from 43.04 days (95% CI: 42.43-43.67) to 60.09 days (95% CI: 59.36-60.85). 
Intuitively, as the proportion of an individual’s daily contacts within their own patch increases, fewer 
contacts with individuals in other patches take place, therefore the epidemic will spread across the 
metapopulation at a slower rate.  
It is important to note that ε1 = 1 does not mean that the 31 metapopulation patches are disconnected 
from one another, as contacts between individuals of different age groups do not depend on the ε1 
parameter. 
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TARGETED VACCINATION IN PRIMARY SCHOOLS ONLY 
TARGETED HOMOGENEOUS VACCINATION IN PRIMARY SCHOOLS  
A vaccination programme of targeted coverage in primary schools alone reduces the mean final size 
and the mean peak of ILI epidemics (Figure 6.6) as vaccination coverage increases, though with 100% 
coverage in this age group the mean final size of epidemics in the metapopulation still reached 1.84% 
(95% CI: 1.49-2.22%). Mean duration and mean peak time also reduce. 
 
Figure 6.6 - Results from 5,000 simulations of the metapopulation model with targeted homogeneous 
vaccination coverage in primary schools only 
Table 6.11 shows that the time for all patches to be infected with ILI increased as vaccination coverage 
increased, demonstrating that it became more difficult for the epidemic to spread through all 
metapopulation patches quickly at increasing coverage levels. However, even at full vaccination 
coverage for this programme it was still possible for the epidemic to reach all 31 metapopulation 
patches because the efficacy of the vaccine was less than 100% [22]. 
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 Vaccination coverage 
Mean (95% CI) 
 20% 40% 60% 80% 100% 
ILI Final Size 11.86% 
(11.72-
12.00%) 
7.27% 
(6.96-
7.55%) 
3.76% 
(3.38-
4.15%) 
2.38% 
(2.01-
2.78%) 
1.84% 
(1.49-
2.22%) 
ILI Duration 
(days) 
202.90 
(198.60-
207.15) 
222.70 
(214.77-
230.16) 
191.89 
(179.87-
203.56) 
155.90 
(141.45-
169.75) 
149.58 
(133.46-
166.13) 
ILI Peak 0.266% 
(0.259-
0.273%) 
0.137% 
(0.130-
0.144%) 
0.076% 
(0.068-
0.084%) 
0.059% 
(0.051-
0.068%) 
0.048% 
(0.039-
0.057%) 
ILI time for all 
patches to be 
infected (days) 
65.02 
(62.69-
67.51) 
82.55 
(78.43-
87.06) 
105.66 
(97.71-
114.24) 
102.28 
(89.50-
117.11) 
125.16 
(77.0-
174.0) 
ILI Peak Time 
(days) 
101.81 
(98.95-
104.74) 
111.70 
(106.09-
117.68) 
95.19 
(87.19-
104.01) 
76.60 
(67.81-
86.34) 
68.82 
(55.95-
83.04) 
Table 6.11 - Results from 5,000 simulations of the metapopulation model with targeted homogeneous 
vaccination coverage in primary schools only 
A targeted vaccination policy in primary schools would not eliminate the spread of seasonal influenza 
at the community level, similar to results from Chapter 5 showing that such a vaccination programme 
cannot eliminate nationwide influenza transmission. 
VARYING THE Ε1 PARAMETER 
Figure 6.7 shows the effect of varying the ε1 parameter in the model. As with previous results, 
increasing ε1 to 1 marginally reduced the mean final size of epidemics. The mean duration of epidemics 
in the metapopulation also did not vary greatly with increasing ε1, nor did the mean peak of those 
epidemics and the timing of the peak. The mean time for all metapopulation patches to be infected 
increased as ε1 increased, though as previously discussed the maximum time for complete epidemic 
spread across the metapopulation was seen when simulating epidemics with the unlikely scenario of 
ε1 = 1. 
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Figure 6.7 - Epidemic results with targeted homogeneous primary school vaccination and varying ε1 
parameter 
TARGETED HETEROGENEOUS VACCINATION IN PRIMARY SCHOOLS ONLY 
With a vaccination policy that administers vaccines to those children attending primary schools only 
but sees unintended heterogeneous uptake in those primary schools (i.e. some schools to achieve 
only half the targeted coverage), there is little variation in the mean final size of the ILI epidemics with 
the number of low-coverage primary schools for low coverage levels of 20% (Figure 6.8).  
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Figure 6.8 - Mean ILI final size for epidemics in the metapopulation with targeted heterogeneous 
vaccination coverage in primary schools only 
For increased coverage levels there is a clear trend with increasing mean final size and the increasing 
number of low-coverage primary schools – increasing the number of low-coverage primary schools 
will increase the mean final size of epidemics in the metapopulation, with these effects enhanced at 
higher vaccination levels. 
Results for the mean duration, the mean peak, the mean time for all patches to become infected and 
the mean peak time are displayed in the appendix. 
  
140 
 
THE IMPACT OF A SINGLE LOW-COVERAGE PRIMARY SCHOOL IN THE METAPOPULATION WITH TARGETED VACCINATION IN 
PRIMARY SCHOOLS 
Vaccination coverage 20% 
0 low-coverage schools 1 low-coverage school  
mean (95% CI) mean (95% CI) Wilcoxon Test 
11.80% (11.50-12.07%) 12.06% (11.90-12.22%) W=8,087.5, p=0.7151 
 
Vaccination coverage 40% 
0 low-coverage schools 1 low-coverage school  
mean (95% CI) mean (95% CI) Wilcoxon Test 
7.51% (7.07-7.90%) 7.57% (7.28-7.84%) W=4,118, p=0.714 
 
Vaccination coverage 60% 
0 low-coverage schools 1 low-coverage school  
mean (95% CI) mean (95% CI) Wilcoxon Test 
3.95% (3.47-4.39%) 4.33% (3.76-4.85%) W=1,084, p=0.2552 
 
Vaccination coverage 80% 
0 low-coverage schools 1 low-coverage school  
mean (95% CI) mean (95% CI) Wilcoxon Test 
2.34% (1.93-2.77%) 2.40% (1.97-2.85%) W=459.5, p=0.7941 
   
Vaccination coverage 100% 
0 low-coverage schools 1 low-coverage school  
mean (95% CI) mean (95% CI) Wilcoxon Test 
1.25% (0.87-1.76%) 1.22% (0.95-1.51%) W=139.5, p=0.5243 
Table 6.12 - Comparing the final size of ILI epidemics with targeted heterogeneous vaccination in 
primary schools only 
To examine the impact of a single low-coverage primary school in a scenario with targeted vaccination 
in primary schools we executed an additional 5,000 simulations with 0 or 1 low-coverage primary 
schools. In each case the vaccination coverage for high-coverage schools was varied, with τ equal to 
half the target vaccination level.  
Table 6.12 shows that there is little evidence that a single low-coverage primary school in the 
community has an impact on the mean final size of ILI epidemics. At all vaccination coverage levels in 
the high-coverage primary schools, there was no difference when increasing the number of low-
coverage primary schools from 0 to 1. 
VARYING THE Τ PARAMETER 
The parameter denoting the level of heterogeneity between high-coverage patches and low-coverage 
patches was set to τ = 0.50 in scenarios reported above. Here we executed additional simulations of 
the model for targeted heterogeneous vaccination primary schools for both τ = 0.25 and τ = 0.75. 
Figure 6.9 shows that increasing the τ parameter from 0.25 to 0.75 consistently increases the mean 
final size of epidemics in the metapopulation at all vaccination coverage levels. With the maximum 
number of low-coverage primary schools in the metapopulation, the mean final size of epidemics with 
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τ = 0.25 was 13.00% (95% CI: 12.76-13.24%) and 15.28% (95% CI: 15.07-15.48%) with τ = 0.75 with 
targeted coverage of 20%. With vaccination coverage reaching 100% the mean final size of epidemics 
in the same metapopulation configuration are 2.39% (95% CI: 1.55-3.21%) for τ = 0.25 and 10.75% 
(95% CI: 10.49-10.99%) for τ = 0.75. 
  
Figure 6.9 - Examining variation in the τ parameter on the mean final size 
Further results describing the impact of variation in the τ parameter are displayed in the appendix.  
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INTENDED HETEROGENEITY THROUGH FIXED, CONCENTRATED VACCINATION COVERAGE 
 Homogeneous coverage 
Mean (95% CI) 
Concentrated coverage 
Mean (95% CI) 
Results for the mean final size 
No vaccination 16.40% (16.36-16.44%) N/A 
20% coverage 11.41% (11.26-11.55%) 13.47% (13.38-13.55%) 
40% coverage 7.05% (6.85-7.26%) 9.89% (9.74-10.04%) 
60% coverage 3.96% (3.73-4.17%) 6.13% (5.92-6.35%) 
80% coverage 2.51% (2.31-2.74%) 3.38% (3.15-3.61%) 
 
Results for the mean duration 
No vaccination 169.9 days (168.8-171.0 days) N/A 
20% coverage 186.2 days (183.5-189.0 days) 173.5 days (171.7-175.2 days) 
40% coverage 195.0 days (190.7-199.0 days) 187.5 days (184.6-190.7 days) 
60% coverage 169.4 days (164.1-174.7 days) 183.5 days (178.9-188.2 days) 
80% coverage 141.9 days (134.9-149.0 days) 160.4 days (153.8-166.9 days) 
 
Results for the mean peak 
No vaccination 0.468% (0.466-0.471%) N/A 
20% coverage 0.272% (0.266-0.277%) 0.356% (0.352-0.360%) 
40% coverage 0.150% (0.145-0.155%) 0.227% (0.223-0.232%) 
60% coverage 0.095% (0.091-0.100%) 0.136% (0.131-0.141%) 
80% coverage 0.070% (0.065-0.075%) 0.081% (0.076-0.086%) 
 
Results for the mean time for all patches to become infected 
No vaccination 52.7 days (52.1-53.4 days) N/A 
20% coverage 55.7 days (54.5-56.9 days) 64.7 days (63.5-66.1 days) 
40% coverage 70.7 days (68.5-73.0 days) 80.4 days (78.4-82.3 days ) 
60% coverage 87.3 days (83.3-91.3 days) 103.1 days (99.8-106.7 days) 
80% coverage 101.5 days (93.8-110.2 days) 121.8 days (114.3-129.4 days) 
 
Results for the mean peak time 
No vaccination 85.3 days (84.6-86.2 days) N/A 
20% coverage 90.1 days (88.2-92.0 days) 84.2 days (82.8-85.6 days) 
40% coverage 96.0 days (92.9-99.2 days) 90.7 days (88.6-93.2 days) 
60% coverage 85.9 days (82.4-89.8 days) 88.7 days (85.6-91.8 days) 
80% coverage 67.0 days (62.6-71.6 days) 77.1 days (72.4-81.4 days) 
Table 6.13 - Targeted vaccination coverage in primary schools with both homogeneous coverage and 
concentrated coverage 
Homogeneous targeted coverage in primary schools reduces the mean final size of epidemics from 
16.40% (95% CI: 16.36-16.44%) to 3.96% with 80% coverage (95% CI: 3.73-4.17%). A similar trend is 
seen when the same coverage levels are achieved by vaccinating a number of schools to 100%, leaving 
others without any coverage – the mean final size of epidemics decreased to 13.37% (95% CI: 13.38-
13.55%) with 20% of primary schools fully vaccinated. However, this is greater than the final size with 
homogeneous 20% coverage and results in an additional 1,608 infections in the metapopulation. The 
trend of heterogeneous vaccination coverage resulting in a greater burden of disease continues for all 
vaccination coverage levels, even with the same number of vaccinations administered in both 
scenarios (Table 6.13). Concentrated coverage that results in heterogeneity between primary schools 
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would increase the mean final size of epidemics over the expected mean final size where homogenous 
vaccination is implemented. 
Homogenous vaccination coverage increased the mean duration of epidemics to a maximum of 195.0 
days (95% CI: 190.7-199.0) with 40% coverage, then reduced the duration to 141.9 days (95% CI: 
134.9-149.0) at 80% coverage. The concentrated coverage levels decreased the mean duration for 
coverage of both 20% and 40% (173.5 days (95% CI: 171.7-175.2) and 187.5 days (95% CI: 184.6-190.7) 
respectively) but increased it with higher coverage of both 60% and 80% (183.5 days (95% CI: 179.9-
188.2) and 160.4 days (95% CI: 153.8-166.9) respectively). If the primary aim of a vaccination 
programme is to reduce the mean final size of potential epidemics then heterogeneity in the vaccine 
uptake across the metapopulation will result in both a greater number of infected cases with longer 
epidemics for the highest levels of vaccination coverage. 
Heterogeneity in the uptake of the vaccine across primary schools affects the mean epidemic peak in 
a similar manner to that of the mean final size, i.e. as vaccination coverage increases, the mean 
epidemic peak decreases but heterogeneity will result in greater epidemic peaks than with 
homogeneity. The mean epidemic peak reduced from 0.469% (95% CI: 0.463-0.472%) at baseline to 
0.070% (95% CI 0.065-0.075%) at 80% homogeneous coverage, but epidemics with 80% 
heterogeneous uptake had a mean epidemic peak of 0.081% (95% CI: 0.076-0.086%). 
Heterogeneity in vaccination coverage consistently increased the mean time for all vaccination 
patches to become infected over that of a homogeneous policy. As previously mentioned, at baseline 
epidemics lasted a mean of 169.9 days (95% CI: 168.8-171.0), but they only took 52.7 days (95% CI: 
52.1-53.4) to extend across all patches of the metapopulation. However, at 80% homogeneous 
coverage this increased to 101.5 days (95% CI: 93.8-110.2) to reach all 31 patches. By implementing a 
heterogeneous vaccination policy with coverage concentrated in several fully vaccinated schools, the 
mean time for all patches to be infected increased to 121.8 days (95% CI: 114.3-129.4) at 80% 
coverage. At this level of coverage, all attendees of 20 of the 25 primary schools would have been 
vaccinated. Infection still manages to reach these metapopulation patches because the vaccine 
efficacy was not 100%. 
The timing of the epidemic peak behaves in the same manner as the mean epidemic duration, in that 
increasing coverage first increases the timing of the peak before the highest coverage levels reduce it 
below the baseline result. The mean time of the epidemic peak for 80% homogeneous coverage was 
67.0 days (95% CI: 62.3-71.6), down from 85.3 days (95% CI: 84.6-86.2) at baseline. Heterogeneity at 
this level of coverage saw epidemics peaking on average after 77.1 days (95% CI: 72.4-81.4). 
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INTENDED HETEROGENEITY WITH VACCINATION IN ALL TARGETED PATCHES 
Heterogeneity in the target population whilst maintaining the same mean vaccination coverage does 
not reduce the expected final size of epidemics below the level expected with a homogeneous 
vaccination programme. For all four coverage levels modelled in the metapopulation (Figure 6.10 to 
Figure 6.13) the homogenous vaccination policy consistently resulted in the lowest mean final size of 
epidemics. 
 
Figure 6.10 - Heterogeneity in a targeted vaccination programme for primary schools with mean 
overall coverage of 20% 
With mean overall coverage of 20% in primary schools, the three alternative vaccination scenarios 
failed to reduce the mean final size of epidemics below that seen with a homogenous 20% coverage 
level (Figure 6.10). Homogeneous coverage results in a mean final size of 11.41% (95% CI: 11.28-
11.55%), with the best-performing heterogeneous vaccination coverage achieving 12.03% (95% CI: 
11.97-12.09%) with five schools increasing coverage to 40% and the remaining 20 schools decreasing 
coverage to 15%. 
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The mean duration of epidemics increased from 186.19 days (95% CI: 183.49-188.78) to a maximum 
of 200.24 days (95% CI: 198.49-201.99), again with five schools reporting coverage 40% and 20 schools 
reporting coverage of 15%. The mean time for all metapopulation patches to become infected 
increased above the mean time reported for homogeneous vaccination coverage (55.70 days (95% CI: 
54.46-56.95)) to a maximum of 67.91 days (95% CI: 66.89-68.98) with five schools reporting 80% 
coverage and 20 schools reporting 5% coverage. The mean size of the epidemic peak followed the 
trend of the mean final size, and the mean time to reach the epidemic peak followed the trend of the 
mean duration of epidemics. 
 
Figure 6.11 - Heterogeneity in a targeted vaccination programme for primary schools with mean 
overall coverage of 40% 
Heterogeneous vaccination strategies with a mean overall coverage of 40% follow similar patterns to 
those discussed with 20% coverage. Figure 6.11 shows that the vaccination strategy resulting in the 
greatest mean final size was the strategy with the largest discrepancy between the two groups with 
different vaccination coverage. With five schools vaccinating to 80% coverage and 20 schools 
146 
 
vaccinating to 30% coverage, the mean final size of epidemics increased from 7.05% (95% CI: 6.84-
7.24%) to 8.10% (95% CI: 7.99-8.21%). However, the heterogeneous strategy with the least 
heterogeneity in coverage between the two groups resulted in the longest mean epidemic duration, 
increasing the duration of epidemics from 194.87 days (95% CI: 190.39-199.07) at homogeneity to 
227.42 days (95% CI: 224.02-230.89). Maximum heterogeneity in the vaccination coverage resulted in 
the longest mean time for the epidemic to reach all metapopulation patches, extending this time from 
70.74 days (95% CI: 68.55-72.96) at homogeneity to 86.50 days (95% CI: 84.57-88.52). 
Two heterogeneous vaccination strategies reduced the mean size of the epidemic peak, from 0.150% 
(95% CI: 0.146-0.155%) at homogeneity to 0.142% (95% CI: 0.138-0.145%) and 0.141% (95% CI: 0.138-
0.145%) for strategies with five schools with 60%/20% coverage and 20 schools with 35%/45% 
coverage respectively.  
With mean overall coverage of 60%, all three vaccination strategies with heterogeneity reduced the 
mean size of the epidemic peak from 0.095% (95% CI: 0.091-0.100%) at homogeneity to a minimum 
of 0.082% (95% CI: 0.078-0.085%) using a vaccination strategy consisting of five schools with 40% 
coverage and 20 schools with 65% coverage (Figure 6.12). 
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Figure 6.12 - Heterogeneity in a targeted vaccination programme for primary schools with mean 
overall coverage of 60% 
All other metrics increased with heterogeneity in vaccination coverage introduced to the 
metapopulation. The vaccination strategy with the greatest level of heterogeneity (five schools with 
20% coverage and 20 schools with 70% coverage) increased the mean final size to a maximum of 
4.61% (95% CI: 4.45-4.76%). Heterogeneity also increased the mean duration of epidemics, delayed 
the mean time of the epidemic peak and increased the mean time for all patches to be infected. 
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Figure 6.13 - Heterogeneity in a targeted vaccination programme for primary schools with mean 
overall coverage of 80% 
For vaccination strategies with five schools with 60%/40% coverage and 20 schools with 85%/90% 
coverage respectively, the mean final size of epidemics were very similar to that with homogeneous 
80% coverage – 2.50% (95% CI: 2.34-2.67%) and 2.58% (95% CI: 2.42-2.73%) respectively, compared 
to 2.51% (95% CI: 2.31-2.76%) with homogeneity. There was insufficient evidence to say that the 
strategy with 60% coverage in five schools and 85% in 20 schools reduced the mean final size of 
epidemics (W=21,014, p=0.8949), but very good evidence (W=23,890.5, p=0.01673) that a 
heterogeneous strategy of five schools with 20% coverage and 20 schools with 95% coverage resulted 
in an increase in the mean final size of epidemics to 2.85% (95% CI: 2.69-3.04%). 
All three vaccination strategies with heterogeneity reduced the mean size of the epidemic peak from 
0.070% (95% CI: 0.065-0.075%) with homogeneity to a minimum of 0.055% (95% CI: 0.053-0.059%) in 
a metapopulation with five schools with 60% coverage and 20 schools with 85% coverage. 
Heterogeneity in vaccination uptake increased the mean duration of epidemics, the mean time of the 
epidemic peak and the mean time for all patches to become infected. 
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SUMMARY FOR TARGETED VACCINATION IN PRIMARY SCHOOLS 
Targeted vaccination in primary schools cannot eliminate the potential for epidemics to occur in the 
metapopulation - the mean final size of epidemics with 100% coverage was 1.84% (95% CI: 1.49-
2.22%). 
Uncertainty in the ε1 parameter provided marginal variation in the mean final size of epidemics for 
any level of targeted homogeneous coverage. However, increasing this parameter in the model 
resulted in a longer mean time for epidemics to spread to all metapopulation patches. With ε1 = 1 and 
vaccination coverage reaching 100% epidemics did not spread to all metapopulation patches. 
Unintended heterogeneity through primary schools failing to achieve the targeted vaccination 
coverage consistently increased the expected mean final size of epidemics in the metapopulation. The 
increase in heterogeneity through additional low-coverage schools had the greatest impact on the 
mean final size when the targeted vaccination coverage was high – for vaccination programmes with 
20% vaccination coverage the mean final size of epidemics for both 0 and 24 low-coverage primary 
schools was 11.89% (95% CI: 11.31-12.29%) and 14.34% (95% CI: 14.15-14.54%). With 100% targeted 
coverage the results were 1.55% (95% CI: 0.971-2.21%) and 5.31% (95% CI: 4.29-6.20%) respectively. 
However, the existence of a single low-coverage primary school in the metapopulation had no impact 
of the mean final size of epidemics for all simulated vaccination coverage levels. With 100% 
vaccination coverage it was possible for epidemics to spread to all metapopulation patches once 5 or 
more primary schools achieved only half the coverage of the remaining 20 primary schools.  
Changing the level of heterogeneity between a low-coverage primary school and a high-coverage 
primary school changes the mean final size of epidemics for all levels of coverage. Increasing the 
heterogeneity between low- and high-coverage schools increases the mean final size of epidemics. 
Intended heterogeneity in the vaccination programme by concentrating coverage in primary schools 
consistently increased the mean final size of epidemics, the mean epidemic peak and the mean time 
for all patches to become infected. The impact on the duration of epidemics and the timing of the 
peak was dependent on the targeted vaccination coverage - that is epidemics were shorter with 
concentrated vaccination coverage of 20% and 40% than for homogeneous vaccination coverage, but 
longer for higher coverage of 60% and 80%. Vaccination strategies with intended heterogeneity that 
ensured all primary school patches were included in the vaccination programme consistently failed to 
reduce the mean final size of epidemics, and in many cases increased the total burden of disease by 
introducing heterogeneous uptake between the 25 primary schools. 
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TARGETED VACCINATION IN SECONDARY SCHOOLS ONLY 
TARGETED HOMOGENEOUS VACCINATION IN SECONDARY SCHOOLS 
 
Figure 6.14 - Results from 5,000 simulations of the metapopulation model with targeted homogeneous 
vaccination coverage in secondary schools only 
Figure 6.14 shows the results from the model for vaccinating secondary schools with a homogenous 
vaccination strategy. With results consistent with targeted homogenous vaccination in primary 
schools, sustained influenza transmission in the community cannot be eliminated even with 100% 
vaccination coverage.   
Table 6.14 shows the reduction in the mean final size of ILI epidemics as vaccination coverage in 
secondary schools increases. The results expand on those shown in Figure 6.14, the maximum 
coverage in secondary schools reducing the mean final size of epidemics to 3.58% (95% CI: 3.32-
3.86%).  
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 Vaccination coverage 
Mean (95% CI) 
 20% 40% 60% 80% 100% 
ILI Final Size 12.91% 
(12.79-
13.02%) 
9.53% 
(9.33-
9.72%) 
6.81% 
(6.56-
7.03%) 
4.69% 
(4.40-
4.96%) 
3.58% 
(3.32-
3.86%) 
ILI Duration 
(days) 
198.58 
(194.56-
202.60) 
219.59 
(214.38-
225.56) 
230.63 
(223.84-
237.80) 
209.60 
(200.61-
217.83) 
191.47 
(181.86-
200.91) 
ILI Peak 0.306% 
(0.300-
0.312%) 
0.188% 
(0.182-
0.194%) 
0.123% 
(0.118-
0.128%) 
0.088 
(0.082-
0.093%) 
0.071% 
(0.066-
0.075%) 
ILI time for all 
patches to be 
infected (days) 
62.04 
(59.80-
64.40) 
65.72 
(63.19-
68.68) 
73.41 
(70.01-
77.10) 
72.61 
(68.73-
76.72%) 
75.03 
(70.47-
79.39) 
ILI Peak Time 
(days) 
99.74 
(96.86-
102.70) 
107.10 
(103.00-
111.40) 
116.25 
(110.91-
122.00) 
100.29 
(93.27-
107.23) 
96.95 
(88.67-
104.65) 
Table 6.14 - Results from 5,000 simulations of the metapopulation model with targeted homogeneous 
vaccination coverage in secondary schools only 
VARYING THE Ε1 PARAMETER 
Figure 6.15 shows the effect of varying the ε1 parameter in the model. The variation in the ε1 
parameter has a negligible effect until we consider the mean time for all patches in the 
metapopulation to be infected – here, for all vaccination coverage levels in the secondary school 
patches the epidemics took longer to infect all patches as the ε1 parameter increased to 1. 
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Figure 6.15 - Epidemic results with targeted homogeneous secondary school vaccination and varying 
ε1 parameter 
TARGETED HETEROGENEOUS VACCINATION IN SECONDARY SCHOOLS ONLY 
With a vaccination programme targeting only the secondary schools in the metapopulation but 
coverage heterogeneity persisting, Figure 6.16 shows the impact of the increasing number of low-
coverage secondary schools and the mean final size of the ILI epidemics.  
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Figure 6.16 - Mean ILI final size for epidemics in the metapopulation with targeted heterogeneous 
vaccination coverage in secondary schools only 
At 20% coverage in secondary schools, the mean final size of the epidemics increased from 12.79% 
(95% CI: 12.64-12.93%) to 14.32% (95% CI: 14.23-14.42%) as the number of low-coverage schools 
increased from 0 to 4. The difference between the mean final size with homogeneous targeted 
coverage and the maximum number of low-coverage secondary schools increases as the targeted 
coverage increases to 100%. At 60% coverage, the mean final sizes for epidemics in metapopulations 
with 0 and 4 low-coverage schools were 6.83% (95% CI: 6.58-7.07%) and 10.53% (95% CI: 10.41-
10.65%) respectively. At 100% coverage, this discrepancy extended from 3.29% (95% CI: 3.02-3.57%) 
to 7.08% (95% CI: 6.84-7.32%) respectively. 
Results for the mean duration, the mean peak, the mean time for all patches to become infected and 
the mean peak time are displayed in the appendix. 
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THE IMPACT OF A SINGLE LOW-COVERAGE SECONDARY SCHOOL IN THE METAPOPULATION WITH TARGETED VACCINATION IN 
SECONDARY SCHOOLS 
Table 6.15 shows the comparison of targeted vaccination in secondary schools at four coverage levels 
with the scenario of one low-coverage secondary school when 5,000 additional simulations at varying 
vaccination coverage levels were executed for 0 or 1 low-coverage secondary schools. For all levels of 
vaccination coverage there was strong evidence that a single low-coverage secondary school can 
increase the mean final size of ILI epidemics in the metapopulation. 
Vaccination coverage 20% 
0 low-coverage schools 1 low-coverage school  
mean (95% CI) mean (95% CI) Wilcoxon Test 
12.77% (12.59-12.95%) 13.36% (13.23-13.48%) W=7,060, p<<0.001 
 
Vaccination coverage 40% 
0 low-coverage schools 1 low-coverage school  
mean (95% CI) mean (95% CI) Wilcoxon Test 
9.58% (9.32-9.80%) 10.37% (10.18-10.59%) W=5,291, p<<0.001 
 
Vaccination coverage 60% 
0 low-coverage schools 1 low-coverage school  
mean (95% CI) mean (95% CI) Wilcoxon Test 
6.65% (6.22-7.04%) 7.68% (7.32-8.01%) W=3,200, p<<0.001 
 
Vaccination coverage 80% 
0 low-coverage schools 1 low-coverage school  
mean (95% CI) mean (95% CI) Wilcoxon Test 
4.65% (4.21-5.05%) 5.82% (5.44-6.18%) W=2,255, p<<0.01 
   
Vaccination coverage 100% 
0 low-coverage schools 1 low-coverage school  
mean (95% CI) mean (95% CI) Wilcoxon Test 
3.71% (3.38-4.08%) 4.26% (3.85-4.67%) W=3,357, p=0.02632 
Table 6.15 - Comparing the final size of ILI epidemics with targeted heterogeneous vaccination in 
secondary schools only 
VARYING THE Τ PARAMETER 
The τ parameter was varied to examine the effect of the level of heterogeneity between high-coverage 
secondary schools and low-coverage secondary schools. 
Figure 6.17 shows that the mean final size of epidemics in the metapopulation was increased as the 
level of heterogeneity between low- and high-coverage patches was increased from τ = 0.25 to τ = 
0.75. With the maximum number of low-coverage secondary schools in the metapopulation, the mean 
final size of epidemics increased from 13.59% (95% CI: 13.44-13.71%) with τ = 0.25 to 15.04% (95% CI: 
14.95-15.12%) with τ = 0.75 when vaccination coverage was 20%. At coverage of 100% the mean final 
size of epidemics was 5.08% (95% CI: 4.78-5.36%) for τ = 0.25 and 10.52% (95% CI: 10.37-10.66%) for 
τ = 0.75. 
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Figure 6.17 - Examining variation in the τ parameter on the mean final size 
Further results describing the impact of variation in the τ parameter are displayed in the appendix.  
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INTENDED HETEROGENEITY THROUGH FIXED, CONCENTRATED VACCINATION COVERAGE 
 Homogeneous coverage Concentrated coverage 
Results for the mean final size 
No vaccination 16.40% (16.36-16.44%) N/A 
20% coverage 12.56% (12.45-12.67%) 13.92% (13.85-14.00%) 
40% coverage 9.03% (8.86-9.20%) 11.19% (11.07-11.30%) 
60% coverage 6.40% (6.22-6.57%) 8.11% (7.93-8.28%) 
80% coverage 4.38% (4.20-4.57%) 5.49% (5.31-5.69%) 
 
Results for the mean duration 
No vaccination 169.9 days (168.8-171.0 days) N/A 
20% coverage 184.3 days (182.3-186.4 days) 173.9 days (172.0-175.6 days) 
40% coverage 197.2 days (194.2-200.3 days) 186.5 days (184.2-188.9 days) 
60% coverage 194.0 days (189.9-198.0 days) 194.5 days (190.1-198.2 days) 
80% coverage 172.5 days (168.2-177.1 days) 182.0 days (178.2-186.1 days) 
 
Results for the mean peak 
No vaccination 0.468% (0.466-0.471%) N/A 
20% coverage 0.305% (0.301-0.310%) 0.369% (0.364-0.373%) 
40% coverage 0.193% (0.189-0.198%) 0.263% (0.259-0.268%) 
60% coverage 0.134% (0.130-0.138%) 0.174% (0.169-0.179%) 
80% coverage 0.099% (0.096-0.102%) 0.121% (0.117-0.126%) 
 
Results for the mean time for all patches to become infected 
No vaccination 52.7 days (52.1-53.4 days) N/A 
20% coverage 51.3 days (50.2-52.4 days) 49.3 days (48.3-50.2 days) 
40% coverage 55.6 days (54.2-57.1 days) 51.9 days (50.8-52.9 days) 
60% coverage 59.0 days (57.5-60.7 days) 57.0 days (55.5-58.5 days) 
80% coverage 60.3 days (58.6-62.0 days) 60.5 days (58.8-62.3 days) 
 
Results for the mean peak time 
No vaccination 85.3 days (84.6-86.2 days) N/A 
20% coverage 88.8 days (87.2-90.4 days) 84.5 days (83.1-85.9 days) 
40% coverage 94.6 days (92.3-97.3 days) 89.8 days (88.0-91.5 days) 
60% coverage 93.2 days (90.4-96.4 days) 94.9 days (92.4-97.5 days) 
80% coverage 82.8 days (79.8-85.9 days) 87.9 days (85.0-90.6 days) 
Table 6.16 - Targeted vaccination coverage in secondary schools with both homogeneous coverage 
and concentrated coverage 
Results for intended heterogeneity within a targeted vaccination policy in secondary schools are 
consistent with those results for primary schools, where some schools receive 100% vaccination whilst 
others receive none. The mean final size of epidemics in the metapopulation reduces with an increase 
in vaccination coverage, but heterogeneity increases the mean final size over the same results for 
homogeneous coverage (Table 6.16). 
Concentrating mean vaccination coverage in selected secondary schools is detrimental to public 
health vaccination programmes that seek to minimise the potential final size of epidemics in the 
metapopulation. Similar results are seen for the mean size of the epidemic peak, with an increase in 
vaccination coverage decreases the mean epidemic peak from the baseline result, but concentrated 
vaccination coverage increase the mean epidemic peak over that through a homogeneous policy.  
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The mean duration of epidemics increases above baseline for coverage levels of 20% and 40%, but 
then reduces for the higher coverage levels. At these higher levels of coverage, heterogeneity through 
the concentration of vaccination coverage increases the mean duration of epidemics above that 
expected in the homogeneous case. The mean time of the epidemic peak behaves in a similar way to 
the mean duration when vaccination coverage is increased both with and without heterogeneity. 
INTENDED HETEROGENEITY WITH VACCINATION IN ALL TARGETED PATCHES 
Heterogeneous coverage strategies that administered vaccinations in all secondary school patches 
failed to reduce the mean final size of epidemics, results consistent with the heterogeneous 
vaccination strategies used in primary schools. The four coverage levels included in simulations could 
not improve on the mean final size of epidemics with homogeneous coverage (Figure 6.18 to Figure 
6.21). 
 
Figure 6.18 - Heterogeneity in a targeted vaccination programme for secondary schools with mean 
overall coverage of 20% 
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The mean final size of epidemics reached its maximum when heterogeneity between the two groups 
in the secondary school patches reached its highest degree. With one school with 80% coverage and 
four schools with 5% coverage the mean final size of epidemics was 13.76% (95% CI: 13.71-13.81%), 
up from 12.56% (95% CI: 12.45-12.67%) with homogenous 20% coverage (Figure 6.18). The increase 
in the mean size of the epidemic peak followed the same trend. 
 
Figure 6.19 - Heterogeneity in a targeted vaccination programme for secondary schools with mean 
overall coverage of 40% 
The mean duration of epidemics reached a maximum of 193.53 days (95% CI: 192.09-194.97) with one 
school with 40% coverage and four schools with 15% coverage, up from 184.32 days (95% CI: 182.20-
186.57) with homogeneous coverage. The mean time of the epidemic peak behaved in the same way. 
All three heterogeneous vaccination strategies increased the mean time for the epidemic to reach all 
metapopulation patches, increasing from 51.25 days (95% CI: 50.19-52.30) to a maximum of 58.87 
days (95% CI: 57.99-59.84) with one school with 40% coverage and four schools with 15% coverage. 
However, there was very little variation in this metric across all three heterogeneous vaccination 
strategies at 20% overall coverage. 
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Heterogeneity in vaccination uptake among secondary schools resulted in larger epidemics than those 
occurring with homogeneous 40% coverage (Figure 6.19). The mean final size of epidemics rose from 
9.03% (95% CI: 8.86-9.20%) to a maximum of 9.99% (9.91-10.06%) with one school with 80% coverage 
and four schools with 30% coverage, the highest degree of heterogeneity between the two groups in 
the secondary school patches. This vaccination strategy also resulted in the highest mean peak of 
0.204% (95% CI: 0.201-0.207%), up from 0.193% (95% CI: 0.188-0.198%) with homogeneity. 
There was little variation between the mean duration of epidemics for the heterogeneous vaccination 
strategies: 215.89 days (95% CI: 213.54-218.30), 216.46 days (95% CI: 214.13-218.77) and 216.57 days 
(95% CI: 214.20-218.76) respectively. There was also little variation for the mean time for epidemics 
to spread to all metapopulation patches and for the mean time of the epidemic peak, but all metrics 
for the heterogeneous strategies increased on the homogeneous vaccination strategy. 
 
Figure 6.20 - Heterogeneity in a targeted vaccination programme for secondary schools with mean 
overall coverage of 60% 
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The vaccination strategy with the greatest degree of heterogeneity resulted in the largest increase in 
the mean final size of epidemics above that achieved by the homogeneous vaccination strategy with 
60% coverage (Figure 6.20). Vaccinating one secondary school with 20% coverage and 70% coverage 
in 4 schools resulted in a mean final size of 7.13% (95% CI: 7.02-7.23%), up from 6.39% (95% CI: 6.21-
6.57%) with homogeneity. This strategy also resulted in the longest mean duration (227.51 days (95% 
CI: 224.24-230.58)), highest mean epidemic peak (0.131% (95% CI: 0.128-0.134%)) and the longest 
mean time for the epidemic peak to occur (112.12 days (95% CI: 110.12-115.26)). The vaccination 
strategy with one school with coverage of 80% and four schools with 55% had the longest mean time 
for epidemics to spread to all metapopulation patches, at 71.50 days (95% CI: 69.94-73.30). 
 
Figure 6.21 - Heterogeneity in a targeted vaccination programme for secondary schools with mean 
overall coverage of 80% 
There was very little variation in the mean epidemic duration, the mean time for all patches to be 
infected and the mean time of the epidemic peak between the three vaccination strategies using 
heterogeneous uptake for mean overall coverage of 80% (Figure 6.21). The largest variation between 
these three strategies is seen in the mean final size and the mean size of the epidemic peak.  
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Vaccinating four secondary schools with 95% coverage and one school with 20% coverage resulted in 
a mean final size of 5.33% (95% CI: 5.21-5.46%), up from 4.38% (95% CI: 4.22-4.56%) with 
homogeneity. The same heterogeneous strategy had a mean epidemic peak of 0.100% (95% CI: 0.098-
0.103%), though not statistically different to the mean epidemic size with homogeneity of 0.099% 
(95% CI: 0.095-0.103%). 
SUMMARY FOR TARGETED VACCINATION IN SECONDARY SCHOOLS 
Vaccinating only secondary schools is not sufficient to eliminate the potential for epidemics to spread 
in the metapopulation - 100% coverage reduces the mean final size of epidemics to 3.58% (95% CI: 
3.32-3.86%). In terms of reducing the mean final size of epidemics, targeted vaccination in primary 
schools is more effective than in secondary schools. 
Variation in the proportion of an individual’s contacts that take place in their own patch has a strong 
relationship with the mean time for all metapopulation patches to become infected. Also, unlike the 
simulated scenarios with 100% homogeneous coverage in primary schools, epidemics still spread to 
all 31 patches with full coverage in secondary schools. 
Unintended coverage heterogeneity increases the mean final size of epidemics as the number of low-
coverage secondary schools increases, for all levels of coverage. At 20% targeted coverage, the mean 
final size of epidemics increased from 12.79% (95% CI: 12.65-12.92%) to 14.32% (95% CI: 14.23-
14.41%) as heterogeneity in uptake increases. For maximum targeted coverage, the mean final size 
increased from 3.29% (95% CI: 2.99-3.58%) to 7.09% (95% CI: 6.85-7.33%). In addition, there was very 
strong evidence that the existence of a single low-coverage secondary school in the metapopulation 
directly increases the mean final size of epidemics at all levels of coverage. 
Variation in the τ parameter to change the difference between a low-coverage secondary school and 
a high-coverage secondary school affected the mean final size of epidemics and the mean size of the 
epidemic peak. Increasing the difference between the low- and high-coverage schools increases the 
number of susceptible individuals in the metapopulation sufficiently to result in a larger burden of 
disease. 
Concentrating vaccination coverage in specific secondary schools rather than achieving homogenous 
vaccination across them all consistently increased the size of epidemics in the metapopulation. This 
result was also seen for the mean epidemic peak. Contrary to the results for intended heterogeneity 
in the primary school population, heterogeneous coverage in secondary schools decreased the mean 
time needed for the epidemics to spread across all patches of the metapopulation, other than for 80% 
coverage – an average time of 60.3 days (95% CI: 58.6-62.0) for homogenous coverage and 60.5 days 
(95% CI: 58.8-62.3) for concentrated coverage through heterogeneity. Using heterogeneous coverage 
with all five secondary schools included in the vaccination strategy consistently resulted in a greater 
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mean final size than the equivalent homogenous coverage level. The only metric that reduced was the 
mean size of the epidemic peak, though only with overall coverage of 60% or 80% and still with 
minimal heterogeneity between the two groups in the secondary school patches. 
VACCINATION IN BOTH PRIMARY AND SECONDARY SCHOOLS  
HOMOGENEOUS VACCINATION IN BOTH PRIMARY AND SECONDARY SCHOOLS 
 
Figure 6.22 - Results from 5,000 simulations of the metapopulation model with homogeneous 
vaccination coverage in both primary and secondary schools.  
Increasing homogeneous vaccination coverage decreases ILI final size, ILI Duration, ILI Peak and ILI 
Peak Time (Figure 6.22). ILI epidemics with a final size greater than 0.5% do not occur once vaccination 
coverage exceeds 47.8%. The relationship between vaccination coverage and the time for all 
metapopulation patches to become infected is less clear, but after vaccination coverage reaches 
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44.5% further ILI epidemics of a final size greater than 0.5% did not occur that included infection in all 
metapopulation patches. 
Further results from the model are shown in Table 6.17. For simulations with vaccination coverage of 
20% in both primary and secondary schools the mean ILI final size was 7.29% (95% CI: 6.99-7.57%), 
reduced from 16.40% (95% CI: 16.36-16.44%) when the school-based vaccination programme was not 
available. ILI duration and the epidemic peak reduce as vaccination coverage increases.  
 Vaccination coverage 
Mean (95% CI) 
 20% 40% 60% 80% 100% 
ILI Final Size 7.29% (6.99-7.57%) 0.873% (0.715-1.07%) N/A N/A N/A 
ILI Duration 
(days) 
237.28 (229.21-245.04) 130.52 (115.70-146.92) N/A N/A N/A 
ILI Peak 0.128% (0.121-0.134%) 0.028% (0.024-0.031%) N/A N/A N/A 
ILI time for all 
patches to be 
infected (days) 
79.71 (75.94-83.63) 107.89 (71.00-151.00) N/A N/A N/A 
ILI Peak Time 
(days) 
122.82 (115.87-129.33) 60.50 (49.38-71.85) N/A N/A N/A 
Table 6.17 - Results from 5,000 simulations of the metapopulation model with homogeneous 
vaccination coverage in both primary and secondary schools 
VARYING THE Ε1 PARAMETER 
By varying the ε1 parameter we examined the impact on epidemics in the metapopulation of different 
proportions of an individual’s daily contacts taking place within their own patch (Figure 6.23). Results 
for the mean final size of epidemics in the metapopulation follow those results discussed for other 
vaccination scenarios, that is that there is little variation as the ε1 parameter is increased, though for 
the lowest level of vaccination coverage ε1 = 1 saw the lowest mean final size of 6.89% (95% CI: 6.60-
7.18%). A more obvious result for a metapopulation configuration with homogeneous vaccination 
coverage is that epidemics can occur in the metapopulation with homogeneous vaccination coverage 
of 60% at values of ε1 less than 0.75, indicating that the ε1 parameter is a key determinant of the mean 
final size at vaccination coverage levels near to those required to eliminate epidemics in the 
metapopulation. 
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Figure 6.23 - Epidemic results with homogeneous primary and secondary school vaccination and 
varying ε1 parameter 
HOMOGENEOUS VACCINATION IN BOTH PRIMARY AND SECONDARY SCHOOLS WITH HETEROGENEOUS UPTAKE WITHIN 
PRIMARY SCHOOLS 
Maintaining homogeneous vaccination coverage across both primary and secondary school groups 
whilst varying the number of low-coverage primary schools, Figure 6.24 shows that the final size of ILI 
epidemics across the metapopulation is associated with the number of low-coverage primary schools 
only when the normal vaccination coverage reaches high levels – with coverage of 20% there is 
noticeable variation when the number of low-coverage primary schools is increased. With higher 
vaccination coverage the mean final size of epidemics steadily increased. Coverage of 60% sees 
epidemics occurring when 6 or more primary schools have lower coverage. When coverage reached 
80% or greater then epidemics occurred only with 14 or more low-coverage primary schools, and no 
outbreaks occurred with any level of heterogeneity with targeted coverage of 100%. 
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Figure 6.24 - Mean ILI final size for epidemics with different homogeneous vaccination coverage with 
an increasing number of low-coverage primary schools 
Results for the mean duration, the mean peak, the mean time for all patches to become infected and 
the mean peak time are displayed in the appendix. 
THE IMPACT OF A SINGLE LOW-COVERAGE PRIMARY SCHOOL IN THE METAPOPULATION WITH HOMOGENOUS COVERAGE 
ACROSS PRIMARY AND SECONDARY SCHOOLS 
5,000 additional simulations to examine the impact of one low-coverage primary school in the 
metapopulation with vaccination coverage set between the same five intervals as in Figure 6.24 are 
show in Table 6.18. Results from Wilcoxon Tests comparing the mean final size of ILI epidemics with 0 
low-coverage primary schools to epidemics with 1 low-coverage primary schools indicate no evidence 
for a difference between the metapopulations with 20% and 40% coverage. At 60% vaccination 
coverage the addition of a single low-coverage primary school facilitated epidemic spread when 
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achieving 60% homogeneous coverage did not. Epidemics did not occur for vaccination coverage of 
both 80% and 100%. 
Vaccination coverage 20% 
0 low-coverage schools 1 low-coverage school  
mean (95% CI) mean (95% CI) Wilcoxon Test 
7.11% (6.93-7.30%) 7.27% (7.09-7.44%) W=113,915, p=0.4279 
 
Vaccination coverage 40% 
0 low-coverage schools 1 low-coverage school  
mean (95% CI) mean (95% CI) Wilcoxon Test 
1.17% (1.03-1.32%) 1.11% (0.990-1.25%) W=2,864, p=0.529 
 
Vaccination coverage 60% 
0 low-coverage schools 1 low-coverage school  
mean (95% CI) mean (95% CI) Wilcoxon Test 
N/A 0.566% (0.566-0.566%) N/A 
Table 6.18 - Comparing the final size of ILI epidemics with homogenous vaccination, but with 
heterogeneous coverage in primary schools only   
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HOMOGENEOUS VACCINATION IN BOTH PRIMARY AND SECONDARY SCHOOLS WITH HETEROGENEOUS UPTAKE WITHIN 
SECONDARY SCHOOLS 
 
Figure 6.25 - Mean ILI final size for epidemics with different homogeneous vaccination coverage with 
an increasing number of low-coverage secondary schools 
Figure 6.25 shows the impact of an increasing number of low-coverage secondary schools in a 
metapopulation with homogeneous vaccination in both primary and secondary schools. For 
vaccination coverage of both 20% and 40%, increasing the unintended heterogeneity in uptake 
increases the mean final size of epidemics steadily. For vaccination coverage of 60%, the lack of 
association between mean final size and heterogeneity is mostly likely due to a very small number of 
outbreaks that occurred with such high vaccination coverage. No epidemics occurred with vaccination 
coverage of 80% and 100%. 
Results for the mean duration, the mean peak, the mean time for all patches to become infected and 
the mean peak time are displayed in 10.7 in the appendix. 
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THE IMPACT OF A SINGLE LOW-COVERAGE SECONDARY SCHOOL IN THE METAPOPULATION WITH HOMOGENOUS COVERAGE 
ACROSS PRIMARY AND SECONDARY SCHOOLS 
Vaccination coverage 20% 
0 low-coverage schools 1 low-coverage school  
mean (95% CI) mean (95% CI) Wilcoxon Test 
7.16% (6.98-7.34%) 7.74% (7.58-7.91%) W=89,601, p<<0.001 
 
Vaccination coverage 40% 
0 low-coverage schools 1 low-coverage school  
mean (95% CI) mean (95% CI) Wilcoxon Test 
1.01% (0.912-1.11%) 1.12% (1.00-1.25%) W=3,246.5, p=0.4147 
 
Vaccination coverage 60% 
0 low-coverage schools 1 low-coverage school  
mean (95% CI) mean (95% CI) Wilcoxon Test 
N/A 0.709% (0.579-0.840%) N/A 
Table 6.19 - Comparing the final size of ILI epidemics with homogeneous vaccination coverage across 
both primary and secondary schools but heterogeneity within secondary schools 
Table 6.19 shows the comparison of homogenous vaccination across both primary and secondary 
schools at four coverage levels with the scenario of one low-coverage secondary school obtained by 
executing a further 5,000 simulations of the model with varying vaccination coverage levels. One low-
coverage secondary school does not impact the mean final size of ILI epidemics in the metapopulation 
at 40% vaccination coverage but it can for the lowest level of coverage at 20%, and epidemics did not 
occur in the metapopulation with coverage of 80% or 100%. 
THE IMPACT OF A SINGLE LOW-COVERAGE PRIMARY SCHOOL AND A SINGLE LOW-COVERAGE SECONDARY SCHOOL IN THE 
METAPOPULATION WITH HOMOGENEOUS COVERAGE ACROSS PRIMARY AND SECONDARY SCHOOLS 
Homogeneous vaccination across the metapopulation but with one primary school and one secondary 
school failing to achieve the same level of vaccination coverage as the other schools increases the 
mean final size of ILI epidemics in the community (Table 6.20). 5,000 simulations were executed to 
expand on results presented in Table 6.18 and Table 6.19. For both 20% and 40% coverage levels, 
there was strong evidence that the existence of a low-coverage primary school and a low-coverage 
secondary school increased the mean final size of epidemics in the metapopulation. Epidemics did not 
occur with vaccination coverage greater of 80% and 100%. 
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Vaccination coverage 20% 
0 low-coverage schools 1 low-coverage school  
mean (95% CI) mean (95% CI) Wilcoxon Test 
7.34% (7.16-7.53%) 8.01% (7.86-8.15%) W=86,057, p<<0.001 
 
Vaccination coverage 40% 
0 low-coverage schools 1 low-coverage school  
mean (95% CI) mean (95% CI) Wilcoxon Test 
0.994% (0.896-1.10%) 1.31% (1.19-1.46%) W=3,343.5, p=0.002461 
 
Vaccination coverage 60% 
0 low-coverage schools 1 low-coverage school  
mean (95% CI) mean (95% CI) Wilcoxon Test 
N/A 0.762% (0.515-0.957%) N/A 
Table 6.20 - Comparing the final size of ILI epidemics with homogeneous vaccination coverage across 
both primary and secondary schools but heterogeneity within both primary and secondary schools 
INTENDED HETEROGENEITY THROUGH FIXED, CONCENTRATED VACCINATION COVERAGE 
Theorising a vaccination programme targeting several schools for 100% coverage, there were 4 
different configurations for 20% coverage in primary and secondary schools - baseline homogeneity, 
9 primary schools with 0 secondary schools, 5 primary schools with 1 secondary school and finally 1 
primary school with 2 secondary schools (Figure 6.26). At this coverage level the introduction of 
heterogeneity in vaccination uptake increases the mean final size of epidemics from 6.85% (95% CI: 
6.66-7.03%) to a maximum of 11.14% (95% CI: 11.01-11.26%) with full vaccination in 1 primary school 
and 2 secondary schools. This heterogeneity also increases the mean size of the epidemic peak from 
0.140% (95% CI: 0.135-0.144%) to a maximum of 0.266% (95% CI: 0.261-0.271%). 
In contrast, both the mean epidemic duration and mean time of the epidemic peak decreased after 
heterogeneity was introduced. The mean duration decreased from 200.3 days (95% CI: 196.1-204.1 
days) to a minimum of 183.4 days (95% CI: 181.1-185.7 days), reducing the duration of epidemics by 
approximately 17 days. The mean time of the epidemic peak also decreased from 97.6 days (95% CI: 
94.4-100.8 days) to 88.2 days (95% CI: 86.5-89.8 days). 
The metric with the most variation was the mean time for all metapopulation patches to become 
infected. At baseline it took a mean time of 66.0 days (95% CI: 64.2-67.8 days) for all 31 patches to be 
infected. Configuring the metapopulation to fully vaccinate only 9 primary schools increased that time 
to 93.4 days (95% CI: 81.2-85.6 days), almost one month longer. However, concentrating the low level 
of vaccination coverage in secondary schools by fully vaccinating 2 secondary schools plus 1 primary 
school decreased the mean time for all patches to become infected to 57.2 days (95% CI: 55.9-58.5 
days).  
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Figure 6.26 - Different configurations of 20% coverage achieved in primary and secondary schools 
Two configurations of 20% coverage concentrated in specific schools are shown in Figure 6.27 (9 
primary schools) and Figure 6.28 (1 primary school and 2 secondary schools). Concentrating 
vaccination coverage in primary schools reduces the epidemic peak in the primary school age group 
below the peak of the secondary school age group, as well as seeing that several primary schools have 
only minor epidemics in their patch. In contrast, concentrating coverage in secondary schools in the 
second configuration allows 24 primary schools to experience full epidemics, resulting in a larger 
epidemic peak in the primary school age group. 
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Figure 6.27 - The patch epidemic curves for a metapopulation configuration with concentrated 
vaccination coverage in 9 primary schools 
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Figure 6.28 - The patch epidemic curves for a metapopulation configuration with concentrated 
vaccination coverage in 1 primary school and 2 secondary schools 
There were 6 different configurations for 40% coverage in primary and secondary schools (Figure 
6.29). Introducing heterogeneity in the vaccination coverage across the metapopulation increased all 
metrics for disease burden. The mean final size of epidemics rose from 1.18% (95% CI: 1.08-1.29%) at 
baseline to a maximum of 4.78% (95% CI: 4.60-4.95%), though with very little variation between the 
5 configurations of the metapopulation with heterogeneous vaccination coverage. Indeed, similar 
results are seen by an increase in the mean duration of the epidemics, the mean epidemic peak and 
the mean epidemic peak time, all with little variation once heterogeneity was introduced. 
The mean time for all metapopulation patches to be infected varied according to the configuration of 
vaccine administration. With homogenous 40% coverage across the schools the mean time for all 
patches to be infected was 81.6 days (95% CI: 75.2-89.0). This increased to a mean of 111.2 days (95% 
CI: 106.1-116.3) with 40% coverage concentrated in the primary school population. As the vaccination 
coverage became less concentrated in primary schools through the increase in the number of 
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secondary schools that were fully vaccinated, the mean time for all metapopulation patches to 
become infected decreased. With the 40% coverage concentrated in secondary schools as much as 
possible (i.e. 2 primary schools and 4 secondary schools fully vaccinated) the mean time for the 
epidemic to reach all metapopulation patches reduced to 75.9 days (95% CI: 73.2-78.7), a time quicker 
than the baseline result. 
 
Figure 6.29 - Different configurations of 40% coverage achieved in primary and secondary schools 
Two metapopulation configurations with concentrated vaccination coverage of 40% of school children 
are shown in Figure 6.30 (18 primary schools), along with Figure 6.31 (2 primary schools and 4 
secondary schools). Concentrating vaccination coverage in primary schools sufficient protection to the 
primary school age group to see that 18 of 25 primary schools had very minor epidemics on their 
patch, but secondary schools were completely unprotected. In this configuration, the epidemic peak 
for the primary school age group reached 0.15% but the secondary school peak reached 0.35%. 
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However, switching concentration to secondary schools reduced the epidemic peak in that age group 
to 0.1%, with primary school epidemics peaking at almost four times that. 
 
Figure 6.30 - The patch epidemic curves for a metapopulation configuration with concentrated 
vaccination coverage in 18 primary schools 
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Figure 6.31 - The patch epidemic curves for a metapopulation configuration with concentrated 
vaccination coverage in 2 primary schools and 4 secondary schools 
There were 5 different configurations for 60% coverage in primary and secondary schools (Figure 
6.32). All metrics to examine the potential burden of disease increased when vaccine coverage 
heterogeneity was introduced to the metapopulation, most notably in the mean final size of epidemics 
which jumped from a mean of 0.609% (95% CI: 0.536-0.685%) to a maximum of 1.43% (95% CI: 1.31-
1.55%).  
The most interesting result is that the epidemics spread to all metapopulation patches, even with a 
large number of patches reporting 100% vaccination coverage. Previous results show that epidemics 
are unable to reach all metapopulation patches with homogeneous coverage of 44.5% or greater, but 
with heterogeneity introduced with 60% coverage the simulated epidemics were able to reach all 
metapopulation patches in 91.6 days (95% CI: 89.2-94.1 days) with 19 primary schools and 2 secondary 
schools reporting 100% vaccination coverage.  
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The mean duration of epidemics in the metapopulation increased from a mean of 76.7 days (95% CI: 
69.0-82.8 days) to a maximum of 110.9 days (95% CI: 104.0-118.1 days) with 19 primary schools and 
2 secondary schools reporting 100% vaccination coverage. Maintaining 60% vaccination coverage 
across the school patches but with increased heterogeneity extended the mean epidemic duration by 
approximately one month, even with overall vaccination coverage that would otherwise be sufficient 
to stop epidemics altogether (Figure 6.22). 
 
Figure 6.32 - Different configurations of 60% coverage achieved in primary and secondary schools 
There were 4 different configurations for 80% coverage in primary and secondary schools - baseline 
homogeneity, 24 primary schools with 3 secondary schools, 20 primary schools with 4 secondary 
schools and finally 16 primary schools with 5 secondary schools (Figure 6.33). 
In contrast to the results reported for 60% vaccination coverage with heterogeneity, 80% coverage 
prevents epidemics from spreading to all 31 metapopulation patches. There is little variation in the 
other metrics for reporting the total disease burden for different configurations of the 
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metapopulation. However, even with very high overall vaccination coverage of 80%, the introduction 
of heterogeneity in coverage allows for sustained transmission of influenza that results in epidemics 
with a mean final size above 0.6% of the population, with such epidemics lasting up to a mean of 88 
days (95% CI: 72.9-104.8 days).   
 
Figure 6.33 - Different configurations of 80% coverage achieved in primary and secondary schools 
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INTENDED HETEROGENEITY WITH VACCINATION IN ALL TARGETED PATCHES 
 
Figure 6.34 - Heterogeneous vaccination coverage with 20% vaccination in all school patches 
Vaccinating each primary school to achieve 4% coverage and each secondary school to achieve 40% 
coverage did not reduce the total burden of disease over a homogenous 20% vaccination strategy 
(Figure 6.34). The mean final size of epidemics increased from 6.85% (95% CI: 6.65-7.05%) to 8.38% 
(95% CI: 8.28-8.49%). The mean duration of epidemics increased from 200.29 days (95% CI: 196.36-
204.10) to 226.53 days (95% CI: 223.51-229.31), almost a month longer than with the homogeneous 
coverage. The mean time for all metapopulation patches to become infected increased to 69.83 days 
(95% CI: 68.54-71.20), from 66.04 days (95% CI: 64.16-67.86). 
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Figure 6.35 - Heterogeneous vaccination coverage with 40% vaccination in all school patches 
Achieving mean overall coverage of 40% in the two school groups with different heterogeneous 
vaccination strategies has very different results (Figure 6.35). There was little difference between the 
mean final size of epidemics with homogeneous coverage (1.19% (95% CI: 1.08-1.30%)) and two 
heterogeneous strategies – vaccinating primary schools to 24% coverage and secondary schools to 
60% coverage (1.22% (95% CI: 1.14-1.32%), W=141943.5 and p=0.9507), and then vaccinating primary 
schools to 56% coverage with secondary schools at 20% coverage (1.24% (95% CI: 1.13-1.35%), 
W=10,484 and p=0.8054). The largest increase in the mean final size of epidemics was with the 
heterogeneous vaccination strategy that used the greatest degree of heterogeneity between the two 
school groups – vaccinating primary schools to just 8% coverage and secondary schools to 80% 
resulted in a mean final size of 2.59% (95% CI: 2.48-2.71%).  
Heterogeneous vaccination coverage was successful in reducing the mean size of the epidemic peak 
when vaccinating 24% of primary school children and 60% secondary school children (0.035% (95% CI: 
0.033-0.036%)) and also when vaccinating 56% of primary school children and 20% of secondary 
school children (0.036% (95% CI: 0.034-0.038%)), down from 0.043% (95% CI: 0.041-0.046%) with 
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homogeneous coverage. However, heterogeneous vaccination coverage was unable to reduce any of 
the other metrics when compared to the performance of the homogeneous strategy. 
 
Figure 6.36 - Heterogeneous vaccination coverage with 60% vaccination in all school patches 
Figure 6.36 shows that the vaccination strategies with the highest degree of heterogeneity between 
the primary and secondary school groups resulted in the largest mean final size of epidemics in the 
metapopulation. Two strategies with coverage heavily concentrated in the primary school population 
had epidemics with a mean final size of 0.871% (95% CI: 0.766-1.01%) (92% coverage in primary 
schools and 20% coverage in secondary schools) and 1.06% (95% CI: 0.947-1.20%) (100% coverage in 
primary schools and 10% coverage in secondary schools) respectively. Concentrating vaccination 
coverage in secondary schools and reducing the degree of heterogeneity did not result in epidemics 
that were statistically different in size to those that occurred with 60% homogeneous coverage. 
60% homogeneous coverage prevents the epidemics from reaching all metapopulation patches. 
However, the four vaccination strategies with the highest degrees of heterogeneity between the two 
groups (i.e. those vaccination strategies that concentrated coverage the most in either group) resulted 
in epidemics able to spread to all 31 metapopulation patches. Concentrating coverage in primary 
schools, the epidemics spread to all patches in 72.58 days (95% CI: 66.10-79.30) (92% coverage in 
primary schools and 20% coverage in secondary schools) and 66.90 days (95% CI: 60.20-73.37) (100% 
coverage in primary schools and 10% coverage in secondary schools). With concentration highest in 
secondary schools, the epidemics spread to all patches in 29.48 days (95% CI: 25.15-33.50) (44% 
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coverage in primary schools and 80% coverage in secondary schools) and 25.60 days (95% CI: 21.70-
29.54) (28% coverage in primary schools and 100% coverage in secondary schools).  
No epidemics occurred in the 4 metapopulation configurations with overall 80% vaccination coverage 
in primary and secondary schools. 
SUMMARY FOR TARGETED HOMOGENEOUS VACCINATION ACROSS PRIMARY AND SECONDARY SCHOOLS 
The potential for epidemics in the metapopulation is completely reduced with 47.8% homogeneous 
vaccination in both primary and secondary schools. 5,000 simulations with the level of homogeneous 
vaccination assigned to a value between 0 and 1 resulted in no epidemics at all above this level of 
vaccination, and no epidemics spreading to all metapopulation patches with coverage above 44.5%. 
However, reducing the ε1 parameter to 0, 0.25 and 0.50 resulted in epidemics occurring in the 
metapopulation with homogeneous vaccination coverage of 60%. Epidemics occurring with 60% 
coverage did not spread to all 31 metapopulation patches. Those epidemics that did reach all patches 
of the metapopulation with vaccination coverage of 20% and 40% did so in a slower mean time as the 
ε1 parameter was increased. 
Unintended heterogeneity in vaccination coverage through low-coverage primary schools has a 
similar impact on the mean final size of epidemics as a metapopulation with targeted vaccination in 
primary schools – each additional low-coverage primary schools incrementally increases the mean 
final size of epidemics. In addition, with 60% homogeneous coverage across both school groups a large 
number of low-coverage primary schools of 6 or greater saw epidemics occur in the metapopulation. 
For 80% coverage this threshold was 14 low-coverage primary schools. However, a single low-
coverage primary school in the metapopulation did not increase the mean final size of epidemics. 
Unintended heterogeneity through low-coverage secondary schools only has an impact at 60% 
coverage, as no epidemics occurred at 80% coverage even with 4 low-coverage secondary schools. In 
contrast to the results on the impact of a single low-coverage primary school, a single low-coverage 
secondary school has a measurable impact on the mean final size of outbreaks in the metapopulation 
at 20% coverage – the final size of epidemics increased from 7.16% (95% CI: 6.98-7.34%) to 7.74% 
(95% CI: 7.58-7.91%) with one secondary school achieving 10% coverage whilst all other primary and 
secondary schools achieved 20% coverage. For higher levels of homogeneous coverage the evidence 
for an impact of a low-coverage secondary school was much weaker. However, epidemics in a 
metapopulation with either 20% or 40% homogeneous vaccination coverage will have larger mean 
final sizes if both a primary school and a secondary school achieve only half the targeted coverage 
level. At 60% homogeneous coverage the evidence for a difference was again much weaker. 
Intended heterogeneity through targeting 100% vaccination coverage in specific primary or secondary 
schools consistently increased the mean final size of epidemics from an equivalent homogeneous 
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coverage level. With overall 20% coverage, the mean final size increased from 6.85% (95% CI: 6.66-
7.03%) with homogeneous coverage to 9.75% (95% CI: 9.58-9.90%) concentrated in 9 primary schools, 
to a maximum of 11.14% (95% CI: 11.01-11.26%) when concentrated in 2 secondary schools and 1 
primary school. Similar trends were seen for the 40%, 60% and 80% coverage concentrated in specific 
primary or secondary schools, with heterogeneous coverage consistently increasing the mean final 
size of epidemics in the metapopulation. In contrast, the mean duration of epidemics increases with 
heterogeneity at overall 40%, 60% and 80% but decreases with heterogeneity at overall 20% coverage. 
Also, concentrating overall 20% and 40% coverage in secondary schools decreased the mean time 
required for the epidemic to spread to all metapopulation patches. 60% homogeneous coverage stops 
epidemics from spreading in the same way, but not overall 60% concentrated coverage in which 
epidemics always spread to all metapopulation patches.  
Heterogeneous vaccination strategies that include all school patches in the vaccination programmes 
fail to reduce the mean final size of epidemics in the metapopulation when compared to their 
homogenous coverage equivalents. With strategies that achieve 60% coverage overall, those 
strategies that had the highest degree of heterogeneity with concentration of coverage in primary 
schools resulted in the largest outbreaks in the metapopulation. Highly heterogeneous coverage 
between both school groups resulted in epidemics that spread to all metapopulation patches, when 
other strategies with less or no heterogeneity in uptake resulted in epidemics confined to fewer than 
all 31 patches. Concentrating vaccination coverage in secondary schools caused the epidemics to 
spread to all 31 patches faster than those epidemics in metapopulations with vaccination 
concentrated in primary school patches. This is unsurprising as concentrating coverage in secondary 
schools increases the level of coverage in only five of the 31 metapopulation patches, leaving 26 
patches with reduced vaccination coverage. 
DISCUSSION 
This study sought to examine the impact of both unintended and intended heterogeneities in the 
uptake of a school-based vaccination programme using an age-structured stochastic transmission 
model and a theoretical patch-structured metapopulation.  
The effectiveness of vaccination programmes was studied by estimating the reduction in the total 
burden of disease at different levels of coverage. In addition, the impact of heterogeneity in 
vaccination coverage – both unintended heterogeneity (through low uptake in some schools) and 
intended heterogeneity (through vaccination programme design by concentrating coverage in certain 
schools) – was estimated by comparing the total burden of disease for vaccination programmes 
without heterogeneity to those programmes with different heterogeneities. 
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MAIN DIFFERENCES BETWEEN THE THREE VACCINATION PROGRAMMES 
Neither the homogenous targeted vaccination policies in primary or secondary schools is sufficient to 
stop epidemics occurring in the metapopulation. Only vaccination in both school groups was sufficient 
to reduce the potential of epidemics, with results from Figure 6.23 showing that vaccination coverage 
above 47.8% would suffice. 100% coverage in primary schools and secondary schools separately 
resulted in epidemics with mean final sizes of 1.84% (95% CI: 1.49-2.22%) and 3.58% (95% CI: 3.32-
3.86%) respectively. Targeted vaccination policies that vaccinate all individuals in the target 
population reduce the size of the mean epidemic peak and the mean duration of the epidemics greater 
when targeting primary schools, rather than secondary schools, but both policies are inferior to 
homogeneous vaccination of both groups. 
THE IMPACT OF THE MIXING PARAMETER 
Increasing ε1 from 0 to 1 with no additional vaccination in place other than those in clinical at-risk 
groups decreased the mean final size of epidemics in the metapopulation. Epidemics with ε1 = 0 had 
a mean final size of 16.50% (95% CI: 16.47-16.54%) and epidemics with ε1 = 1 had a mean final size of 
16.28% (95% CI: 16.23-16.32%). As previously discussed, both extrema are unlikely to represent true 
values for this parameter, as ε1 = 0 corresponds to school children not having daily contacts with other 
individuals in their school, whilst ε1 = 1 corresponds to no inter-patch mixing takes place within age 
groups.  
There was strong evidence for an albeit minor difference in the mean final size with ε1 set to 0.25 and 
0.75 (a mean of 70 fewer infections when ε1 = 0.75), as well as between 0.50 and 0.75 (a mean of 47 
fewer infections when ε1 = 0.75), but no evidence for an impact on the mean final size between 0.25 
and 0.50. Excluding the unrealistic extrema, all other metrics had similar degrees of small variation 
except for the mean time for all patches to become infected. These results make intuitive sense, as 
increasing the proportion of an individual’s daily contacts in their own patch will decrease the 
proportion of daily contacts with individuals in other patches, slowing the spread of the epidemic. 
With vaccination programmes in place, variation in ε1 was associated with minimal variation in all 
metrics other than the mean time for all metapopulation patches to become infected. However, it is 
clear that to understand the potential total burden of disease caused by ILI or influenza, the 
proportion of daily contacts that an individual makes in their patch is not a key parameter. This is likely 
due to the fact that variation in the ε1 parameter does not change the total number of daily contacts 
made by someone in our metapopulation, therefore an infectious individual will have just as many 
daily contacts when ε1 = 0 as when ε1 = 1. This means that the total number of new infections in the 
metapopulation at each time step is not affected by variation in ε1.  
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THE IMPACT OF THE Τ PARAMETER 
Variation in the degree of heterogeneity in vaccination uptake between low-coverage and high-
coverage schools was directly associated with changes in the mean final size of epidemics and the 
mean size of the epidemic peak. The default value for the τ parameter was 0.5, but increasing 
vaccination coverage heterogeneity by increasing τ to 0.75 directly increased both the mean final size 
and the mean size of the epidemic peak for all coverage levels in both targeted vaccination 
programmes.  
The impact of unintended heterogeneity 
FINAL SIZE OF EPIDEMICS 
For all levels of vaccination coverage, increasing the number of low-coverage schools in the 
metapopulation consistently increases the expected mean final size of epidemics.  
The difference between the mean final size of those epidemics in metapopulations with no 
heterogeneous uptake and those epidemics in metapopulations with maximum heterogeneity in 
uptake increases as the targeted vaccination coverage increases. These results are unsurprising but 
emphasise the importance of achieving homogeneity in vaccination uptake when administering 
targeted vaccination programmes that require very high acceptance rates. 
A single low-coverage metapopulation patch is not a major cause for concern for public health officials 
if that low-coverage patch is a primary school – for all vaccination coverage levels considered, the 
existence of a single low-coverage primary school did not increase the mean final size of epidemics. 
However, a single low-coverage secondary school did increase the mean final size of epidemics for all 
targeted coverage levels considered in the model. Again, this is an unsurprising result as the 
population of a secondary school metapopulation patch represents a larger proportion of the 
metapopulation than the population of a primary school metapopulation patch.  
With homogeneous vaccination across both primary and secondary schools, unintended 
heterogeneity through low-coverage primary schools increases the mean final size of epidemics, but 
more importantly increases the potential for epidemics to occur when homogeneous coverage would 
prevent this. 6 low-coverage primary schools in a vaccination programme targeting 60% 
homogeneous coverage introduced epidemics to the metapopulation. 14 low-coverage primary 
schools facilitated epidemic spread at 80% coverage. For public health officials, it is therefore 
important to ensure that several low-coverage primary schools is avoided when vaccination coverage 
is high, else the greatest potential benefit of such a vaccination programme would not be realised. 
A single low-coverage primary school in a metapopulation with homogeneous coverage across both 
school groups will not increase the mean final size of epidemics at any coverage level. However, a 
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single low-coverage secondary school would increase the final size of epidemics when targeted 
coverage reaches only 20% in other schools. Public health officials should therefore be vigilant for 
single schools reporting low uptake during a homogeneous vaccination programme. 
DURATION AND THE TIMING OF THE PEAK OF EPIDEMICS 
The impact of unintended heterogeneity on the mean duration and mean timing of the epidemic peak 
is less straightforward than the impact on the mean final size. Variation in the mean duration of 
epidemics with targeted vaccination in primary schools was minor, most likely due to chance through 
the stochastic processes of the transmission model. A stronger relationship was seen when secondary 
schools were targeted for vaccination – at low levels of coverage the epidemics were shortened with 
an increasing number of susceptible individuals in the secondary school patches, but for high levels of 
coverage the opposite effect was achieved. For the lowest coverage levels, increasing uptake 
heterogeneity reduces the effectiveness of the vaccination programme by increasing the pool of 
susceptible individuals, facilitating a quicker epidemic. At the highest levels of coverage, an effective 
vaccination policy is compromised by increasing the pool of susceptible individuals, allowing the 
epidemic to run for longer but with greater difficulty due to relatively high vaccination coverage. This 
trend is repeated for the timing of the peak. 
With homogeneous coverage across both school groups, coverage levels of 40% saw longer epidemics 
as heterogeneity increased through low-coverage primary schools. The same is true for heterogeneity 
introduced through secondary schools. Such a trend was not visible for the less effective programme 
with 20% coverage. 
SIZE OF THE EPIDEMIC PEAK 
The mean size of the epidemic peak is closely related to the mean final size of epidemics in the 
metapopulation. For both targeted vaccination policies in either primary or secondary schools, 
increasing heterogeneity in vaccine uptake increases the mean size of the epidemic peak and it 
increases quicker with higher targeted vaccination coverage. With homogenous vaccination across 
both school groups this trend continues. 
TIME FOR ALL METAPOPULATION PATCHES TO BECOME INFECTED 
Increasing unintended heterogeneity in vaccination uptake in both a targeted vaccination policy and 
a homogeneous vaccination policy either reduces the mean time required for all metapopulation 
patches to become infected, or allows the epidemic to spread to all patches when a vaccination policy 
without heterogeneity would succeed in stopping this. 
At 100% targeted vaccination coverage in primary schools, epidemics failed to reach all 
metapopulation patches until 5 primary schools had low-coverage, sufficiently increasing the pool of 
susceptible individuals in that age group. The threshold to stop epidemics spreading to all 
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metapopulation patches was much lower with the homogeneous vaccination programme across both 
school groups, but with 60% coverage epidemics spread to all 31 patches when 14 primary schools 
had low-coverage. However, even with 4 low-coverage secondary schools the epidemic did reach this 
far. The reason for this discrepancy between the impacts of heterogeneity between the two age 
groups is most likely due to the greater number of assortative daily contacts in the primary school age 
group than in the secondary school age group. 
THE IMPACT OF INTENDED HETEROGENEITY THROUGH FIXED, CONCENTRATED COVERAGE 
FINAL SIZE OF EPIDEMICS 
Although vaccination consistently reduced the mean final size of epidemics from 16.40% (95% CI: 
16.36-16.44%) with no school-based vaccination programme, both targeted vaccination programmes 
using concentrated coverage of 100% uptake in specific schools were less effective than their 
homogeneous equivalents - that is the mean final size of epidemics in metapopulations with 
homogeneous vaccination coverage was always smaller than the mean final size of epidemics with 
concentrated vaccination coverage. For example, at 20% homogeneous vaccination coverage in 
primary schools the mean final size of epidemics was 11.41% (95% CI: 11.26-11.55%), whilst with 
concentrated coverage the mean final size reduced to only 13.47% (95% CI: 13.38-13.55%), with the 
same trend seen for 40%, 60% and 80% overall coverage. Any vaccination programme using 
concentrated coverage in this manner would be less effective than its homogeneous coverage 
equivalent and would therefore be dominated in an incremental cost-effectiveness analysis. 
When vaccinating both school groups, heterogeneity in vaccination uptake through the concentration 
of coverage in specific schools increased the expected final size of epidemics for all coverage levels. 
Indeed, with 80% homogeneous coverage the heterogeneity in uptake saw epidemics occur in the 
metapopulation where homogeneous 80% coverage would prevent it. Intended heterogeneity 
through the concentration of vaccination coverage is less effective at reducing the mean final size of 
epidemics in the metapopulation than the homogeneous equivalent and would therefore be 
dominated in an incremental cost-effectiveness analysis. 
DURATION AND THE TIMING OF THE PEAK OF EPIDEMICS 
Concentrated vaccination coverage of 40%, 60% and 80% increased both the mean duration of 
epidemics and the timing of the epidemic peak over the homogeneous equivalents. Aside from the 
primary aim of reducing the expected final size of epidemics, vaccination programmes should also 
reduce the expected duration of an epidemic in the population, so concentrated vaccination 
programmes with coverage above 20% fail to meet these criteria. 
If many primary and secondary schools have no vaccination protection, the epidemic duration in each 
school would be quicker in each school and would spread quickly to each metapopulation patch. For 
187 
 
those schools with full vaccination coverage, Figure 6.27 shows that epidemics in these patches were 
short, with sporadic cases incapable of seeding sustained transmission in each patch. 
SIZE OF THE EPIDEMIC PEAK 
The size of the epidemic peak was consistently increased by concentrating vaccination coverage in 
specific schools, at all levels of coverage. At 20% overall coverage the vaccination strategy with the 
smallest epidemic peak, other than the homogeneous strategy, was one that saw most coverage 
concentrated in primary schools with 9 schools receiving full vaccination. Moving coverage from 
primary schools to secondary schools increased the mean size of the epidemic peak. At higher levels 
of coverage there were no statistical differences between epidemic peaks. Similar results were seen 
in the targeted vaccination programme, with the concentration of vaccination coverage in specific 
schools of one age group consistently increasing the mean size of the epidemic peak. 
TIME FOR ALL METAPOPULATION PATCHES TO BECOME INFECTED 
When vaccinating both school groups, the mean time for all patches to become infected for the 20% 
and 40% coverage levels was greatest when a greater number of primary schools received full 
vaccination. Moving coverage concentration into the larger secondary school patches reduced the 
time for the epidemic to spread to all patches. This result is unsurprising - the metapopulation contains 
many more primary schools than secondary schools, so maximising the number of patches with full 
vaccination leads to a reduction in the number of susceptible individuals in each of those patches.   
At 60% overall coverage there was little difference between the heterogeneous vaccination strategies, 
though each heterogeneous strategy meant that the epidemic could spread to all metapopulation 
patches when the homogenous strategy prevented this. Each heterogeneous strategy required a large 
number of primary school patches to be fully vaccinated, limiting the potential for the epidemic to 
spread to all patches. Variation in the number of primary schools with full vaccination is not sufficient 
to change the time for all patches to become infected. 
THE IMPACT OF INTENDED HETEROGENEITY WITH VACCINATION IN ALL TARGETED PATCHES 
FINAL SIZE OF EPIDEMICS 
Modifying a vaccination programme with homogenous vaccination coverage in a small community to 
one that incorporates heterogeneous coverage between two target populations does not reduce the 
expected mean final size of epidemics, at any coverage level. In an economic evaluation comparing 
two or more potential vaccination strategies the key performance metric is the reduction in the mean 
final size. As the heterogeneous vaccinations strategies failed to perform better at homogenous 
strategies in reducing the mean final size of epidemics it is highly unlikely that a heterogeneous 
vaccination strategy would dominate a homogenous strategy. 
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At just 20% overall coverage between both primary and secondary school groups, heterogeneous 
coverage concentrated in the secondary schools increased the expected mean final size from 6.85% 
(95% CI: 6.65-7.05%) to 8.38% (95% CI: 8.28-8.49%). As the expected expenditure on this 
heterogeneous coverage level would be equal to the expenditure of 20% overall coverage between 
both school groups, the fewer health benefits realised by the heterogeneous coverage strategy means 
that it would be dominated by the homogeneous strategy in an economic analysis. Indeed, an 
increased mean final size of epidemics would also increase healthcare resource use in the population, 
making the heterogeneous vaccination strategy more expensive and less effective, therefore strongly 
dominated by the homogeneous vaccination strategy. 
At 40% overall coverage, all alternative heterogeneous vaccination strategies again fail to perform 
better than the homogenous vaccination strategy. Heterogeneous vaccination strategies matching 
60% overall coverage also failed to reduce the mean final size of epidemics. The most interesting result 
was that the worst performing heterogeneous vaccination strategies were those that concentrated 
coverage in the primary school patches, rather than those that concentrated coverage in secondary 
school patches which performed worse at 40% overall coverage. Heterogeneous vaccination 
strategies that spread coverage more evenly performed better in reducing the mean final size, but did 
not perform better than the homogenous 60% coverage. Therefore, in an economic evaluation a more 
cost-effective intervention than homogenous 60% coverage would not be likely. 
With overall coverage of 80%, epidemics did not occur in the population. Heterogeneity in coverage 
between the primary and secondary school groups did not increase the potential for sustained 
community-level transmission in the metapopulation. 
DURATION AND THE TIMING OF THE PEAK OF EPIDEMICS 
Heterogeneous vaccination coverage does not reduce the duration of epidemics in the 
metapopulation, for any vaccination strategy at any coverage level. The timing of the epidemic peak 
also does not occur any earlier than the homogenous vaccination strategy for any coverage level. 
Vaccination strategies with the greatest degree of coverage heterogeneity between the two school 
groups resulted in the longest epidemics, due to the pool of susceptible individuals created in one 
school group caused by concentrating vaccination coverage in the other school group. 
SIZE OF THE EPIDEMIC PEAK 
Heterogeneous coverage did perform better in reducing the mean size of the epidemic peak, but only 
with specific strategies at a particular overall coverage level. With heterogeneity in the vaccination 
coverage between the two school groups but vaccinating the equivalent of 40% of the school 
population, the mean size of the epidemic peak decreased when vaccinating 24% of primary school 
children and 60% secondary school children (0.035% (95% CI: 0.033-0.036%)) and also when 
vaccinating 56% of primary school children and 20% of secondary school children (0.036% (95% CI: 
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0.034-0.038%)), down from 0.043% (95% CI: 0.041-0.046%) with homogeneous coverage. However, 
for strategies at 20% and 60% coverage the mean size of the epidemic peak is not reduced by 
heterogeneous coverage. 
TIME FOR ALL METAPOPULATION PATCHES TO BECOME INFECTED 
With both 20% and 40% coverage, the mean time for all metapopulations to become infected is either 
increased by heterogeneous vaccination coverage, or remains the same as the homogeneous 
coverage strategy. Increasing the time required for all patches to become infected is likely to be an 
advantage to public health and outbreak response teams reacting to the outbreak. 
However, heterogeneous vaccination strategies with 60% coverage overall failed to perform as well 
as the equivalent homogenous vaccination coverage strategy – the epidemics with 60% homogeneous 
coverage did not reach all metapopulation patches, but the heterogeneous vaccination strategies with 
the greatest degree of coverage heterogeneity between the two school groups facilitated this by 
providing a sufficiently large pool of susceptible individuals in one of the school groups to feed 
epidemics in the other. The strategies with the highest concentration of coverage in the primary 
school patches saw epidemics reach all 31 patches after two months, and strategies with large 
concentration in secondary schools saw epidemics reach all 31 patches in less than one month. The 
imperfect vaccine modelled in this exercise permitted infections even in metapopulation patches with 
100% coverage. 
LIMITATIONS OF THE STUDY 
THEORETICAL COMMUNITY AND POPULATION STRUCTURE 
Though we structured the population to be representative of a small administrative district of England, 
in both age distribution of the population and the appropriate number of schools, we needed to 
assume that the number of daily contacts that individuals in the school patches had with individuals 
in their own age group was influenced by the ε1 parameter. Results from our analysis demonstrate 
that this assumption does not impact on the mean final size of epidemics if it is agreed that the 
extreme case of ε1 = 1 is highly unlikely. But the ε1 parameter did influence the speed at which the 
epidemics spread across all metapopulation patches. Without any data on an appropriate distribution 
for the values of the ε1 parameter, our results could certainly be improved if this data were available. 
STOCHASTIC FADEOUT AND RESEEDING OF EPIDEMICS 
62.9% of simulated epidemics resulted in an overall ILI final size less than 0.5% of the total population 
and were therefore considered to be stochastic fadeouts. This proportion of simulations is high, 
though our model used data previously fit to models describing a mild influenza season. We chose not 
to reseed epidemics that faded quickly for simplicity, though it is an option that would have been 
interesting to explore. Indeed, this technique is not uncommon and would not have been 
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computationally expensive [23]. By not reseeding epidemics we may have underestimated the total 
burden of seasonal influenza outbreaks in our metapopulation by removing the potential for 
additional simulated outbreaks that may have exceeded the size of those we reported. 
VACCINATION PROGRAMMES AND STRATEGIES 
We investigated the impact of many different vaccination programmes and strategies, some of which 
are unlikely to be implemented. Our aim was to study the consequences of heterogeneous uptake. 
Many vaccination programmes report heterogeneity in uptake between different areas or regions [1, 
7, 13, 24, 25] but none with heterogeneity as extreme as those strategies investigated in parts of this 
analysis.  
It is highly unlikely that a school-based vaccination programme would be implemented that would 
result in one or more schools receiving no vaccinations whilst others in the same district would achieve 
100% coverage. However, this exercise in modelling heterogeneity through concentrated coverage 
was a useful exercise in examining the consequences of high vaccination concentration in patches of 
a metapopulation. Some schools in communities may have a large concentration of children from 
families with religious or philosophical reasons to reject the offer to participate in school-based 
vaccination programmes [7, 26] but a scenario where one or more schools in a community report no 
vaccination coverage whilst others achieve complete coverage is unlikely. Vaccinating 100% of an 
eligible population or sub-population is unlikely because vaccination is clinically inappropriate for 
some children.  
CONTACT PATTERN UNCERTAINTY 
The contact patterns used in our model were taken from the POLYMOD contact matrix [14], dividing 
the population into seven age groups. We did not explore the consequences of uncertainty in these 
contact patterns, instead we used the mean daily number of contacts for individuals in each age group 
in order to inform our model with widely-used contact pattern data.  
MEASURING THE Ε1 PARAMETER TO INCLUDE IN FUTURE MODELS 
The daily contact patterns of school children have been estimated in many studies using different 
techniques. The use of both contact diaries [14, 27] and electronic sensors [28, 29] have been very 
successful in quantifying the mean daily number of contacts for school children. These data, however, 
are unable to provide an estimate for the value of the ε1 parameter used in our model: the studies by 
both Beutels et al. (2006) and Mossong et al. (2008) report the total number of conversational and 
physical contacts with all individuals, whilst the studies by both Fournet et al. (2014) and Stehle et al. 
(2011) measured the number of face-to-face interactions of twenty-second duration within between 
individuals standing up to 1.5m apart within the same school. However, these datasets cannot be 
combined to estimate the ε1 parameter in our model. 
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To ascertain an estimate for the ε1 parameter we require the proportion of the total number of daily 
contacts for an individual and the total number of daily contacts for an individual within their assigned 
metapopulation patch. In a contact diary-type study, this would require the individual to notify data 
handlers of the number of contacts within their age group that occurred both inside and outside their 
school. For an electronic sensor-type study, this requires electronic sensors to be distributed further 
than the confines of a chosen school, thereby greatly increasing the total number of electronic sensors 
needed for a study which may make the study unfeasible.   
ADDITIONAL PARAMETER UNCERTAINTY 
Several parameters used in the model were point-estimate parameters taken from the literature. 
These included the length of the incubation and infectious periods; the age-specific hospitalised case 
fatality ratio; and other key parameters. Further use of the level of uncertainty in the estimates for 
these parameters allows for additional modelling opportunities to establish the parameter space over 
which the conclusions reached are valid. 
USE OF A SPATIAL MODEL 
Other modelling studies that use a spatially explicit metapopulation have provided useful results on 
epidemic transmission in populations. For example, Hosseini et al. (2013) showed that a gigantic 
metapopulation patch in such a framework can alter the dynamics of epidemic transmission, due to 
its connectivity to nearby smaller patches and the pool of susceptible individuals within it [30]. Our 
metapopulation model included a large patch containing all adult inhabitants of the theoretical 
community, and even with extremely high targeted vaccination coverage in either of the two school 
groups, community-wide transmission was sustained in our metapopulation model. It may be that the 
susceptible adults and young children in the external patch permitted this sustained transmission and 
ensured that epidemics spread even to those patches with very high vaccination coverage, but we are 
unable to confirm this hypothesis without expanding the model structure further. 
In addition, we assumed that a proportion 1-ε1 of daily contacts within an individual’s age group would 
take place outside of their own patch, but we assumed that these would be split evenly over all other 
patches for simplicity. In reality, this proportion is likely to be influenced by other factors not included 
in our model, such as household structure, population concentration within the studied district and 
the proximity of an individual’s school to other schools in their district. 
MODELLING VACCINATION COVERAGE AND EPIDEMICS OVER A SINGLE INFLUENZA SEASON 
Similar to the issues reported in Chapter 5, we only modelled vaccination uptake and epidemics over 
the course of a single influenza season. Modelling over a longer time horizon requires the addition of 
extra complexity to the model to account for immunity-waning, multiple strains of influenza and 
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antigenic drift. Increasing the time horizon of our study would allow for comparisons with other 
analyses of seasonal influenza vaccination coverage that have used multiple influenza seasons [10]. 
A consequence of using a longer time horizon is that the model would then need to account for the 
annual migration of a proportion of primary school children to secondary schools, with a proportion 
of secondary school children migrating to the adult population and external metapopulation patch. 
This will impact the proportion of susceptible individuals through previously-acquired immunity. 
CONCLUSION 
Chapter 5 demonstrated that at the national level and without heterogeneities within the two school-
age groups, a heterogeneous vaccination strategy between primary and secondary schools is the 
optimal strategy from the perspective of the healthcare provider. However, this study has 
demonstrated that including coverage heterogeneities within each of the two school age groups at a 
local level reports a reduction in the effectiveness of school-based vaccination programmes. 
Heterogeneity in coverage, by accident or design, does not perform better than the equivalent 
homogenous vaccination strategy at any coverage level. 
To our knowledge, this is the first attempt at modelling school-level uptake for seasonal influenza 
vaccination. Our model may provide public health officials with important information on how to 
design their seasonal influenza vaccination programmes if our suggested modifications to the 
modelling framework can be addressed in future research projects. 
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Chapter 7 - The effect of measles on health-related quality of 
life: a patient-based survey 
Portions of this section were presented as a poster presentation at the Public Health England Annual 
Conference in Warwick in September 2013; published in The Lancet as a conference abstract in 
November 2013 [1]; delivered as an oral presentation at The Lancet Public Health Science conference 
in London in November 2013; and published in PLoS ONE in September 2014 [2]. 
ABSTRACT 
BACKGROUND 
Measles is a highly contagious and potentially fatal illness preventable through vaccination. Outbreaks 
in the UK and many other European countries have been increasing over recent years, with over 3,207 
laboratory-confirmed cases reported by Public Health England from January 2012 to the end of June 
2013. To aid rational decision making regarding measles control versus other use of healthcare 
resources, it is important to measure the severity of measles in units that are comparable to other 
diseases. The standard metric for this in the UK is the quality-adjust life year (QALY). To our knowledge, 
the impact of measles on health-related quality of life (HRQoL) in terms of QALYs has not been 
quantified.  
OBJECTIVE 
We sought to quantify the impact of measles on HRQoL. 
METHODS AND FINDINGS 
Individuals with confirmed measles were sent questionnaires requesting information on the short-
term impact of the illness on their HRQoL using the EuroQol EQ-5D-3L questionnaire. HRQoL was 
reported for the day the questionnaire was received, the worst day of infection and at follow-up three 
weeks later. 507 questionnaires were sent to individuals with confirmed measles with 203 returned 
(40%). The majority of respondents were not vaccinated. The mean time off work or school was 9.6 
days. The mean duration of perceived illness was 13.8 days.  The mean number of QALYs lost was 
0.019 (equivalent to 6.9 days). The overall burden of disease in terms of QALYs lost in England based 
on the total number of confirmed cases in the twelve month period from 1st June 2012 was estimated 
to be 44.2 QALYs. 
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CONCLUSION 
The short-term impact of measles infection on HRQoL is substantial, both at the level of the individual 
patient and in terms of the overall disease burden. This is the first attempt to quantify QALY-loss due 
to measles at a population level, and provides important parameters to guide future intervention and 
control measures.  
INTRODUCTION 
So far the focus of this thesis has been the societal and economic impact of influenza infection and 
the mathematical modelling of preventive vaccination programmes. During the course of this research 
programme we had the opportunity to investigate the societal and economic impact of measles 
infection by working closely with colleagues from Public Health England and their Outbreak 
Investigation Teams in both Liverpool (for the measles outbreak in Cheshire and Merseyside) and 
Colindale (for investigating the outbreaks from a national perspective) during the measles outbreaks 
in the United Kingdom that occurred in 2012 and 2013. 
This section discusses a plan to investigate the societal impact of measles infection, including the first 
attempt to quantify the impact of measles on health-related quality of life.  
BACKGROUND 
Measles is a highly infectious notifiable disease that can be severe in infants, pregnant women and 
immunocompromised individuals [3, 4]. Measles is preventable through the measles-mumps-rubella 
vaccination programme (MMR), with measles vaccination introduced in the UK in 1968 [3]. Previous 
measles outbreak reports focus on the epidemiology of the disease [5-7], rather than the overall 
disease burden in terms of health-related quality of life (HRQoL). The impact of infectious diseases on 
HRQoL is a developing field of research, whose aim is to express the burden of disease not only in 
number of cases but also in disease days and the impact of these disease days. Doing so enables a 
comparison between diseases and helps in the fair allocation of resources. In England the evaluation 
of resource allocation is formalised in cost-effectiveness analyses [8, 9]. 
A standard method to measure the disease burden is the use of quality-adjusted life years (QALYs), a 
generic measure incorporating both the length of time that patients experience health reduction and 
the magnitude of the health reduction [10]. To calculate QALYs first the condition-specific health 
utilities, which give an estimate of the impact on HRQoL for the condition in question, must be 
established.  
To our knowledge, no measure of health utilities has previously been attempted for measles, despite 
the global significance of this infection. This study attempts to gather health utilities specific to 
measles during the 2012-13 regional measles epidemics in England, as well as other direct and indirect 
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effects of a measles epidemic on a population including symptoms during infection; disruption at 
home due to time off work or school for individuals with confirmed measles; hospitalisations and carer 
time off work. 
RESEARCH QUESTIONS 
1. What is the impact of measles infection at home, in terms of days of school/work missed 
through illness and as acting as a primary caregiver for those with measles infection? 
2. What is impact of measles infection in terms of HRQoL and how does this compare to other 
infectious disease outbreaks? 
3. What was the overall burden of disease during the 2012-13 regional measles epidemics in 
England? 
METHODS 
In this study, standardised postal questionnaires were sent to individuals with confirmed or suspected 
measles. Questionnaires were sent to individuals with suspected measles in the North West England 
outbreak from 1st June 2012 and the study was extended throughout England from 2nd October 2012 
to 5th July 2013 targeting only individuals with confirmed measles. 
CASE DEFINITION 
Individuals with suspected measles were confirmed positive if they were measles immunoglobulin M-
positive on saliva or through polymerase chain reaction testing in urine, saliva or a throat swab. A 
suspected measles case was defined using the following criteria from Vivancos et al. 2012 [7]: 
 Clinical presentation: fever and measles-like rash and one or more of the following 
symptoms: cough, conjunctivitis, coryza, or Koplik’s spots. 
 Residence / reported from: residence or history of travel to endemic, outbreak or adjacent 
areas, or being a close contact of a confirmed or probable case of measles. 
EXCLUSION CRITERIA 
Individuals in traveller communities with laboratory-confirmed measles were not invited to 
participate in the study, because Public Health England engages with this community through different 
protocols and procedures [11]. A member of the traveller community was defined as someone self-
identifying as a member of the traveller community or someone living on a traveller site, whether 
authorised or not authorised. 
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We excluded individuals with confirmed measles with a reported symptom onset date more than two 
weeks before case status was confirmed to minimise the time between perceived symptom onset and 
receiving the first questionnaire. 
EUROQOL EQ-5D-3L 
The EuroQol EQ-5D-3L is a generic multi-attribute health-state classification system [12, 13]. HRQoL is 
assessed in five dimensions: mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression. Each dimension is assessed using three levels: no problems, some problems and 
severe problems, facilitating the evaluation of 243 (= 35) different health states. The EuroQol scoring 
algorithm converts the responses into a health utility specific to the individual’s health state. A visual 
analogue scale (VAS) invites the individual to rate their health state on a scale from 0 – 100, with 0 
being the worst health state imaginable and 100 being the best health state imaginable.  
Three age-specific EQ-5D-3L questionnaires were used: the standard EQ-5D-3L for all individuals aged 
13 years and older; the child-friendly EQ-5D-Y for all individuals aged between 7 – 12 years [14] and a 
proxy version of the standard EQ-5D-3L for individuals aged less than 7 years to be completed by the 
child’s parent or guardian. All three versions of the questionnaire use both the same algorithm and 
scoring tariff to convert responses into health utilities. 
QUESTIONNAIRES 
Individuals were sent an initial questionnaire requesting details of their illness and its impact on their 
HRQoL for both the worst day of infection and the day that the questionnaire was received using the 
EQ-5D-3L. Three weeks later they were sent a follow-up questionnaire to obtain a further HRQoL 
measurement at recovery. Individuals who did not return the first questionnaire were sent it a second 
time along with the follow-up questionnaire three weeks later. We assumed that a three week period 
was sufficient for typical symptoms of measles to subside [15], and we assumed that if individuals 
reported that they had recovered then they were no longer suffering a measles-related reduction in 
their HRQoL. The value of HRQoL reported by individuals who reported having recovered was treated 
as their baseline HRQoL for the purposes of calculating QALY loss. 
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Figure 7.1 - Assumed short-term loss in health-related quality of life caused by measles infection 
To assess the impact of measles infection on HRQoL, patients must complete the EQ-5D-3L when 
healthy (at recovery) and for the worst day of infection. We assumed that the QALY loss associated 
with measles for each individual can be represented by a triangular shape, as shown in Figure 7.1. As 
a comparison, we also estimated HRQoL directly using the VAS, with HRQoL given by VAS score divided 
by 100. 
Notification of potential study participants was received by the specialist epidemiologist for measles 
at Public Health England in Colindale who excluded ineligible patients. Letters and questionnaires 
were sent using a database updated daily with new notifications of suspected measles cases. In the 
analysis that follows, we consider only those individuals with laboratory-confirmed measles. 
ANONYMISED DATA 
All questionnaires sent to confirmed or suspected measles cases were anonymised. A questionnaire 
was linked to the appropriate follow-up questionnaire using the HP Zone ID, an anonymised ID data 
field used on Public Health England databases. Sensitive patient identifiers such as the distribution 
address were handled by Public Health England, whereas the returned and anonymous questionnaires 
were processed by researchers at the London School of Hygiene and Tropical Medicine, with no links 
or access to the original sensitive information. All medical records used in the analysis were also 
anonymised by Public Health England using the HP Zone ID.  
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ETHICS APPROVAL 
In accordance with The Health Service (Control of Patient Information) Regulations 2002 No. 1438 
Section 251 Regulation 3 [16], Public Health England may process confidential patient information 
with a view to monitoring and managing the following: 
 Outbreaks of communicable disease; 
 Incidents of exposure to communicable disease; 
 The delivery, efficacy and safety of immunisation programmes. 
DATA ANALYSIS 
Data were analysed using Microsoft Excel 2007 and R (version 3.0.2) [17]. Public Health England 
obtained hospitalisation records for individuals who received the questionnaire, so hospitalisation 
rates were compared between responders and non-responders to test for severity bias. HRQoL data 
were analysed only for those patients who completed all five dimensions of health on the EQ-5D-3L 
in addition to reporting the duration of their illness. Reported 95% confidence intervals of the means 
are based on 1,000 bootstrap replications.  
The EQ-5D-3L requires the respondent to complete all five dimensions of the classification system in 
order to calculate a health-state utility. Omitting the response to any of the dimensions means the 
remaining responses cannot be used for this purpose, therefore a missing-value regression analysis 
was conducted using the VAS score to estimate the EQ-5D-3L utility where patients had completed 
the VAS but not all five dimensions of health. When assessing the HRQoL in individuals with 
haemophilia Miners et al. [18] showed a correlation between EQ-5D-3L utility and the VAS scores (R = 
0.67, p < 0.0001). 
RESULTS 
683 questionnaires were sent; 507 to individuals with confirmed measles and 176 to individuals with 
unconfirmed/suspected measles. 203 questionnaires were returned from those with confirmed 
measles (40.0%). 45 questionnaires from individuals with unconfirmed/suspected measles were 
returned (25.6%). From the 203 individuals with confirmed measles who returned their first 
questionnaires we received 63 follow-up questionnaires (31.0%). 103 of the returned first 
questionnaires had been completed after recovery from measles so the HRQoL measurement on the 
day of completion could be used as the recovery HRQoL measurement.  
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REPONSES, DEMOGRAPHICS AND VACCINATION DATA 
RESPONSES 
Figure 7.2 shows a flow chart detailing the process of identifying individuals with confirmed measles 
through to receiving their returned questionnaires and using their responses to calculate HRQoL 
results from the EQ-5D-3L questionnaires.  
 
Figure 7.2 - Flow chart for the study showing the number of questionnaires that were distributed to 
confirmed measles cases; the number of questionnaires returned for analysis; and the number of 
questionnaires returned for analysis that included the necessary information for EQ-5D-3L health 
utilities to be calculated 
202 
 
709 individuals with confirmed measles were identified as potentially suitable for recruitment to the 
study but 302 of these were excluded on the basis that the individuals were members of the traveller 
community. From the remaining 507 individuals sent a questionnaire we received completed 
responses from 203. These 203 responses were used in all parts of the analysis except for the HRQoL 
calculations with the EQ-5D-3L, as only 91 returned questionnaires contained all the data necessary 
to facilitate those calculations. 
70 returned questionnaires came from individuals with confirmed measles aged under seven years; 
25 questionnaires came from individuals aged between seven and twelve years and the remaining 108 
questionnaires came from individuals aged over 12 years. 
DEMOGRAPHICS AND VACCINATIONS 
101 (49.8%) of the 203 responses were from female patients. 68 (33.5%) of the respondents were 
under five years old (Figure 7.3). 188 (92.6%) had not yet received their first dose of the MMR vaccine. 
The age distribution of those individuals who returned the questionnaire was similar to the age 
distribution of confirmed measles cases invited to participate (Figure 7.3). 
 
Figure 7.3 - Age-specific distribution of questionnaires sent, questionnaire response, and vaccination 
status for confirmed cases of measles 
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SEVERITY BIAS  
Among the 507 individuals with confirmed measles to whom questionnaires were sent, Public Health 
England could not obtain hospitalisation records for 20 individuals (3.9%) as their GP’s database had 
not been updated with any details of potential hospitalisations post-notification. Of the remaining 
individuals, 75 of the 199 individuals who were hospitalised returned their questionnaire and 120 of 
the 288 individuals not hospitalised returned theirs. We found that there was no evidence that 
hospitalised individuals were more likely to return the questionnaires (χ2 = 0.78 and p = 0.38). 
The remaining results refer only to the 203 questionnaires returned by individuals with confirmed 
measles.  
MEASLES INFECTION 
REPORTED SYMPTOMS 
Symptom Number of individuals with 
confirmed measles 
Rash 189 (93.1%) 
Tiredness 188 (92.6%) 
Poor appetite 188 (92.6%) 
Cough 183 (90.1%) 
Severe temperature 183 (90.1%) 
Sore mouth 166 (81.8%) 
Runny nose 155 (76.4%) 
Aches and pains 150 (73.9%) 
Watery eyes 143 (70.4%) 
Blood-shot eyes 137 (67.5%) 
Swollen eyelids 134 (66.0%) 
Sneezing 126 (62.1%) 
None 2 (1.0%) 
Table 7.1 - Reported symptoms of 203 individuals with confirmed measles 
189 (93.1%) individuals with confirmed measles reported a rash on their worst day of infection (Table 
7.1). The rash was the most common reported symptom on the worst day of infection, followed by 
tiredness (92.6%), poor appetite (92.6%), cough (90.1%), severe temperature (90.1%) and a sore 
mouth (81.8%). 
REPORTED COMPLICATIONS 
Table 7.2 shows the number of individuals with confirmed measles reporting complications of their 
infection. The most common complication was fever, with 187 individuals reporting this (92.1%). 50 
individuals (24.6%) reported having otitis media. Only 7 individuals (3.4%) reported no complications 
of their infection with the remaining 196 (96.6%) reporting at least one from the list above. 
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Complication Number of individuals with 
confirmed measles 
Fever 187 (92.1%) 
Coughing 162 (79.8%) 
Confusion 153 (75.4%) 
Diarrhoea 129 (63.5%) 
Conjunctivitis 114 (56.2%) 
Vomiting 113 (55.7%) 
Laryngitis 89 (43.8%) 
Otitis media 50 (24.6%) 
Table 7.2 - Reported complications of measles infection from 203 individuals with confirmed measles 
IMPACT AT HOME 
128 (63.1%) individuals with confirmed measles reported spending time off work or school due to 
measles infection (Table 7.3), of whom those who had fully recovered reported a mean time spent at 
home of 9.6 days (95% CI: 9.3 - 11.7). 75 (36.9%) individuals with confirmed measles reported that a 
caregiver spent time away from work during their infection, of whom those who had fully recovered 
reported a mean time spent away from work by carers of 7.3 days (95% CI: 5.7 - 7.9). 74 (36.5%) 
individuals reported spending at least one night in hospital, of whom those who had fully recovered 
reported a mean length of stay of 4.2 nights (median 4.0 nights). The median worst day of perceived 
symptoms was the fifth day and the mean duration of perceived symptoms was 13.8 days (95% CI: 
12.6 – 15.1). 
CONTACT WITH THE HEALTH SERVICES 
193 (95.1%) individuals with confirmed measles reported at least one contact with the health services. 
The remaining 10 individuals may have come to the attention of the local Health Protection Unit (HPU) 
through contact tracing of another confirmed measles case or may have been reported directly to the 
HPU by a teacher, parent or guardian, thereby not having any contact with the health services before 
their case status was confirmed. The median number of contacts with the health services was 3.0 
during the period of infection but this was highly skewed with a mean of 4.0 and 5 people having more 
than 10 contacts. The mean time between perceived symptom onset and first contacting the different 
local health services was about 3.6 days irrespective of which service (NHS Direct, GP, A&E, etc.) was 
first contacted. 
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 Among confirmed 
measles cases (n=203)  
Age under 7 years 
(n=70) 
Age 7-12 years 
(n=25) 
Age 13 years and over 
(n=108) 
Worst day (median, mean, mode) 5, 5.61, 4 5, 5.58, 5 6, 7.56, 5 5, 5.15, 4 
Mean duration of perceived symptoms (95% CI) 13.8 days (12.6 – 15.1) 12.8 days (11.0 – 14.9) 13.5 (10.4 – 17.1) 14.4 (12.7 – 16.2) 
Individuals reporting time off work or school 128 (63.1%) 26 (37.1%) 22 (88.0%) 80 (74.1%) 
Mean time off work or school for patients (95% CI) 9.6 days (9.3 – 11.7) 8.6 days (6.8 – 10.5) 9.1 days (7.4 – 10.8) 10.1 days (8.8 – 11.5) 
Individuals reporting time off work for primary caregivers 75 (39.6%) 31 (44.3%) 10 (40.0%) 34 (31.5%) 
Mean time off work for primary caregivers (95% CI) 7.3 days (5.7 – 7.9) 7.0 days (4.9 – 9.2) 7.7 days (4.3 – 11.3) 7.2 days (5.0 – 9.5) 
Individuals reporting at least one night in hospital 74 (36.5%) 23 (32.9%) 2 (8.0%) 49 (45.4%) 
Number of nights spent in hospital (median, mean, 
mode) 
4.0, 4.2, 1.0 3.0, 4.0, 1.0 4.0, 4.0, 4.0 4.0, 4.4, 1.0 
Table 7.3 - Impact of measles infection. The mean time off work or school for patients and for primary caregivers is the mean time for those who reported at least 
one day of absence. Likewise, the number of nights in hospital applies only to those individuals who reported at least one night in hospital. 95% confidence intervals 
of the mean are based on 1,000 bootstrap replications. The first column shows results for the whole sample; the subsequent 3 columns split the sample into the 
three age groups considered 
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EQ-5D-3L DIMENSIONS RESULTS 
91 of the 203 confirmed measles cases completed all five dimensions of health for the EQ-5D-3L on 
the worst day of infection and after a full recovery from measles infection and reported the duration 
of perceived symptoms, thus enabling the calculation of QALYs lost. On the worst day of infection, 
these individuals reported their health according to each of the EQ-5D-3L dimensions of health as 
shown in Table 7.4. 
194 of the 203 individuals with confirmed measles (95.6%) who returned a questionnaire also 
returned a completed VAS.  
 Evaluating HRQoL on the worst day of infection (n = 91) 
EQ-5D dimensions of health No problems Some problems Severe problems 
Mobility 10 (11.0%) 35 (38.5%) 46 (50.5%) 
Self-care 20 (22.0%) 35 (38.5%) 36 (39.6%) 
Usual activities 3 (3.3%) 17 (18.7%) 71 (78.0%) 
Pain or discomfort 9 (9.9%) 45 (49.5%) 37 (40.7%) 
Anxiety or depression 33 (36.3%) 34 (37.4%) 24 (26.4%) 
Table 7.4 - Responses to each dimension of health for the worst day of infection for individuals with 
confirmed measles who provided the full data set to facilitate the calculation of QALY loss associated 
with measles 
HEALTH-RELATED QUALITY OF LIFE 
The overall QALY loss, calculated using the EuroQol EQ-5D-3L, associated with measles was 0.019 
QALYs per patient (95% CI: 0.016 – 0.022), the equivalent of 6.9 QALDs per patient (95% CI: 5.84 – 
8.02) (Table 7.5).  
207 
 
 Health-related quality 
of life results (n = 91) 
Age under 7 years 
(n=15) 
Age 7-12 years 
(n=18) 
Age 13 years and over 
(n=58) 
EQ-5D Baseline HRQoL (95% CI) 0.96 (0.93 – 0.98) 0.89 (0.78 – 0.98) 0.98 (0.96 – 1.00) 0.94 (0.91 – 0.97) 
EQ-5D Worst day HRQoL (95% CI) 0.00 (-0.09 – 0.09) -0.26 (-0.43 – -0.08) -0.07 (-0.22 – 0.10) -0.05 (-0.13 – 0.04) 
VAS Background (95% CI) 92 (90 – 94) 93 (91 – 95) 91 (87 – 95) 89 (86 – 91) 
VAS Worst day (95% CI) 21 (17 – 24) 18 (14 – 22) 19 (13 – 25) 19 (15 – 23) 
Overall QALY loss (95% CI) 0.019 (0.016 – 0.022) 0.017 (0.012 – 0.022) 0.020 (0.014 – 0.028)  0.019 (0.016 – 0.023) 
Overall QALD loss (95% CI) 6.90 (5.84 – 8.02) 6.29 (4.51 – 8.11) 7.28 (5.07 – 10.10) 6.94 (5.73 – 8.33) 
Table 7.5 - Impact on HRQoL of measles for the 91 individuals with confirmed measles for whom QALY loss could be calculated using the EQ-5D-3L. 95% confidence 
intervals of the mean are based on 1,000 bootstrap replications. The first column shows results for the whole sample; the subsequent 3 columns split the sample 
into the three age groups considered 
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HRQOL THROUGH THE VAS 
The overall QALY loss associated with measles using the VAS score was the equivalent of 4.92 QALDs 
(95% CI: 4.15 – 5.86) or 0.013 QALYs (95% CI: 0.011 – 0.016). There is very strong evidence that the 
VAS gives different results when compared to the EQ-5D-3L algorithm using the paired Wilcoxon test 
(V = 649, p < 0.0001) using the HRQoL results from the 91 individuals with confirmed measles who 
completed all aspects of the EuroQol EQ-5D questionnaire.  
OVERALL BURDEN OF REGIONAL EPIDEMICS 
Public Health England reported that there had been 2,366 laboratory-confirmed cases of measles in 
England for twelve months from 1st June 2012, the beginning of the study period [19, 20]. Using our 
estimates above for the burden of measles infection, the age-adjusted overall burden of disease in 
this period was approximately 16,164 QALDs (95% CI: 15,740 – 16,645), or 44.2 QALYs (95% CI: 43.2 – 
45.6). 1,534 of these confirmed cases would have taken time off work or school, resulting in 14,527 
age-adjusted days of lost productivity (95%CI: 14,215 – 14,848). When including primary caregivers 
taking time off work, a further 904 people would have taken time off work resulting in an age-adjusted 
total number of 23,110 days of lost productivity (95%CI: 22,661 – 23,522). 95% confidence intervals 
of the mean are based on 1,000 bootstrap replications. 
MISSING DATA ANALYSIS 
Each patient was sent a maximum of three EQ-5D-3L questionnaires: for the worst day of infection, 
for the date that the first questionnaire was received and the recovery HRQoL reading. From a 
maximum of 744 eligible questionnaires from both individuals with confirmed measles and individuals 
with unconfirmed/suspected measles, 397 contained both a EQ-5D-3L questionnaire with responses 
to all dimension of HRQoL and a completed VAS score. 
Assuming that EQ-5D responses were missing at random and that the VAS score can be used to predict 
missing EQ-5D utilities, we used a multiple imputation method through the Amelia II statistical 
package in R [21] to impute EQ-5D utilities where the individual had completed the VAS. This added 
26 more observations and the overall QALY loss from the interpolated data was equivalent to 6.81 
days (95% CI 5.68 – 8.04), very similar to the QALY and equivalent QALD loss from non-interpolated 
data reported in Table 7.5. 
IMPLICATIONS FOR MISSING HRQOL DATA 
49 (70%) of the 70 EQ-5D proxy questionnaires for children aged under 7 years for the worst day of 
infection returned were missing in the self-care dimension ( 
Table 7.6). This suggests that parents or guardians have difficultly completing this dimension of the 
EQ-5D-3L as a proxy for their young children. 28 of the returned EQ-5D proxy questionnaires (40%) 
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did not have a response recorded in the mobility dimension. Fewer missing responses were returned 
for the remaining three dimensions. 
None of the 25 EQ-5D-Y questionnaires for children aged 7 – 12 years had a missing response for any 
of the five dimensions on the worst day of infection. Few EQ-5D-3L questionnaires for individuals aged 
13 years and older had missing responses for the dimensions of health: 5 questionnaires (4.6%) were 
missing a response in the mobility dimension, with fewer missing responses in the remaining 
dimensions. 
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Table 7.6 - Number of missing responses to each EQ-5D dimension of health on the worst day of infection 
  
 Responses Complete responses Missing: Mobility Missing: Self-care Missing: Usual activities Missing: Pain Missing: Depression 
EQ-5D proxy 70 20 (28.6%) 28 (40.0%) 49 (70.0%) 16 (22.9%) 8 (11.4%) 12 (17.1%) 
EQ-5D-Y 25 25 (100.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
EQ-5D 108 102 (94.4%) 5 (4.6%) 3 (2.8%) 3 (2.8%) 2 (1.9%) 2 (1.9%) 
 203 (100%) 147 (72.4%)      
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MEASURING HRQOL USING AGE-SPECIFIC EQ-5D-3L  
The standard EQ-5D-3L was used by individuals aged 13 years and older. The mean QALD-loss 
attributable to measles for this group was 6.9 days (95% CI: 4.9 – 9.1). For individuals aged between 7 
– 12 years the EQ-5D-Y was used to report a mean QALD-loss of 7.3 days (95% CI: 3.7 – 13.0). For 
infants aged under 7 years the EQ-5D (proxy) was used to report a mean QALD-loss of 6.2 days (95% 
CI: 3.6 – 9.0). Using the independent Mann-Whitney test there was no evidence that the measured 
HRQoL loss is dependent on the EQ-5D-3L questionnaire used (W = 483.5 and p = 0.64 when compared 
to EQ-5D-Y; W = 433.5 and p = 0.99 when compared to EQ-5D proxy). 
DISCUSSION 
We have used the confirmed measles cases reported since June 2012 to calculate the short-term 
impact on HRQoL of measles, with measurements taken during the 2012-13 regional measles 
epidemics in England. We found that measles infection causes a short-term QALY-loss of 0.019 QALYs, 
or 6.9 QALDs, per patient, with perceived symptoms lasting 13.8 days. For context, the short-term 
impact on HRQoL of H1N1v influenza was 0.008 QALYs, or 2.92 QALDs, per patient [22]. The impact 
on HRQoL of natural varicella was 0.0027 QALYs, or 0.99 QALDs (<15 years old) [23] and 0.0038 QALYs, 
or 1.39 QALDs (≥15 years old) per patient [24]. 
To our knowledge this is the first attempt to calculate the impact on HRQoL of measles infection. This 
study was a patient-based retrospective study that invited all eligible confirmed cases of measles since 
mid-2012 in the general population to participate. The response rate was reasonable for a postal 
survey with a return rate of 40%. In addition to quantifying the short-term impact of measles on 
HRQoL we have also described the wider impact in terms of time off work or school for individuals 
with measles and their primary caregivers. 
With MMR coverage still below the herd immunity threshold, the potential for further measles 
outbreaks still exists within England. Following this study, cost-effectiveness analyses for possible 
interventions for such outbreaks may now be performed using QALYs, so that a single generic metric 
is compared across all analyses. 
Using the VAS to derive health QALDs underestimates the impact of measles infection on HRQoL in 
comparison to the EQ-5D-3L, according to our sample of individuals with confirmed measles. Indeed, 
the VAS is not a preference-based system so it should not be used alone to calculate QALYs [25]. 
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55.2% of individuals with confirmed measles who returned their questionnaires did not provide all of 
the data necessary to calculate QALY loss associated with measles infection. Completion was poor for 
the EQ-5D proxy version administered to parents or guardians to complete on behalf of a child aged 
less than 7 years; 70% of returned EQ-5D proxy questionnaires had a missing response to the self-care 
dimension ( 
Table 7.6). This is hardly surprising, since it is unclear how one ought to answer such a question, but 
it means that the proxy form of the EQ-5D-3L may not be appropriate for evaluating a young child’s 
HRQoL. Fewer completion issues were evident with the EQ-5D-3L for individuals with confirmed 
measles aged 13 and older, and no completed issues were evident for the EQ-5D-Y administered to 
children aged 7 – 12 years. In contrast to the missing responses to the questions about health 
dimensions, 95.6% of individuals with confirmed measles who returned a questionnaire also returned 
a completed VAS; this suggests that individuals with confirmed measles found it easier to complete 
the VAS than the EQ-5D-3L dimensions. 
We found that estimated HRQoL loss is not dependent on the EQ-5D-3L questionnaire used, i.e. the 
EQ-5D proxy and EQ-5D-Y give similar values of HRQoL when compared to the standard EQ-5D-3L. 
However, we note that both the EQ-5D-Y and EQ-5D proxy questionnaires currently use the same 
scoring tariff as the EQ-5D-3L. That is, the value of different health states measured by the EQ-5D-3L 
is assumed to be identical for all respondents in our study. This assumption has been challenged in 
the past [26-28] and EuroQol are currently developing a child-specific tariff for the EQ-5D-Y. 
We note that in the regional epidemics in Cheshire and Merseyside only 18% of confirmed cases were 
hospitalised [7], in comparison to 36.5% of our sample reporting spending at least one night in 
hospital, though the authors of that study suggested that the hospitalisation data from that study may 
underestimate the true rate. From our sample of confirmed cases we did not find evidence that the 
more severe cases were more likely to respond to our questionnaire. 
LIMITATIONS 
RETROSPECTIVE ANALYSIS 
This study was a retrospective evaluation of the impact of measles infection on short-term HRQoL, 
using self-reported metrics. It would be preferable to evaluate short-term HRQoL loss in a controlled 
environment with daily EQ-5D-3L questionnaire completion and additional laboratory confirmation of 
items such as onset date and duration of infection. However, our study protocol followed similar 
evaluations of HRQoL loss for other infectious disease and was successfully designed and executed 
during a nationwide measles outbreak. 
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LINEAR DETERIORATION IN HRQOL 
We assumed that the deterioration in HRQoL is linearly related to the duration of infection and used 
a triangular shape to describe the QALY loss. This assumption could be tested if HRQoL were measured 
more often over the course of measles infection, providing sufficient information to gauge how HRQoL 
varies during infection. However, this proposal may be infeasible as it places a larger burden on the 
individuals with measles during their period of infection. When Hollmann et al. (2013) [29] calculated 
the impact of H1N1 influenza on patients in Spain they assumed that the health utility corresponding 
to the worst day of infection is experienced constantly throughout infection. This assumption means 
that HRQoL drops to its lowest possible level from day one of infection and returns to its highest level 
upon recovery. In comparison to our method, this doubles the impact on HRQoL. 
CHANGE THE EQ-5D TARIFF TO THE NEW EQ-5D-Y TARIFF 
At the time of writing the EuroQol EQ-5D-Y instrument for estimating health utilities in children of 
ages 8 – 15 years does not have its own tariff for the valuation of health states. Instead, researchers 
using the EQ-5D-Y are recommended to use the adult tariff from the EQ-5D. We administered EQ-5D-
Y questionnaires but each response was valued using the EQ-5D adult tariff. It is unclear if the new 
tariff will significantly change the total burden of disease for measles during the outbreaks in 2012-13 
but the analysis should be updated when the new EQ-5D-Y tariff is published. 
ECONOMIC COSTS 
Our study to estimate the impact of measles infection on HRQoL did not include the financial impact 
of measles infection for those individuals with measles or their caregivers. Collecting information to 
describe this financial impact falls outside the blanket ethical approval obtained by Public Health 
England to collect data was part of regular outbreak surveillance. The process of obtaining additional 
ethical approval to collect data on the financial impact of measles infection in the home would have 
delayed the distribution of questionnaires by several months, so we did not include such a section in 
the questionnaires. 
However, our study to estimate the economic impact of the measles outbreak in Merseyside (see 
Chapter 8) was unable to quantify the impact of infection at home in a way that would have been 
possible with additional ethical approval for Public Health England. The authors of the original costing 
analysis did not have access to the details of each notified case in Merseyside so were unable to gather 
data on out-of-pocket expenses incurred by families affected during the outbreak. 
Public Health England is the only organisation in England that has the ability to reach each individual 
with suspected measles during future outbreaks. Applying for ethical approval to collect data on out-
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of-pocket expenses incurred at home before an outbreak has occurred would permit an easy 
extension to the study to quantify the full impact of measles outbreaks in the community. 
POTENTIAL RECALL BIAS 
Individuals were unlikely to complete the EQ-5D-3L for the worst day of their illness on that day, as 
we were unable to send questionnaires to individuals until after confirmation of measles was received, 
which was likely to be after the worst day of illness. This may be a source of recall bias but we 
attempted to minimise this by sending questionnaires to confirmed cases as quickly as possible. The 
median time between the perceived symptoms onset and the date of completing the questionnaire 
was 12.0 days (mean 16.8 days, mode 5.0 days). Using the independent Wilcoxon test we found no 
evidence that the short-term impact on HRQoL was associated with the length of time between 
perceived symptoms onset and the date of completion of the questionnaire. Those individuals 
completing the questionnaire within one week of perceived symptoms onset reported a mean QALD-
loss of 7.88 days (95% CI: 5.1 – 11.92), as compared to those completing the questionnaire between 
8 – 14 days (5.64 QALDs, 95% CI: 3.03 – 8.16, W = 200 and p = 0.29) and to those completing the 
questionnaire more than 14 days after symptom onset (6.03 QALDs, 95% CI: 4.30 – 8.12, W = 543 and 
p = 0.19). 
POTENTIAL MISCLASSIFICATION BIAS 
10 patients reported that they did not have any contact with the health services before their case 
status was confirmed. This may be because they were already known to the local HPU through contact 
tracing of another confirmed case or were separately reported to the HPU without contacting the 
health services. However, we recognise that they may have failed to report a contact with the health 
services before notification to the HPU and therefore could be a source of misclassification bias in our 
study. 
PERCEIVED LENGTH OF SYMPTOMS, RATHER THAN THE DURATION OF ILLNESS 
In our calculation of QALY loss due to measles we used the reported perceived length of symptoms 
rather than duration of illness as obtained through serology. However, we feel that this assumption 
and use of a proxy is justified as an individual will only report a lower health state to their preferred 
health state when their symptoms affect their wellbeing; thus perceived symptoms are the relevant 
factor.  
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Chapter 8 - The cost of the measles outbreak in Cheshire and 
Merseyside 2012-13 
Portions of this section were published in Vaccine in March 2016 [1]. 
ABSTRACT 
BACKGROUND 
During 2012 and 2013 in England and Wales there were 3,873 laboratory-confirmed cases of measles, 
with the outbreak in Liverpool declared over at the end of August 2013 after 650 laboratory-confirmed 
cases of measles had been diagnosed by the Cheshire & Merseyside Health Protection Unit (CMHPU). 
CMHPU commissioned the development of a costing model based on a critical literature review and 
experience to date to identify the total cost of the outbreak for the period 1st February – 31st May 
2012. 
OBJECTIVE 
We sought to use the commissioned model results to estimate the total cost of the full outbreak in 
Liverpool to the date 31st August 2013. 
METHODS AND FINDINGS 
Identified costs were divided into non-recurrent fixed costs incurred at the beginning of the outbreak 
and ongoing running costs incurred throughout the outbreak. Additional information on the impact 
of the outbreak at home was used to inform the model and update the estimates of the cost due to 
loss of productivity. The full outbreak cost was estimated to be £4.4m (sensitivity analysis £3.9m to 
£5.2m). In comparison, a further 11,793 MMR vaccinations would have been needed to achieve herd 
protection at an estimated cost of £182,909. Therefore, investing an additional £1 on immunisation 
through MMR would have saved £23 incurred as a result of this outbreak had the herd immunity 
threshold been achieved. 
CONCLUSION 
The total cost of the measles outbreak in Cheshire & Merseyside was higher than previous studies on 
other outbreaks suggested, however our model included a wider range of costs to present the 
economic impact of measles outbreaks from the societal perspective. Approximately 40% of the total 
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cost was incurred through direct public health activities to manage the outbreak and contain infection. 
In contrast, the total cost of meeting the targeted vaccination coverage in the area was just 4.2% the 
total cost of the outbreak. This study emphasises the importance and economic benefit of preventive 
measures to control outbreaks of measles through vaccination with MMR. 
INTRODUCTION 
The previous chapter details the investigation into both the societal and health-related quality of life 
impact of measles infection in England. In addition to this investigation, the nationwide measles 
outbreak provided researchers with the opportunity to estimate the economic impact of localised 
measles outbreaks. Researchers from the Liverpool office of Public Health England commissioned a 
consultancy firm to design a costing model to be used to investigate the economic cost of the first 
four months of the measles outbreaks that occurred in Merseyside 2012. We used this model to 
estimate the total economic cost of the full outbreak. 
BACKGROUND 
MEASLES OUTBREAKS IN CHESHIRE & MERSEYSIDE AND NATIONWIDE 
Merseyside is a county in the north west of England, comprising of five metropolitan boroughs: 
Knowsley, St Helens, Sefton, Wirral and the City of Liverpool. In 2012, Liverpool had an estimated 
population of 469,700 people (78,609 of whom were aged 16 years old or younger) [2] and over 65% 
of the population live in the most socioeconomically deprived national quintile [3].  
During 2012 and 2013 in England and Wales there were 3,873 laboratory-confirmed cases of measles 
of which 1,245 were attributed to outbreaks in North West England [4] (Figure 8.1). Declining MMR 
vaccination coverage in the late 1990s and early 2000s increased the number of susceptible individuals 
in England and Wales and therefore raised the potential for sustained community-wide measles 
transmission [5].  
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Figure 8.1 - Confirmed measles cases in North West England during 2012 and 2013 
In 2012-13 under-vaccinated areas such as Liverpool [6], North-East England [7] and Manchester [8] 
experienced large measles outbreaks. The outbreak in Liverpool was declared over at the end of 
August 2013, after 650 laboratory-confirmed cases of measles had been diagnosed by the Cheshire & 
Merseyside Health Protection Unit (CMHPU).  
An MMR catch-up campaign was announced jointly by Public Health England and the Department of 
Health with a target of achieving high MMR vaccination coverage sufficient to reach the herd 
immunity threshold and limit the spread of measles in the community [9], targeting young 
unvaccinated and partially-vaccinated people. In recent years MMR vaccination coverage dropped 
well below the threshold for herd immunity (Figure 8.2), providing a large pool of susceptible 
individuals that was ultimately able to sustain measles transmission in the community for several 
months. 
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Figure 8.2 - Annual first dose MMR coverage at 24 months and 5 years, England: April 1997 - March 
2012 
Figure credit: [9]. 
In addition to increasing MMR vaccination coverage in the community, the local Public Health England 
(Cheshire & Merseyside Health Protection Unit, CMPHU) responded to the outbreak to facilitate the 
containment and management of all confirmed and possible cases of measles. This response required 
that healthcare professionals and organisations from primary care, secondary care, community care, 
public health and other local authorities collaborate to end community transmission of measles in the 
local area. 
CASE DEFINITION 
Vivancos et al. (2012) detailed the case definition applied during the outbreak to identify confirmed 
cases of measles [6]. That definition was: 
1. Clinical presentation of fever and measles-like rash, with one or more of the following: cough, 
conjunctivitis, coryza, or Koplik’s spots 
2. Residence in Liverpool or adjacent areas, or close contact with a confirmed or probable case 
of measles, or a history of recent travel to geographical areas with endemic or outbreak 
measles 
3. Incomplete or unknown MMR vaccination status 
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Each notification received by the CMHPU was treated as a suspected case, and all suspected cases 
incurred costs during the outbreak. Suspected cases were further defined using guidance adapted 
from the HPA National Measles Guidelines [10]: 
Confirmed case. An individual with measles IgM positive (blood or saliva) in absence of a history of 
recent vaccination or confirmed wild measles RNA positive on any clinical specimen. 
Probable case. An individual with signs and symptoms consistent with measles who was in contact 
with a laboratory-confirmed case 7-18 days before the onset of symptoms, or assessed as likely by a 
member of the Health Protection Team based on epidemiological features. 
Possible case. An individual with some clinical symptoms, though not specific to measles and where 
another diagnosis is possible. 
MANAGING THE OUTBREAK IN CHESHIRE & MERSEYSIDE 
A co-ordinated response involved managing all confirmed and suspected cases of measles in the 
community in all healthcare settings, from the initial identification of a suspected case through to the 
vaccination of people suspected of being in contact with an individual with confirmed measles. 
Activities carried out during the period of the epidemic are listed below. 
Identification of suspected cases. General Practitioners and staff at Accident and Emergency units 
notified the CMPHU of individuals suspected of having symptoms consistent with measles. For each 
identified individual, laboratory testing was required to confirm their case status. 
Laboratory work and courier. The main laboratory used to confirm measles infection in individuals 
suspected of infection was the HPA laboratory at Manchester Royal Infirmary. PCR rapid testing of 
saliva samples were used, with samples couriered between Manchester and the outbreak area. All 
results were shared with the CMHPU and the individual’s GP. 
Identification of contacts with confirmed or probable cases. Along with the CMPHU, both primary 
care and secondary care organisations traced the contacts of suspected measles cases. This activity 
was a significant time burden on staff involving many telephone conversations with individuals at risk 
of measles infection to inform them of the risk to their health. 
Direct healthcare costs for suspected cases. Some individuals with measles required hospitalisation 
with complications arising from their infection. In addition, some individuals required the assistance 
of ambulance crews to transport them to an appropriate facility to receive care for their condition. 
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Creation of the UrgentCare24 (NHS UC24) clinic. A new clinic was set-up in the community to deal 
directly with suspected cases, relieving the burden on other primary care organisations. 
Vaccination of healthcare staff and eligible members of the public, including checking immunisation 
status of individuals. Staff in all healthcare organisations with direct access to individuals with 
suspected measles required their MMR vaccination status to be up to date. This meant several 
organisations needed to ascertain the vaccination status of all their members of staff and vaccinate 
those individuals without the recommended two doses of MMR. In addition, staff in General Practice 
clinics notified patients registered to their practice if their records indicated that they had not received 
the recommended two doses of MMR and had been eligible to do so. Checking the vaccination status 
of registered patients was a considerable administrative burden on General Practice staff. 
Prophylaxis for contacts of confirmed or probable cases. Individuals exposed to measles and for 
whom either their vaccination status could not be obtained or was inadequate were offered 
prophylactic treatment in the form of immunoglobulin [11]. 
Infection control in hospitals. Both the admission of patients with complications arising from measles 
infection and the presentation of suspected measles cases in Accident and Emergency units in the 
local NHS Trusts gave rise to concern of hospital-based measles transmission. All local NHS Trusts were 
therefore instructed by the CMHPU to ensure that their Infection Prevention and Control teams were 
working to prevent such transmission to other patients on their wards. 
Media costs to inform public and local authorities and institutions. The CMHPU informed the public 
through media campaigns of the risk of measles infection and the steps to take should any member 
of their household present with symptoms consistent with measles infection. The stepping-up of the 
MMR vaccination campaign offered an opportunity for those individuals without sufficient protection 
from measles infection to rectify this, so public engagement activities and information were 
commissioned to remind people to check the vaccination status of all individuals in their household. 
Productivity cost to the community. Measles infection is associated with increased absenteeism due 
to infection as well as absenteeism for those individuals required to act as primary caregivers to 
people in their household otherwise incapable of looking after themselves [12].  
Staff costs due to time spent managing the outbreak. All activities required to contain and manage 
the epidemic caused a significant time and administrative burden on all organisations involved in the 
coordinated response. Time spent managing the outbreak was spent at the cost of other duties 
normally conducted outside of outbreak containment and management. In addition, several 
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organisations required additional temporary staff to be hired as well as requiring staff to work extra 
hours and cancel some planned leave to direct resources to the outbreak response. 
ECONOMIC IMPACT OF PREVIOUS MEASLES OUTBREAKS 
Measles outbreaks can have a large economic impact on health services and society. A study published 
in 2002 estimated the average cost per measles case to be $307 in the UK [13]. A similar study in Spain 
covering measles cases diagnosed between 1997 and 2006 reported a mean cost per uncomplicated 
case of measles of €1,834 and a mean cost per case with complications of €3,559 [14]. Additional 
results are reported in Table 8.1.  
Study Year of 
publication 
Reported costs 
Carabin et al. [13] 2002 $254 (Canada) 
$276 (The Netherlands) 
$307 (UK) 
Santos Sancho et al. [14] 2009 €1,834 without complications 
€3,559 with complications 
Filia et al. [15] 2007 €1,429 hospitalised cases without complications 
€1,960 hospitalised cases with complications 
Zwanziger et al. [16] 2001 Between $2,089 - $2,251 to prevent a single case of 
measles 
Sugerman et al. [17] 2010 $10,376 per case 
$775 family cost for quarantine per child 
Table 8.1 - Reported costs of measles cases 
Further to the mean cost per case of measles, the study published by Filia et al. (2007) reported that 
the direct cost attributed to managing the measles outbreaks in Italy between 2002-03 was between 
€17.6m-€22.0m [15].  The regional measles outbreak in Liverpool provided CMHPU an opportunity to 
describe the total cost of managing the outbreak and to further understand the economic impact of 
measles infection in the UK. 
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Figure 8.3 - The total burden of outbreaks of infectious diseases 
Figure 8.3 shows the different ways and perspectives to describe the burden of infectious disease. The 
direct disease burden consists of the total number of cases, hospitalisations and deaths in the 
population, described in outbreak reports (e.g. Vivancos et al. [18]). The direct economic burden 
quantifies the economic value of that disease burden, assigning monetary values to cases of disease 
in the form of direct healthcare costs (e.g. citations in Table 8.1). The quantifiable societal burden 
includes productivity loss in the form of workplace- and school-absenteeism, assigning monetary 
values to the wider costs in society due to infection. A further burden less straight-forward to describe 
is the unquantifiable societal burden, consisting of disruption to ordinary routine, the loss of leisure 
time for individuals acting as caregivers for others infected with disease, etc.   
COMMISSIONED COSTING REPORT: METHODS 
In order to understand the economic impact of measles outbreaks in the region, CMHPU 
commissioned ICF GHK to estimate the cost of the outbreak. Together, the two organisations defined 
the time period of interest for the costing exercise to be 1st February 2012 – 31st May 2012 and 
restricted only to the local area. At this time, CMHPU reported 306 laboratory-confirmed cases of 
measles along with 844 potential cases of measles (94 probable, 223 possible and 527 laboratory-
negative). 
Costs were divided into two categories: direct costs (shared by healthcare providers and public health 
institutions) and indirect costs to the local economy. Direct healthcare costs included costs attributed 
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to primary care and secondary care in treating suspected cases, calculated using the Healthcare 
Resource Group (HRG) tariffs recorded for patients. Public health costs related to the containment 
and management of the outbreak, with organisations such as CMHPU, Community Trusts, Acute Trusts 
etc. incurring such costs in controlling the outbreak. Productivity costs were incurred through missed 
work and school for suspected cases and their carers in addition to ward closures, cancelled 
admissions, delayed and cancelled appointments in the healthcare organisations. 
COMMISSIONED COSTING REPORT: INITIAL FINDINGS 
For the period 1st February 2012 – 31st May 2012, ICF reported the total cost of the outbreak was 
£1.4m (between £1.3m and £1.6m after the sensitivity analysis) [19]. 37% of these costs (£526,100) 
were borne by secondary care organisations such as RLBUHT (Royal Liverpool, Broadgreen and 
Liverpool University hospitals) and Alder Hey, followed by 26% (£371,800) borne by CMHPU. The 
mean cost per confirmed case of measles was £4,980, but as all suspected measles incur some costs 
before the final laboratory confirmation of case status they reported a final mean cost per reported 
and suspected case of approximately £1,000. A breakdown of the total cost is presented in Table 8.2, 
with costs rounded to the nearest £100.  
Dividing the total cost into direct healthcare costs, direct public health costs and indirect costs to the 
local economy, ICF reported that 25% (£353,800) of the total cost was for direct healthcare costs, 60% 
(£844,300) for direct public health costs and 15% (£212,200) for costs to the local economy. The direct 
public health costs are comparable to those reported by Parker et al. (2006) [20], who reported a total 
direct public health cost of £110,870 for 40 measles cases (£3,260 mean public health cost per case) 
in an outbreak in Indiana. 
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Organisation Main cost drivers Cost % of total cost 
Primary Care Trusts and 
NHS UC24 
Staff costs 
MMR LES 
£90,100 6% 
Secondary Care RLBUHT 
Alder Hey 
£526,100 37% 
Community Care Staff costs £43,000 3% 
General Practitioners Contact tracing for confirmed 
measles cases 
£103,300 7% 
Cheshire & Merseyside 
HPU 
Staff costs £371,800 26% 
North West Ambulance 
Service 
Providing ambulance service £1,100 <1% 
Manchester Royal 
Laboratory 
IgG, PCR and IgM tests £28,500 2% 
Society lost productivity Estimated lost productivity of 
potential and unreported cases of 
measles 
£231,600 16% 
Local Authority Associated administration £14,800 1% 
Total cost  £1,410,300  
Table 8.2 - Total cost of measles outbreak in Liverpool from 1st February 2012 - 31st May 2012 
Table credit: [19]. 
EXTENDING THE ANALYSIS FOR THE FULL OUTBREAK IN CHESHIRE & MERSEYSIDE 
Though the ICF report describes the many costs incurred during the period 1st February 2012 to 31st 
May 2012, the total duration of the outbreak was much longer. An additional analysis was sought to 
describe the estimated total cost of the full outbreak, from 1st January 2012 to 31st August 2013.  
Though some costs described in the ICF report would continue throughout the full outbreak, some 
costs would be incurred only at the beginning of the outbreak (fixed costs such as setting-up the MMR 
LES and creating additional infection control spaces within acute trusts). This analysis sought to 
describe the estimated total cost of the full outbreak separated the varying costs in the ICF report 
then extrapolated them according to the time extension and increased number of suspected cases. 
Additionally, some calculations used by ICF to estimate the loss of productivity were updated to 
include results published in 2014 that describe the impact of measles infection at home in terms of 
measles-attributed absence from work and school as well as the percentage of individuals with 
confirmed measles who reported requiring a caregiver to be with them during their infection [12]. 
These data were published after ICF had completed their analysis. 
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To further assist public health organisations in understanding the economic impact of measles 
outbreaks, we sought to present the total cost of achieving MMR herd immunity in Liverpool that may 
have prevented the sustained community transmission.   
RESEARCH QUESTIONS 
1. What was the estimated total cost of the measles outbreak in Cheshire and Merseyside 2012-
13, in terms of direct and indirect costs, for all suspected and unreported cases? 
2. What would the cost of preventing the outbreak have been? Is preventing the cost of a 
regional measles outbreak cost-saving in comparison to managing and containing an 
outbreak? 
METHODS 
This section lists the major cost centres and the costs attributed to the outbreak, obtained via 
consultation with ICF and all stakeholders in the production of the initial costing report. 
FULL OUTBREAK COSTS 
PRIMARY CARE AND NHS UC24 
Costs identified by ICF that were incurred by the Primary Care Trusts and the NHS 24hr Urgent Care 
centre related to the implementation of the MMR LES, staff time taken up in managing the outbreak 
and postage and packaging fees to distribute leaflets at the beginning of the outbreak to encourage 
unvaccinated individuals to accept the MMR vaccination. Eight PCTs were affected by the outbreak 
but costs were collected from the four PCTs with the highest case burden (Liverpool, Knowsley, Hafton 
& St. Helens and Sefton) with costs for the others (Central & Eastern Cheshire, Warrington, Western 
Cheshire and Wirral) estimated by assuming proportionality from the data gathered. 
SECONDARY CARE 
The ICF report highlighted the two Trusts worst affected by the measles outbreak were the RLBUHT 
and Alder Hey, but several other smaller NHS Trusts also participated in the outbreak response. Most 
departments within the Trusts responding to the outbreak contributed by assessing patients in A&E, 
admitting patients to their intensive care/critical care units, activating infection prevention and 
control protocols with expertise from their Infectious Disease departments and Virology departments. 
Secondary Care Trusts also incurred costs through tracing both vaccination status of their members 
of staff and the contacts of patients being seen at the Trust. Further costs were incurred through the 
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loss of productivity with ward closures, staff illness and attending meetings with CMHPU to coordinate 
the response across the local area. 
COMMUNITY CARE 
The Liverpool Community Health organisation consists of many departments that all participated in 
the management and containment of the outbreak. Costs were incurred through vaccinations, 
checking the vaccination status of staff members, staff absence during the outbreak and treatment 
costs for patients attending the walk-in centres managed by the organisation. 
GENERAL PRACTITIONERS 
GPs were the first point of contact and access to the local health services for many suspected cases. 
The majority of the work conducted by GPs during the outbreak was in assisting the public health 
response to the outbreak, but an increase in the number of patients requiring a GP appointment 
during the outbreak meant that additional clinics needed to be implemented or telephone-based 
services needed to be offered to patients with suspected measles. GPs also incurred costs in tracing 
the contacts of all individuals with confirmed measles. Costs for GPs were extrapolated from the 
number of cases per GP surgery, multiplied by 1.5 times the cost of a standard GP consultation [13, 
21] as this was the estimated additional time taken to see a suspected measles case.  
CHESHIRE & MERSEYSIDE HEALTH PROTECTION UNIT 
The largest cost for CMHPU was in staff time to manage the public health response to the outbreak. 
Several members of staff worked long overtime hours and cancelled planned breaks to ensure a robust 
response to the outbreak. During the outbreak the majority of time working was spent on the 
outbreak. 
NORTH WEST AMBULANCE SERVICE 
ICF estimated that the North West Ambulance Service was required for a small number of patients 
with suspected measles. In addition, all staff likely to come into contact with an individual with 
suspected measles needed their vaccination status to be established and catch-up vaccinations to be 
administered where required. 
MANCHESTER ROYAL LABORATORY 
The PCR testing to confirm measles infection took place at the laboratory of the Manchester Royal 
Infirmary. Sample used for testing were sent to Manchester from Liverpool via courier. 
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SOCIETY LOST PRODUCTIVITY 
In calculating the total cost of lost productivity in Liverpool, ICF divided the cost into four categories: 
hospitalised confirmed cases of measles, non-hospitalised confirmed cases of measles, potential cases 
of measles and unreported cases of measles. The proportion of individuals with confirmed measles in 
Liverpool was estimated at 20.6% [19], and the rate of employment in the area was taken from the 
Office of National Statistics [22]. ICF assumed that individuals hospitalised due to measles infection or 
complications arising from measles infection were absent from work/school for two weeks and that 
infection without hospitalisation required an absence of three days [23]. The number of unreported 
measles cases was taken from Carabin et al. (2002) [13]. 
Proportion of confirmed cases reporting work/school absence 63.1% 
Absence from work/school for patients 9.6 days (95% CI: 9.3 - 11.7) 
Proportion of confirmed cases requiring a caregiver 39.6% 
Absence from work for caregivers 7.3 days (95% CI: 5.7 – 7.9) 
Table 8.3 - The impact of measles infection in terms of society lost productivity 
Table credit: [12]. 
In estimating the full cost of the outbreak, we included the time off work for a caregiver and the 
proportion of individuals with confirmed measles requiring a caregiver from Thorrington et al. (2014) 
[12] (Chapter 8). The proportion of individuals absent from work/school due to infection in addition 
to the mean absence for both patients and their caregivers were also used in the updated analysis. 
Data are shown in Table 8.3. 
LOCAL AUTHORITY 
Liverpool City Council provided information to parents of young children to inform them of the 
outbreak and potential consequences of measles infection. The cost of producing these materials to 
provide the information were borne by the Council and recorded as a direct public health cost for the 
outbreak. All parents of school-age children were contacted through their child’s school. 
THE COST OF PREVENTION 
Vaccination against measles is an effective method to prevent measles outbreaks. With vaccination 
coverage below the herd immunity threshold of 95% there exists the potential for sustained measles 
transmission within the community.  
In 2012 11,793 children in Liverpool needed to receive their required MMR dose in order to achieve 
the herd immunity coverage level [24]. 8,366 children needed to receive their first MMR dose and 
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3,427 children were eligible for the second dose but had not received it. Administering these 
additional doses in the community would have been the most effective method of preventing the 
measles outbreaks in Liverpool. The breakdown of the total vaccination cost required to prevent the 
outbreaks was calculated to be £182,909 and is presented in Table 8.4. 
Activity Source Unit cost Total cost 
Vaccination administration and delivery, including 
practitioner time per child 
[25] £7.64 £90,099 
MMR vaccination dose [26] £6.37 £75,121 
MMR catch-up campaign promotion per child [25] £1.50 £17,689 
Table 8.4 - The cost of preventing measles outbreaks through vaccination 
SENSITIVITY ANALYSIS 
ICF included a sensitivity analysis to estimate the total cost of the outbreak between 1st February 2012 
and 31st May 2012 was between £1.3m and £1.6m. The sensitivity analysis varied five key parameters 
in the costing model (Table 8.5) that displayed the largest levels of uncertainty after consultation with 
stakeholders.  
 Lower end 
cost 
Best estimate Higher end 
cost 
Costs of treatment in hospitals other 
than the two used to obtain the average 
cost 
£1,196 £1,383 £1,730 
Cost of contact tracing in hospitals other 
than the two used to obtain the average 
cost 
£0 Linked to 
Royal 
Liverpool 
estimate 
Linked to 
Royal 
Liverpool 
estimate 
Staff absence in hospitals other than the 
two used to obtain the average cost 
£0 Linked to 
Royal 
Liverpool 
estimate 
Linked to 
Royal 
Liverpool 
estimate 
Cost of a GP consultation and tracing of 
a measles case 
£362 £381 £574 
Lost productivity costs 0% of cases 
unreported, 3 
days absence 
22.5% of cases 
unreported, 3 
days absence 
45% of cases 
unreported, 4 
days absence 
Table 8.5 - Parameters used in the sensitivity analysis for the calculated costs of the outbreak between 
1st February – 31st May 2012 
Two parameters included in the sensitivity analysis used vaguely-defined distributions to estimate 
values for the best and higher cost calculations: both the cost of contact tracing in the smaller hospitals 
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in addition to the cost of staff absence in these hospitals were estimated from the values obtained 
from RLBUHT and Alder Hey, without sufficient detail given in the methodology. 
 Lower end cost Best estimate Higher end cost 
Costs of treatment in hospitals other 
than the two used to obtain the average 
cost 
£1,196 £1,383 £1,730 
Cost of contact tracing in hospitals other 
than the two used to obtain the average 
cost 
£0 Trust-specific, 
as provided by 
GHK report 
1.5 x Trust-
specific 
estimate from 
GHK 
Staff absence in hospitals other than the 
two used to obtain the average cost 
£0 Trust-specific, 
as provided by 
GHK report 
1.5 x Trust-
specific 
estimate from 
GHK 
Cost of a GP consultation and tracing of 
a measles case 
£362 £381 £574 
Lost productivity costs 0% of cases 
unreported, 9.3 
days absence 
for patients, 5.7 
days absence 
for caregivers 
22.5% of cases 
unreported, 9.6 
days absence 
for patients, 7.3 
days absence 
for caregivers 
45% of cases 
unreported, 
11.7 days 
absence for 
patients, 7.9 
days absence 
for caregivers 
Table 8.6 - Parameters used in the sensitivity analysis for the estimated total costs of the full outbreak 
The revised multi-variate sensitivity analysis used many of the same parameters but with more robust 
distributions sourced from the literature for both the cost of contact tracing and staff absence in the 
smaller hospitals. The parameters used for the best estimated cost were taken directly from the ICF 
report for each Trust, with the higher end cost estimated as 1.5 times the best estimate. In addition, 
the costs relating to a loss in productivity were updated using figures from Thorrington et al. (2014) 
[12] to inform the model with distributions for the length of absence for both patients and their 
caregivers (Table 8.6). The analysis was conducted in Microsoft Excel.  
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RESULTS 
ESTIMATED TOTAL COSTS OF THE OUTBREAK 
TOTAL COSTS 
The estimated total cost of the full outbreak was £4.40m (between £3.85m and £5.15m from the 
sensitivity analysis). Fixed costs occurring at the beginning of the outbreak accounted for £0.16m 
(3.8%) and varying costs accounted for £4.23m (96.2%) (Table 8.7).  
Organisation Confirmed, probable, 
possible and unreported 
cases estimated total cost 
Cost (£) % 
Primary Care Trusts 223,000 5% 
Varying 204,100 5% 
Fixed 18,900 <1% 
Secondary Care 994,200 23% 
Varying 879,500 20% 
Fixed 114,700 3% 
Community Care 91,400 2% 
Varying 91,400 2% 
General Practitioners 315,300 7% 
Varying 314,500 7% 
Fixed 800 <1% 
CMHPU 790,400 18% 
Varying 774,600 18% 
Fixed 15,800 <1% 
Ambulance Service 2,300 <1% 
Varying 2,300 <1% 
MRI Laboratory Costs 60,500 1% 
Varying 60,500 1% 
Society Lost Productivity 1,903,500 43% 
Varying 1,903,500 43% 
Local Authority 14,800 <1% 
Fixed 14,800 <1% 
Total 4,395,400  
Table 8.7 - Estimated total costs of the outbreak by organisation and by the nature of cost (fixed or 
varying costs). Costs round to the nearest £100 
£1.45m (33.0%) was spent on activities related to those individuals with confirmed measles, whilst 
£2.95m (67.0%) was spent on activities related to potential and unreported cases of measles.  
DIRECT HEALTHCARE COSTS 
Direct healthcare costs account for £0.678m (15.4%) of the total cost of the outbreak (sensitivity 
analysis £0.644m to £0.708m). The largest contribution group of organisations to the direct healthcare 
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costs was the group of secondary care organisations (Table 8.8), with Alder Hey and the Royal 
Liverpool Trusts incurring estimated total direct healthcare costs of £0.50m together. 
Organisation Direct Healthcare Direct Public Health Productivity 
Cost (£) % Cost (£) % Cost (£) % 
Primary Care Trusts - 0% 223,000 13% - 0% 
Secondary Care 575,000 85% 370,000 21% 49,200 3% 
Community Care - 0% 91,400 5% - 0% 
General Practitioners 103,300 15% 212,000 12% - 0% 
CMHPU - 0% 790,400 45% - 0% 
Ambulance Service - 0% 2,300 <1% - 0% 
MRI Laboratory - 0% 60,500 3% - 0% 
Society Lost Productivity - 0% - 0% 1,903,500 97% 
Local Authority - 0% 14,800 1% - 0% 
Total 678,300  1,764,400  1,952,700  
Table 8.8 - Estimated total costs of the full outbreak by organisation type of cost (direct healthcare, 
public health, and loss of productivity). Costs round to the nearest £100 
The largest proportion of the direct healthcare costs was itemised treatment costs and costs related 
to admissions for individuals with confirmed or probable measles cases (£0.38m, 42.9%), with other 
large cost bases being GP surgery costs (£0.10m, 12.0%)  and costs related to patients in A&E (£0.10m, 
11.4%) (Table 8.9). 
Direct Healthcare Cost Area Cost (£) % 
Accident and Emergency 96,400 11% 
Critical or Intensive Care 14,800 2% 
Drugs 4,200 <1% 
Infectious Disease protocols 91,900 11% 
Treatment 367,700 43% 
GP consultations 103,300 12% 
 678,300  
Table 8.9 - Estimated direct healthcare costs. Costs are rounded to the nearest £100  
DIRECT PUBLIC HEALTH COSTS 
Estimated total direct public health costs for the outbreak were £1.764m (40.1%) (sensitivity analysis 
£1.762m to £1.879m). Of this total the largest contributor was CMPHU with all incurred costs to the 
organisation associated with the public health response to the outbreak (Table 8.8). Primary and 
secondary care organisations collectively incurred direct public health costs of £0.68m, the largest 
contributions of which came from Alder Hey Trust (£0.27m), Royal Liverpool Trust (£0.09m) and 
Liverpool PCT (£0.09m). 
234 
 
 
 
Of the estimated total direct public health costs, £1.07m (60.8%) were incurred through staff time and 
overtime payments (Table 8.10). The remaining costs were for public health expenditure on activities 
such as tracing vaccination status, contact tracing and related laboratory costs. 
Direct Public Health Cost Area Cost (£) % 
Accident and Emergency 600 <1% 
Cleaning and maintenance 10,000 1% 
Critical or Intensive Care 200 <1% 
Dental Hospital 100 <1% 
Facility management 15,000 1% 
General Practice 229,800 13% 
Infection Control and Prevention teams and protocols 58,000 3% 
Media 15,900 1% 
Microbiology and Virology 270,700 15% 
Miscellaneous uncategorised 23,900 1% 
Occupational Health 68,200 4% 
Staff time 1,072,100 61% 
 1,764,500  
Table 8.10 - Estimated direct public health costs. Costs are rounded to the nearest £100 
LOSS OF PRODUCTIVITY COSTS 
Loss of productivity during the measles outbreaks cost the local community £1.953m (Table 8.8) 
(sensitivity analysis £1.444m to £2.565m), 44.4% of the total cost. Over 97% of the costs due to loss 
of productivity were related to non-hospital staff absence from work or school for confirmed, 
potential and unreported cases of measles (Table 8.11).  
Productivity Cost Area Cost (£) % 
Hospitalised confirmed cases of measles 59,300 3% 
Non-hospitalised confirmed cases of measles 331,000 17% 
Potential cases of measles 1,158,700 59% 
Staff absence due to measles 49,200 3% 
Estimated unreported cases of measles 354,500 18% 
 1,952,700  
Table 8.11 - Estimated costs due to loss of productivity. Costs are rounded to the nearest £100 
ESTIMATED COST OF PREVENTION 
Over the previous five years before the outbreak 8,366 children needed to receive their first MMR 
dose and 3,427 children were eligible for the second dose but had not received it [24]. The overall cost 
of delivering 11,793 MMR doses during this period to achieve herd protection across Cheshire and 
Merseyside was estimated at £182,909 (vaccine administration cost of £90,098, MMR vaccine cost of 
£75,121 and promotion cost of £17,690).  This represents just 4.2% of the full estimated total cost of 
the 2012-13 Merseyside measles outbreak. 
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Spending £182,909 on increasing MMR vaccination coverage to the herd immunity threshold would 
have been the most effective method of preventing the sustained transmission of measles virus in the 
community and avoiding the costs of management and containment of a large measles outbreak. 
Therefore, every £1 spent on additional vaccinations would have saved approximately £23 in 
resources used to control the outbreak, had the herd immunity threshold been achieved. 
COST PER CASE ESTIMATES 
COST PER MEASLES CASE  
We estimated that an additional 553 measles cases occurred in the community but were not reported 
to the healthcare authorities [13]. With 2,458 confirmed, probable and possible measles cases 
reported we therefore estimated a total number of 3,011 suspected measles cases in the Liverpool 
outbreak. The cost per suspected measles case was £1,460 for the outbreak, similar to the average 
cost per suspected measles case of £1,416 reported by Carabin et al. (2002) [13]. 
The outbreak resulted in 650 individuals with laboratory confirmed measles. The total cost per 
confirmed measles case was therefore £6,762.  
HOSPITAL COST PER ADMITTED CASE 
139 individuals were hospitalised with measles infection during the outbreak. The total cost of direct 
healthcare measles-related activity was £270,400, therefore the mean hospital cost per admitted case 
was £1,945. 
DIRECT PUBLIC HEALTH COST PER CONFIRMED MEASLES CASE 
The direct public health cost was £1.76m for the outbreak, so the public health cost per confirmed 
measles case was £2,714.  
DISCUSSION 
COMPARISON WITH OTHER STUDIES 
This study found the cost of the Merseyside measles outbreak to be considerably higher than the 
reported cost of other measles outbreaks reported in the literature. The estimated hospitalisation 
cost per patient admitted (£1,945) was similar to those reported during outbreaks in Spain (£1,521 in 
2012 GBP [14]), Italy (£1,614 in 2012 GBP [15]) and the United States (£2,083 in 2012 GBP [16]), though 
it was likely to be an underestimate as the total number of cases admitted to hospital includes only 
those cases admitted at the time of notification of infection, rather than also including those patients 
who may have been hospitalised long after their notification date. 
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Three studies in the literature considered the direct costs related to public health activities, reporting 
much higher costs per case than our findings (£2,714). Two studies reported fewer cases, with one 
reporting only 3 [27] and a second reporting 7 cases [28], compared to 650 in Merseyside. The other 
study reported a public health cost per case of £3,155 (2012 GBP) for 40 cases [20], similar to our 
finding. Many public health interventions to contain and manage outbreaks of measles infection will 
be wide-reaching and with a large public health cost (e.g. identifying vaccination status of residents 
and healthcare workers in the community), but these activities will have the same burden whether a 
small or large number of cases is reported.  
The total number of contacts traced plays a large role in the public health response to an outbreak 
and therefore to related public health costs. In the described outbreak attempts were made to identify 
all contacts during the early stages (1st February to 23rd March 2012). During this period, for every 
confirmed case there were approximately 16 potential contacts where public health risk assessment 
was undertaken. Although this has large workload and cost implications, the significant public health 
costs incurred mainly relate to follow-up procedures of administering prophylactic treatment and 
catch-up vaccinations to close contacts. 
We were unable to compare the productivity costs of the Merseyside outbreak to those costs 
associated with other outbreaks as we were unable to find such accounts in the literature. This study 
therefore presents a new approach in estimating the total societal burden and economic cost of 
measles outbreaks by including estimates for productivity costs. 
STRENGTHS AND LIMITATIONS 
LOSS OF PRODUCTIVITY CALCULATIONS 
We used wages to measure the loss of productivity caused my measles infection, though this is likely 
to be a conservative method and therefore the total cost of measles infection in the community is 
likely to be conservative also. We did not consider other possible sources of productivity loss such as 
the impact on an individual’s leisure time and other activities not directly related to wages lost. 
Assigning a monetary value to these items is extremely difficult to do and we therefore excluded them 
from our analysis.  
We used the most recent data from Thorrington et al. (2014) [12] on the societal impact of measles 
infection to estimate the loss of productivity associated with measles in the household. This study 
used data from 203 individuals with confirmed measles to report on the proportion of individuals 
absent from work or school due to infection or infection in their household, as well as the distribution 
of the duration of that absence. 
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IMPLICATIONS OF INCREASING COVERAGE IN UNAFFECTED AREAS 
Our analysis does not account for cases that were imported from outside the geographical study area 
that could seed future measles outbreaks if they too do not increase vaccination coverage above the 
threshold for herd immunity. We did not take into account the additional cost of increasing 
vaccination coverage in areas outside of the Merseyside area, thereby potentially underestimating 
the total cost of reaching a situation where future measles outbreaks can be avoided completely, as 
seeding from external populations is always likely to occur if measles is present within the United 
Kingdom. Indeed, Liverpool as a major metropolitan area of the north west region of England attracts 
commuters and tourists from many parts of the country, therefore the future seeding of a new 
measles epidemic could occur if an infected individual visits Merseyside from areas of low vaccination 
coverage. It is possible that our comparison of the costs of outbreak management and containment 
to the cost of outbreak prevention through vaccination could be heavily impacted by also including 
the cost of vaccination in a wider geographical area. 
MORE CONSULTATIONS WITH ORGANISATIONS 
The authors of the initial costing report consulted with staff from the largest NHS Trusts to obtain 
activity and cost data related to measles treatment and public health activities carried out during the 
course of the epidemic, but such consultations did not take place with staff from the smaller NHS 
Trusts in the area. As a result, the cost of activity in these smaller Trusts were estimated from the costs 
provided by the larger Trusts. Whilst this was a reasonable assumption to make in order to facilitate 
the prompt analysis and reporting of the initial costs of the first few months of the epidemic, the 
overall estimate of the total cost of the epidemic would have been improved with additional 
consultations and data from all Trusts that responded to the epidemic. 
UNDERESTIMATING THE TOTAL COST TO ACHIEVE HERD IMMUNITY 
In estimating the total cost required to achieve the herd immunity threshold for MMR vaccination 
coverage in the area we assumed that the relevant cost items were both the number of vaccines 
required to be administered plus the necessary administration costs. However, strongly vaccine-
hesitant parents and guardians may require additional resources to convince them of the benefits of 
vaccination in order for them to consent to vaccination for their children.  
At the time of the outbreak in Merseyside there were many parents and guardians who had not 
vaccinated their children due to wrongly-held beliefs concerning vaccine safety and efficacy, 
preference for vaccination alternatives and other worries [29]. Those parents and guardians that were 
actively anti-vaccine (i.e. those parents and guardians who did not want to vaccinate as opposed to 
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the parents and guardians who forgot or had accessibility issues) may not have responded to pro-
vaccine messages. These messages may have even caused a recognised “backfire effect”, where 
vaccine skeptics with a negative opinion on vaccination grow even stronger in their dislike or mistrust 
of vaccinations [30-32]. Therefore, it is likely that these individuals would require additional resources 
in order to convince them of the benefits of MMR vaccination for prevention of measles infection. 
Horne et al. (2015) describe a method to counter anti-vaccination attitudes in parents and guardians 
[33]. Participants of their study were given three pieces of information from the CDC website that 
would address their belief that measles infection was not a cause for concern. This intervention out-
performed a similar intervention where parents and guardians read information from the CDC website 
that explained the lack of a link between the MMR vaccination and autism. McHale et al. (2015) 
reported that a majority of vaccine-hesitant parents and guardians in the Merseyside area did not 
vaccinate their children because of fear that the vaccine may cause autism [29], but Horne et al. (2015) 
show that correcting this incorrect belief is not as effective as replacing it with new information, 
analogous to the intervention provided by Lewandowsky et al. (2012) [34]. 
It is unclear if this intervention could be applied to parents and guardians during a GP consultation, in 
which case the additional cost to vaccinate sufficient children to reach the herd immunity threshold 
should include a GP consultation for each child in a household with vaccine-hesitant parents and 
guardians (£36 in 2012 [21]). If not, then additional educational and outreach programmes would 
need to be commissioned in order to reach this cohort. 
POLICY IMPLICATIONS 
INVESTMENT IN PREVENTION 
Investment in childhood vaccination programmes will be undermined if the threshold for herd 
immunity in the local community is not achieved. The cost of containing and managing a measles 
outbreak in Merseyside is substantial, and a more cost-effective intervention to reduce the impact of 
such outbreaks already exists in the form of the MMR vaccination programme. It is vital that public 
health officials continue to commission and develop the MMR vaccination programme to achieve a 
level of vaccination coverage that will prevent future outbreaks of measles if both unwanted and high 
expenditure on treatment and associated public health and productivity costs are to be avoided. 
Data from the Health & Social Care Information Centre for 2013-14 show that MMR vaccination 
coverage still falls short of the herd immunity threshold of 95% in Liverpool [35]. Although 96.8% of 
children were vaccinated with one MMR dose by the time of their fifth birthday, the requirement for 
two doses was only achieved by 90.9%. Additional resources may be required by public health 
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organisations tasked with increasing MMR vaccination coverage to reduce the potential impact of 
future measles epidemics in the area. 
The outbreak in Merseyside could have been much larger and had a greater total burden of disease 
than the 650 confirmed cases seen in 2012-13. Many children had not received both doses of the 
MMR vaccination for which they were eligible, so it is very likely that an outbreak larger than that seen 
could have occurred, arguably with greater costs in terms of direct healthcare, direct public health 
and the loss of productivity. It also stands to reason that whilst MMR vaccination coverage in the area 
is still below the herd immunity threshold, such a larger outbreak could occur. The estimated cost to 
achieve the herd immunity threshold was just 4.2% that of the total cost of the outbreak, and this cost 
in additional vaccinations administered would also prevent such a larger outbreak as discussed. 
USE OF RESOURCES DURING THE OUTBREAK 
84.6% of the total cost of the outbreak was not spent on direct healthcare for individuals with 
confirmed measles or potential cases of measles. 40.1% of the cost was borne by the direct public 
health response and 44.5% of the cost was borne by the community through the estimated loss in 
productivity. 
Although a number of individuals with confirmed measles were hospitalised with some measles-
related complications, there were no measles-related deaths nor serious complications such as optic 
neuritis or subacute sclerosing panencephalitis as a result of the outbreak. It is unclear how the costs 
attributed to direct healthcare costs would have been influenced in the event of a measles-related 
death or serious complications from infection in the community, but it is likely that additional costs 
would be borne by the secondary care organisations and their commissioners. It is also likely that the 
extensive, timely public health actions undertaken coupled with the already high MMR vaccination 
coverage reduced the risk of larger outbreaks sufficiently that such major complications were not seen 
in hospitals. Complications such as encephalitis (£20,887 per admission), pneumonia (£9,798 per 
admission) and otitis media (£3,057 per admission [36]) were not observed but would have 
substantially increased direct healthcare costs if they had occurred. Furthermore, conditions such as 
subacute sclerosing panencephalitis which cost £6,217 per admission [36] may take many years to 
develop, eventually requiring many follow-up visits for specialist care, support, and longer period of 
home-care, and therefore the treatments costs associated with the outbreak may increase if assessed 
over a longer period than this analysis. 
It is also unclear how cost-effective the expenditure on public health programmes and activities was 
during the outbreak without a comparison to another outbreak with less direct public health 
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expenditure. However, the impact of key public health messages on preventative vaccination cannot 
be underestimated. We estimated that an additional investment of £1 in preventative vaccination 
over the previous five years in the community would have saved £23 in costs related to the outbreak, 
had the herd immunity threshold been achieved.  
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Chapter 9 - Discussion and identifying areas for further 
research 
The strengths and limitations of each study have been discussed in the previous chapters. We present 
a brief summary of the main findings of each study before proposing future directions for research in 
this field. 
A SUMMARY OF THE KEY FINDINGS AND THEIR IMPLICATIONS FOR PUBLIC HEALTH POLICY 
We established that the wide-ranging problems involved in estimating child- and adolescent health 
utilities have not been solved, though progress has been made in developing new child-specific 
instruments to obtain QALYs for a variety of conditions in these age groups. With that, we successfully 
described the health-related quality of life loss due to both seasonal influenza in primary schools and 
measles infection nationwide. We also reported on the social and economic impact of both diseases 
– seasonal influenza outbreaks in primary schools and the impact at home; and measles outbreaks 
nationwide.  
We also established that the new seasonal influenza vaccination programme in England that offers an 
annual live-attenuated vaccine to school-children is only likely to provide the most benefit when 
rolled-out across both primary- and secondary school age groups. Finally, at the community level it is 
important that public health organisations strive to achieve homogeneous vaccination coverage 
within all schools in the targeted geographic location as schools failing to achieve the same vaccination 
coverage as other schools in the area can provide a sufficiently-sized pool of susceptible individuals to 
maintain community-based seasonal influenza transmission and outbreaks. 
ESTIMATING HEALTH UTILITIES AND HEALTH-RELATED QUALITY OF LIFE IN CHILDREN AND ADOLESCENTS  
There is extensive variation in the methods used to estimate health utilities in the paediatric 
population, and still no consensus on the use of proxy-reporting to estimate health utilities in children 
and adolescents.  
There is an over-reliance on adult-specific methods and instruments that had been administered to 
the paediatric population to estimate health utilities (in agreement with Kromm et al. (2012) [1]), as 
well as very little discussion on missing questionnaire data.  
Ten years after the Griebsch et al. (2005) review [2] we reported on the development of new child- 
and adolescent-specific instruments to estimate health utilities in the paediatric population, such as 
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the EuroQol EQ-5D-Y [3] or the CHU-9D [4]. However, the task of paediatric health utility estimation 
is still not standardised and the absence of a recommended instrument to use in these investigations 
from a body such as the National Institute for Health and Clinical Excellence (NICE) means that 
researchers in this field lack a clear way forward in resolving these issues and standardising the 
estimation of health utilities in children and adolescents. 
THE SOCIAL AND ECONOMIC IMPACT OF SEASONAL INFLUENZA OUTBREAKS IN PRIMARY SCHOOLS 
We reported on the socio-economic impact of the illness in terms of the total loss of productivity due 
to illness, using the mean absence from school for children; mean total time off work for primary 
caregivers; and the mean QALY-loss per infected individual. We also reported on the costs incurred by 
families during a child’s infectious period. 
The proportion of parents and guardians who stated that they would be willing to accept an annual 
seasonal influenza vaccination for their children was greater than the reported school-based uptake 
in primary schools in England during the 2014-15 influenza season (81.6% vs. 56.8%) [5]. These figures 
suggest that a minimum of 18.4% of parents and guardians face some form of non-attitudinal barrier 
that prevents their children from participating in school-based vaccination programmes. 
This study highlights the importance of an effective seasonal influenza vaccination programme in 
primary schools. A programme like the current seasonal influenza vaccination programme in England 
can have a direct impact on those children vaccinated in reducing the risk of illness, and a substantial 
indirect impact in preventing disruption at home caused absence from work for parents and guardians 
required to look after their children during their illness. The indirect impact would also extend to 
preventing many parents and guardians incurring out-of-pocket expenses during this illness. Though 
our study did not measure the impact of secondary transmission in the household, it is important to 
note that seasonal influenza vaccination for schoolchildren can prevent secondary household 
transmission that would otherwise have a significant impact at home [6].  
MATHEMATICAL MODELLING OF NATIONWIDE SEASONAL INFLUENZA VACCINATION PROGRAMMES 
We established that a vaccination programme focused solely on either primary or secondary schools 
would not eliminate the potential for sustained influenza transmission, even at the highest possible 
levels of coverage. However, homogeneous vaccination across both school groups would effectively 
eliminate nationwide transmission at 66% coverage. The most cost-effective vaccination strategy 
would see 48% vaccination coverage in primary schools and 34% coverage in secondary schools. 
We’ve previously discussed the importance of an effective seasonal influenza vaccination programme 
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in primary schools and this mathematical modelling study reports the importance of ensuring that the 
programme continues its increased roll-out to all school age groups, particularly to secondary schools 
once all primary school age groups are included in the programme.  
An effective vaccination programme extended to secondary schools would not only be cost-effective 
for the healthcare provider in England but also of substantial benefit to the wider population in terms 
of a reduction of school absence, work absence and out-of-pocket expense for parents and guardians 
even if only the measured benefits to parents and guardians of children in primary schools is taken 
into account. 
The reported coverage achieved during recent pilots and early stages of the roll-out of the vaccination 
programme indicate relatively high coverage can be achieved in primary schools [5, 7], though it is 
likely to fall short of the coverage required in both primary and secondary schools to effectively 
eliminate nationwide transmission. The reasons for non-participation in the programme were not 
studied, but if our study in primary schools is representative of the wider population then policy 
makers seeking to increase coverage should concentrate on parents’ and guardians’ misunderstanding 
of the risks related to influenza infection as well as concerns over vaccine safety. 
MATHEMATICAL MODELLING OF SEASONAL INFLUENZA VACCINATION PROGRAMMES AT THE COMMUNITY LEVEL WITH 
FURTHER HETEROGENEITY IN COVERAGE 
With results similar to those reported in Chapter 5, a targeted vaccination policy in either primary or 
secondary schools alone would not be sufficient to eliminate seasonal influenza transmission in the 
community. However, a homogeneous policy with 47.8% coverage in both primary and secondary 
school groups would eliminate transmission.  
An increase in the number of low-coverage schools in the metapopulation resulted in an increase in 
the expected mean final size of epidemics. However, a single low-coverage primary school in the 
metapopulation did not increase the expected final size of epidemics, though a single low-coverage 
secondary school would result in larger seasonal influenza epidemics due to the relative size of a 
secondary school to a primary school. 
Heterogeneity by design in a vaccination programme was unable to reduce the total burden of disease 
in the metapopulation beyond that of an equivalent homogeneous vaccination policy. Indeed, several 
combinations of coverage levels that used heterogeneity in uptake underperformed in reducing the 
total burden of disease when compared to the equivalent homogeneous coverage policy. This study 
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reinforced the importance of extending the seasonal influenza vaccination policy in England to both 
primary and secondary school groups, not just targeting primary schools. 
This study also emphasised the importance of maintaining homogeneous vaccination coverage in an 
effective seasonal influenza vaccination programme administered in schools. We established that low-
coverage schools in the community cannot be compensated for by increasing coverage in already high-
coverage schools, so policy makers should have contingency plans to increase coverage in low-
coverage schools. 
THE SOCIAL IMPACT OF MEASLES INFECTION, IN PARTICULAR ITS IMPACT ON HEALTH-RELATED QUALITY OF LIFE 
Measles infection was associated with a substantial mean loss HRQoL per individual; in addition to a 
long absence from work or school for 63.1% of those infected and a long absence from work for the 
primary caregivers of those infected requiring a primary caregiver during their infection. Measles 
infection was also associated with a substantial societal burden in terms of both primary and tertiary 
care use.  
This study was the first estimation of the impact of measles infection on health-related quality of life. 
The results from this study can be used to inform cost-utility analyses of new interventions designed 
to prevent or mitigate measles outbreaks in the community. 
Another key result arising from this investigation was the suitability of using the new EuroQol EQ-5D 
proxy questionnaire for those individuals aged under 7 years. 70 of these questionnaires were 
returned from individuals with confirmed measles but only 20 (28.6%) of them included all the 
information required to estimate the health-related quality of life impact of measles infection, with 
the majority (70%) of these returned questionnaires missing a response to the EQ-5D item detailing 
the impact of infection on the individual’s ability to continue to self-care. As discussed in Chapter 7, 
this question and others on the EQ-5D proxy questionnaire may not be appropriate for the age group 
targeted in the investigation. This result was also picked-up in the systematic review of all instruments 
and methods used to estimate health utilities in children and adolescents (Chapter 3), as another 
example of the overreliance of adult-specific measures being used to solicit health utilities from the 
paediatric population. We recommended that EuroQol revisit the EQ-5D proxy instrument and 
develop a new instrument based on EQ-5D that is appropriate for young children. 
Another important finding from this study was the impact of measles infection at home. In a 2015 
study that reported on the reasons for non-participation in measles vaccination programmes in 
Merseyside, several respondents claimed that additional information from the healthcare services 
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that demonstrated the severity of measles infection would have been useful in persuading them to 
vaccinate their child [8]. Informing parents and guardians of the impact that measles infection will 
have both on the health of their children and the day-to-day life at home during any infection may 
therefore be helpful in increasing participation in MMR catch-up campaigns. 
THE ECONOMIC IMPACT OF MEASLES OUTBREAKS IN THE COMMUNITY 
The measles outbreak in Cheshire and Merseyside in 2012 and 2013 is estimated to have incurred 
substantial costs to the community, much higher than previous studies on economic impact of other 
outbreaks have suggested, but we included a wider range of costs using a societal perspective so this 
is unsurprising. 
The cost of achieving 95% MMR vaccination coverage in the region over the previous 5 years is 
estimated to be £182,909, based on a cost-per-dose of vaccine stock, logistics and administration. This 
represents just 4.2% of the total cost of the outbreak and means that every £1 spent on prevention 
could have saved £23 in resources used to control the outbreak if the 95% coverage target had been 
met.  
This study emphasised the importance of adherence to a well-funded and effective preventative 
vaccination programme. The economic impact of measles outbreaks in the community of Cheshire 
and Merseyside was substantial, whilst both a very effective vaccine and well-funded vaccination 
programme exist. Achieving the herd protection vaccination threshold of 95% MMR coverage 
homogeneously across all areas of Cheshire and Merseyside would have enormous benefits to the 
local population, in terms of both health benefits in prevented measles cases and in economic terms 
also. It is important for policy makers to note that whilst local MMR coverage does not exceed 95%, 
the risk of sustained community-wide measles outbreaks remains.  
IDENTIFYING AREAS FOR FURTHER RESEARCH 
ESTIMATING HEALTH UTILITIES AND HEALTH-RELATED QUALITY OF LIFE IN CHILDREN AND ADOLESCENTS  
CLARITY ON THE MOST SUITABLE INSTRUMENTS FOR ESTIMATING HEALTH UTILITIES IN THE PAEDIATRIC POPULATION IS 
REQUIRED 
There is increased emphasis on the need for a well-sourced cost-effectiveness analysis in the process 
of adopting a new healthcare technology or intervention. A lack of suitable tools available to 
researchers to properly assess the potential health benefits of that new healthcare technology is a 
stumbling-block to its adoption. Policy makers and administrative bodies such as NICE should develop 
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suitable protocols for cost-effectiveness analyses that involve children and adolescents, including the 
use of an instrument that accurately estimates health utilities in this group. 
EQ-5D-Y NEEDS A TARIFF FOR CHILD HEALTH PREFERENCES 
The EuroQol EQ-5D-Y classification system is a commonly-used method of obtaining utility weights 
from children. The protocol for use is well established as the child-friendly version of the EQ-5D 
mirrors this adult version in all but a minor re-wording of the questions. However, it still uses the same 
tariff as the adult version, which therefore implicitly assumes that child preferences for health are 
identical to adult preferences for health. Previous research has indicated that this assumption may 
not be valid [9-12]. For investigations into the health-related quality of life impact of both seasonal 
influenza and measles infection, we were able to administer an EQ-5D-Y to the children affected, 
facilitating an estimation of this impact. However, if the EQ-5D-Y tariff does not accurately reflect the 
health preferences of children then we may have misrepresented the impact of seasonal influenza 
and measles on the HRQoL of children. 
Children and adolescents have previously reported utility weights through the Standard Gamble 
procedure (SG) successfully [10, 11], with Ratcliffe et al. (2011) also using a Best-Worst Scaling Discrete 
Choice Experiment (BWS DCE) [13] and comparing both responses and response rates of the SG and 
BWS DCE. The BWS DCE requires a respondent to compare two options using the best and worst 
attributes of each option and is reported to be easier to understand than the SG procedure for eliciting 
utility weights [13]. A tariff derived directly from children and adolescents could therefore be obtained 
for the EQ-5D-Y with a sufficiently large sample size of respondents. 
THE DEVELOPMENT OF AN EQ-5D CLASSIFICATION SYSTEM FOR USE IN VERY YOUNG CHILDREN 
The EQ-5D-Y was developed by adapting the wording of the existing EQ-5D questions to make a new 
classification system that was more acceptable to children [14], but keeping the same five dimensions 
of health that were evaluated in the original EQ-5D system. The EQ-5D proxy, however, may need the 
five dimensions re-evaluated to ensure that an EQ-5D-type measure is suitable for very young 
children. The study on the impact of measles infection demonstrated that the large proportion of 
missing responses for an individual’s ability to self-care during illness may indicate that the dimension 
of self-care is not applicable to young children and may require removal or replacement with a 
different dimension of health. 
Stevens (2010) identified eleven dimensions of health important for children in assessing their HRQoL 
through a series of face-to-face interviews, of which nine were later incorporated into the new CHU-
9D classification system [4]. Children were individually asked about previously health problems they 
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had encountered, ensuring that both chronic and acute conditions were raised with each child. A 
discussion about how each identified health problem affected the children followed in terms of school 
work, health service resource use and absenteeism. Each interview sought to obtain the different 
consequences of the identified health problems, subsequently using each consequence in the 
development of the dimensions of health for the new classification system.  
THE SOCIAL AND ECONOMIC IMPACT OF SEASONAL INFLUENZA OUTBREAKS IN PRIMARY SCHOOLS 
INCLUDE SECONDARY INFECTIONS IN HOUSEHOLD TO CAPTURE GREATER DISEASE BURDEN 
Our study to investigate the social and economic impact of seasonal influenza outbreaks in primary 
schools in England could only capture the impact of primary infections in the household. A survey sent 
at a later date with additional questions pertaining to any secondary infections within the household 
would have captured details on the wider impact of school-located outbreaks.  
In order to understand the full impact of ILI infection at home, we need to include the possibility of 
secondary transmission within the household, with the household primary case assumed to be 
infection from the school-based outbreak. Neuzil et al (2002) reported 126 episodes of illness from 
secondary infection in a survey of 216 families with children attending schools in Seattle [15], so the 
burden of secondary infections is not likely to be insignificant. 
To capture the impact of secondary infections in the household, a revised study would include the 
prompt distribution of follow-up questionnaires to parent and guardians who reported that their child 
was ill with ILI infection during the notified school outbreak. The questionnaire would be identical to 
those in the original questionnaire but framed to address illness in a member of the household, not 
necessarily a school-attending child. 
Addressing the problem of secondary infections and their impact would help policy makers better 
understand the impact of seasonal influenza from a societal perspective. Secondary infections in the 
household are likely to increase the economic burden on that household, particularly if at least one of 
the secondary infections is either a caregiver or in employment. Our original study has only measured 
the impact of a primary case in a household where more than one case of ILI may have occurred.  
INCLUDE HRQOL MEASURES FOR CAREGIVERS DURING A CHILD’S ILLNESS 
The true impact of ILI infection in the household should also include the impact of the infection of the 
primary case on the HRQoL in other household members. Prosser et al. (2015) measured the impact 
of chronic illness on other household members and found this impact to be not insignificant [16]. 
Though the impact of chronic illness in the household would be different to the impact of short-term 
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acute illness, the assumption that this illness only affects the primary case in the household is likely to 
miss any impact felt by other household members, however small. Indeed, if measuring HRQoL using 
the EuroQol EQ-5D, the dimensions of health relating to usual activities and anxiety may well be 
sensitive to change for a caregiver during their child’s illness through ILI. 
Any successful interventions to avoid ILI infection being introduced to the household would avoid all 
potential loss of HRQoL in caregivers for the primary case. Therefore, this potential impact on HRQoL 
for caregivers should be quantified. 
DAILY HRQOL MEASUREMENTS 
When calculating the loss of HRQoL for each individual with ILI we assumed that health utility would 
fall linearly with time from baseline to the lowest health utility on the worst day, then it would recover 
linearly with time until the last day of infection, at which point it returns to the baseline level. This 
assumption has been used successfully in the past to measure the impact on HRQoL of H1N1v 
pandemic influenza [17], but the full nature of the loss of HRQoL deserves investigation. 
We measured health utility using the EuroQol EQ-5D twice during infection. Intermediate 
measurements between around the time of the worst day of infection would provide further data to 
understand the magnitude of the loss of HRQoL by challenging the assumption of linear reduction and 
recovery. Our assumption of the shape of the polygon plotted when using the vertices at the two 
baseline measurements and the worst day of infection was that of a triangle. However, if the health 
utility experienced on the worst day of infection is felt for a longer period that one day then this 
polygon would be a trapezium and would increase the area of the shape of the assumed polygon 
representing the loss of HRQoL.  
Some ways to fully understand the shape of the polygon representing the loss in HRQoL would be 
through  challenge studies with volunteers willing to be infected with ILI and to have their period of 
infection monitored by completing daily EQ-5D measurements, or through a prospective cohort 
recruited in a similar fashion to that of the annual Flusurvey [18] with daily HRQoL measurements 
taken during periods of illness. Enrolling individuals at school who have ILI to complete daily EQ-5D 
measurements would be very difficult to administer. 
EXTENDING THE STUDY TO INCLUDE SECONDARY SCHOOLS AND BOARDING SCHOOLS 
Our study was originally intended to reach all primary and secondary schools that reported a 
suspected ILI outbreak during the 2012-13 and 2013-14 influenza seasons. A combination of the late 
introduction of the study during the first influenza season and the reduced influenza activity during 
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the second resulted in a small sample size consisting of primary schools exclusively. If it were possible 
to run the study again it would be important to capture the potential impact of ILI in secondary schools 
and boarding schools as well, thereby obtaining sufficient data to report the impact of ILI in the general 
school population. 
Brousseau et al. (2015) evaluated the impact of influenza vaccination on age-specific respiratory 
disease incidence in children attending private boarding schools in England during 2013-14 [19]. They 
recruited 43 schools consisting of 14,776 pupils by working in collaboration with the Medical Officers 
of Schools Association (MOSA), asking the head nurse of each MOSA school to complete a weekly 
online survey about the number of respiratory illnesses in pupils. Though this study evaluated the 
impact of influenza vaccination, rather than the impact of influenza infection, it highlights a new 
method of identifying those schools with ILI epidemics during the influenza season. 
Both MOSA and PHE have an existing long-standing relationship to manage a school-based 
surveillance programme in boarding schools. Using the same protocol as the Brousseau et al. (2015) 
study to identify respiratory illnesses in pupils, an adapted questionnaire could be delivered to those 
pupils with illness attending the boarding school in order to assess the impact of illness on their 
routine. This impact would be limited to HRQoL and attendance in classes, as the impact on the wider 
family would not be applicable as the children are not in the household. However, given that the 
impact of influenza vaccination in boarding schools has already been measured in terms of a reduction 
of ILI in pupils (RR 0.46, 95% CI: 0.28-0.76, [19]) then additional data on the impact of ILI infection on 
a pupil’s HRQoL as well as a societal measure such as their loss of productivity would give public health 
teams sufficient information to present to vaccine hesitant parents in order to increase vaccination 
coverage at boarding schools. 
MATHEMATICAL MODELLING OF NATIONWIDE SEASONAL INFLUENZA VACCINATION PROGRAMMES 
MODELLING THE TIMING OF SEASONAL VACCINATION 
One assumption in our model was that all vaccinations are administered before the beginning of 
seasonal influenza outbreaks. Though this assumption was useful in simplifying the model, it may not 
bear resemblance to vaccination attitudes of individuals eligible for seasonal influenza vaccination.  
Vaccine stocks are delivered to GP practices, pharmacies and to Public Health England central stocks 
from September each year, but vaccination for seasonal influenza continues through winter until 
February [20]. Vaccination coverage does not reach its maximum before the beginning of nationwide 
influenza outbreaks, nor does vaccination uptake increase linearly with time during the winter period 
(Figure 9.1).  
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Figure 9.1 - Cumulative weekly influenza vaccine uptake by target group in England 
Figure credit: [21]. 
Improvements to the model would include a time-dependent vaccination coverage parameter for 
each population group eligible for the seasonal influenza vaccine. In addition to including time-
dependent coverage, the vaccination coverage parameter should account for the time needed 
between vaccination administration and the delay between immunity onset. Baguelin et al. (2013) 
assumed coverage increased at regular intervals during the influenza season [22], but additional data 
from vaccination uptake surveillance programmes would inform this further. 
Public Health England releases weekly national influenza reports during the influenza season and 
these weekly reports include weekly vaccination coverage data. Baguelin et al. (2012) assumed that 
the time delay between vaccination administration and immunity onset was two weeks [23], though 
this estimate could be improved with data from challenge studies. 
MODELLING REACTIVE VACCINATION DECISIONS 
Data gathered from primary schools that reported a suspected ILI outbreak during the 2012-13 and 
2013-14 influenza seasons suggest that parents or guardians of children attending schools with recent 
outbreaks are keen to accept the offer of seasonal influenza vaccination, but uptake data from the 
2013-14 pilot study in six primary schools suggest that the willingness to accept a vaccine does not 
equate to high vaccination uptake [7]. The intention to study the difference between a willingness to 
vaccinate and achieved vaccination coverage was discussed in Chapter 4, but the high proportion of 
parents and guardians reporting a willingness to vaccinate their children against seasonal influenza 
may have been influenced by the recent suspected ILI outbreak at their child’s school. This begs the 
question of how many decisions to vaccinate are influenced by recent local ILI or influenza outbreaks. 
It is not clear from the uptake data reported in Figure 9.1 if any weekly increase in vaccination 
coverage is due to reports of local outbreaks – such detail on local uptake is lost in the reporting of 
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national uptake figures. However, if data on vaccine decisions were gathered during the influenza 
season at the time of vaccine administration then the impact of local outbreaks on the decision to 
vaccinate could be studied. A spatially explicit model could account for a possible increase in local 
vaccination uptake due to localised influenza outbreaks. 
STAGGERED DELIVERY OF VACCINES 
We’ve previously discussed modelling time-dependent vaccination uptake, but vaccine programmes 
may have time-dependent delivery and administration of vaccines to different targeted groups. 
Rather than administering vaccines to all targeted groups simultaneously, it may be logistically easier 
and more cost-effective to administer vaccines to different targeted groups one-after-another [24]. 
Therefore, if simultaneous delivery during one influenza season to both primary and secondary school 
groups is unfeasible, it is sensible to explore whether primary or secondary schools should be offered 
the vaccination first, as well as the wider issue of vaccinating healthy children before or after risk 
groups. Such a scenario would require a model to account for the increase in vaccination coverage as 
the influenza season progresses. 
MATHEMATICAL MODELLING OF SEASONAL INFLUENZA VACCINATION PROGRAMMES AT THE COMMUNITY LEVEL WITH 
FURTHER HETEROGENEITY IN COVERAGE 
MODIFYING THE MODEL FOR OTHER METAPOPULATIONS, WITH VACCINE UPTAKE MODELLED USING DEMOGRAPHIC FACTORS 
Our model of heterogeneous vaccination coverage in the community investigated the impact of 
heterogeneous seasonal influenza vaccination coverage at the school-level. However, at a national 
level there is sufficient evidence to suggest that heterogeneities in coverage will be seen based on the 
implementation of different vaccine-administration methods [5, 7]; level of deprivation and 
urban/rural areas [25]; and the different educational or promotional material released by the 
healthcare and education authorities [26]. Our metapopulation model was unable to address this 
issue, but we can use it to propose the basis for a new model that may assist in answering the question 
of nationwide coverage heterogeneities.  
Green et al. (2015) used vaccination coverage data in England from the first year of the roll-out phase 
of the new JCVI influenza vaccination programme and modelled vaccine uptake using collected 
demographic factors [27]. Factors including ethnicity, deprivation and religious beliefs were important 
factors in determining vaccine uptake. The data were aggregated by clinical commissioning group 
(CCG) and Public Health England Region. Data for those individuals aged 2 and 3 years old were 
available for the whole country, whilst data for those aged 4-11 years old were available for the six 
pilot sites administering vaccinations in schools. 
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Data on the demographic factors for those individuals receiving their seasonal influenza vaccination 
at their GP practice were available to Green et al., aggregated at GP practice level. With each GP 
practice assigned to a CCG covering a discrete geographical area, it is possible to build a patch-
structured metapopulation model of the CCGs in England, each with estimated vaccine coverage. This 
spatially-structured model could then be used to simulate seasonal influenza epidemics in England, 
subsequently providing Public Health officials with information on where best to focus their efforts on 
reducing vaccine coverage heterogeneity. 
In addition, demographic factors on the individuals aged 4-11 years old that received their vaccination 
in schools participating in the pilot study could be extrapolated to cover England and estimate uptake 
at CCG level using demographic factors for 4-11 year olds in each CCG. An influenza transmission 
model within a structured metapopulation model with 211 CCGs would be computationally expensive 
to execute, so the merits of a stochastic model versus a simpler deterministic model would need to 
be established during this project. This extrapolation, however, will increase the uncertainty in 
predicted coverage level for each CCG as the original sample size is very small. As the roll-out of the 
new seasonal influenza vaccination coverage continues, additional demographic data can be modelled 
with uptake in each CCG to improve the model.  
Studies to map or predict vaccination uptake have been conducted on a variety of different 
vaccinations in different countries. Coverage of seasonal influenza vaccination programmes has been 
studied in the United Kingdom [25], Kenya [28], Japan [29] and the United States [30], modelling 
coverage with socio-economic and demographic factors (Figure 9.2). 
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Figure 9.2 - Influenza vaccination and socio-economic factors for (top) 2010-11 and (bottom) 2011-12 
in North Carolina, USA 
Figure credit: [30]. 
In addition, several studies have modelled vaccination coverage for pandemic influenza [31], MMR 
[32-34] and the regular childhood vaccination schedule in New Zealand [35], all with various socio-
economic and demographic indicators. Spatially-explicit metapopulation models using these data 
could be implemented to model the potential burden of disease for each setting, to better inform the 
allocation of resources for vaccination programmes. 
THE SOCIAL AND ECONOMIC IMPACT OF MEASLES OUTBREAKS 
DAILY HRQOL MEASUREMENTS 
In estimating health utilities and the total burden of disease for measles in England during 2012-13 
we assumed that HRQoL would fall linearly with time until a minimum at the worst day of infection, 
after which the HRQoL of the individual will increase linearly with time until returning to the baseline 
level after symptoms have gone.  
We proposed measuring HRQoL daily through an individual’s infection with influenza, and here we 
propose to do the same for measles infection. The daily impact on HRQoL of measles infection was 
assumed to decline and recover linearly but this assumption should be challenged by the 
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administration of additional questionnaires to individuals with measles. Successfully estimating the 
loss of HRQoL through QALYs and QALDs would result in a more accurate estimation of the total 
burden of disease due to measles infection. 
COST-UTILITY ANALYSES OF PREVENTATIVE OR REACTIVE INTERVENTIONS FOR MEASLES OUTBREAKS 
To our knowledge, our study to estimate the impact of measles infection in terms of QALYs using a 
validated health-state instrument was the first attempt to do so. Information on the estimated QALY-
loss caused by acute infectious disease is important for cost-utility analyses of interventions designed 
to prevent or manage outbreaks of those infectious diseases. Previous cost-effectiveness analyses 
have been able to estimate the cost to prevent each measles case in an outbreak [36-40], but now a 
suitable transmission model linked to an economic analysis using QALYs to estimate potential health 
benefits through case prevention will facilitate the calculation of the cost-per-QALY ratio. 
THE WIDER PICTURE: THE CHALLENGES FOR PUBLIC HEALTH OF VACCINE-PREVENTABLE OUTBREAKS OF 
INFLUENZA AND MEASLES 
ERADICATION OF MEASLES 
The World Health Organisation aims to achieve elimination of measles infection in at least five WHO 
regions by the end of the year 2020 [41]. Measles remains a leading cause of morbidity and mortality 
for children around the world, despite the availability of an effective and ineffective vaccine against 
the disease and a 73% decline in worldwide annual incidence between 2000-2014 [42].  
In 2013 the WHO’s Strategic Advisory Group of Experts (SAGE) on Immunisation warned that several 
WHO regions were unlikely to meet their 2015 elimination goals for both measles and rubella. The 
outbreaks of measles in the United States and Europe in 2012-14, due to declining MMR vaccination 
uptake in the late 90s and early 00s, were likely a contributor to this warning. Areas of the world 
plagued by conflict, including Iraq, Syria and Sudan, reported measles outbreaks throughout 2014, 
demonstrating the difficulties in meeting this worldwide target of elimination [43].  
The eradication programme faces significant challenges: at the national and local level, individuals still 
face barriers to measles vaccination for many reasons [44], and clusters of unvaccinated individuals 
can trigger far-reaching outbreaks in the community [45-47], the impact of which has been described 
in Chapter 7 and Chapter 8 of this thesis.  
Increasing the demand for the measles vaccine at the national and local level can be achieved by 
improving the quality of the vaccine supply [48], advocacy undertakings with parents and guardians 
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responsible for making vaccine decisions [49], and increasing the awareness of the dangers of measles 
infection in the minds of the general public [50]. Effective public health campaigns making use of clear 
educational messages are required to address the misplaced scepticism towards the measles vaccine 
and to accept vaccination to protect both their children and the wider community. 
THE CONTRIBUTION OF THIS THESIS 
Global disease eradication programmes depend on the success of the constituent national disease 
eradication programmes, which in turn rely on successful local and community-wide public health 
campaigns and engagement activities to increase awareness of both the dangers of infection and 
socio-economic burden of disease as well as the benefits of vaccination. 
The importance of a well-resourced preventative vaccination programme was outlined in Chapter 8, 
comparing the total economic burden of a local measles outbreak to the total estimated cost of 
achieving herd protection. The economic burden of sustained community-wide measles transmission 
was much larger than the estimated total cost of achieving herd protection through an existing 
vaccination programme. This analysis demonstrates the necessity for continued investment in 
vaccination programmes and increased support for commissioning public health campaigns designed 
to increase participation in vaccination programmes.  
In addition to the importance of a measles vaccination programme from the perspective of public 
health organisations and the wider community, this thesis offers additional detail on the individual 
burden of disease through the reported results in Chapter 7. Taken together, the results from both 
chapters should support public health organisations in making a very compelling case for renewed 
vigour in further commissioning and support for the MMR vaccination programme, whilst individuals 
not currently reached by this programmes have additional information on the impact of measles 
infection that should increase demand for the vaccine. 
The contribution of well-resourced and far-reaching national vaccination programmes to a global 
measles eradication programme cannot be underestimated. It is the pockets of low-vaccination 
coverage distributed across different countries that continue to periodically revive large-scale 
outbreaks, so it is therefore of the utmost importance that individuals in these communities are fully 
engaged with local public health organisations and their vaccination programmes to reduce the 
potential for further future outbreaks. 
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PUBLIC HEALTH CHALLENGES WITH SEASONAL INFLUENZA 
In 2011 the ECDC identified several challenges in increasing engagement with seasonal influenza 
vaccination programmes in European countries [51]: 
 Communication 
 Doubts on vaccine safety and effectiveness 
 Involvement of healthcare workers in the programmes 
Vaccination coverage in Europe for seasonal influenza is heterogeneous but can be high in some 
targeted groups in several countries – indeed, both The Netherlands and the UK achieved over 75% 
coverage in the elderly population in 2012-13 [52]. However, many other countries still experience 
significant challenges to increase coverage in their targeted risk groups. These challenges include a 
lack of awareness of influenza; a lack of education on the disease; a gap in trust towards public health 
authorities; a lack of adequate advice from those healthcare services with which the population is 
engaged; and unclear messages from new media sources that may also promote anti-vaccination 
attitudes [51, 53].  
Many studies have previously concluded that increased engagement with primary care services can 
increase vaccination coverage in both high-risk groups [54] and the general population as a whole 
[55], with strategies that use outreach programmes and reminder systems proving to be the most 
effective. An effective communication strategy in the primary care setting can help overcome the 
barriers to vaccination programme engagement caused by issues in communication. Public health 
efforts to address misconceptions about vaccine safety and effectiveness are crucial to improving the 
public’s understanding of the benefits of seasonal influenza vaccination, particularly among minority 
groups [56], parents of children eligible for childhood vaccination programmes [57] and university 
students [58]. Engagement with healthcare workers is essential, and this requires a thorough 
understanding of the motivators for healthcare workers to consent to seasonal influenza vaccination. 
These motivators primarily concern the personal benefit of vaccination, highlighted in this thesis, 
rather than indirect benefits that may be experienced by the healthcare workers’ patients [59]. 
THE CONTRIBUTION OF THIS THESIS 
This thesis reported on the importance of maintaining the current planned roll-out of the childhood 
seasonal influenza vaccination programme (Chapter 5) whilst targeting consistent coverage levels in 
the community (Chapter 6) and both the social and economic impact of influenza infection that should 
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be used to inform parents and guardians of the importance of the participation of their children in the 
childhood seasonal influenza vaccination programme (Chapter 4). Both Chapter 5 and Chapter 6 
should inform public health organisations of the significance of maintaining good vaccination coverage 
in the community, it is the results from Chapter 4 that may assist the ECDC in tackling the challenges 
identified to increase engagement in these vaccination. 
The results from Wooten et al. (2012) on concerns over vaccine safety and efficacy acting as a barrier 
to engagement with seasonal influenza vaccine programmes were reiterated in this thesis [56]. 
Addressing these issues with well-publicised vaccination campaigns that inform the population of the 
efficacy of vaccines can address this issue [26], though an important component of any such campaign 
is a warning of the dangers of infection to counter anti-vaccine or vaccine hesitant attitudes [50], 
which the results of Chapter 4 can inform. Communicating the risks posed by infection of vaccine-
preventable diseases can have significant changes in vaccination intentions. Communicating the risk 
of infection in terms of the severity of illness in addition to the socio-economic impact at home 
through media outlets would ensure that this message has its widest possible reach [60]. 
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